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Abstract 
 
An Abstract of a Dissertation Submitted to Nova Southeastern University in 
Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy 
 
PROTECTIVE ACTIONS OF OXYTOCIN ON AORTIC WISTAR AND SHR VSMCS 
By 
VARUN KUMAR SOTI 
AUGUST 2019 
 
Background. Oxytocin, known as a female reproductive hormone, has emerged as a 
cardiovascular hormone showing cardioprotective effects, for instance, negative 
chronotropic and inotropic effects and ANP release in cardiomyocytes and endothelium. 
However, oxytocin’s effect in VSMCs remains to be explored. Objectives. This study had 
three goals: characterizing oxytocin’s effect on proliferation, inflammation, oxidative 
stress, and vasocontraction pathway in Wistar VSMCs; determining oxytocin’s effect on 
Ang II; describing oxytocin’s effect and its interaction with Ang II in SHR VSMCs. 
Methods: Aortic VSMCs were isolated from Wistar rats and SHRs. Hemocytometer, MTT 
and 3H-Thymidine incorporation assays, and flow cytometry were employed for cell 
proliferation studies. Two key proliferation pathways — ERK1/2 and PI3K/Akt pathways, 
and vasocontraction (ROCK) pathway were investigated for mechanistic studies utilizing 
Western blotting. IL-6 and ROS were measured to assess inflammation and oxidative 
stress, respectively. Results. Cell proliferation studies and Western blotting outcomes in 
Wistar and SHR VSMCs, demonstrated that oxytocin (100 nM) significantly decreased 
cell proliferation and reduced phosphorylation of ERK1/2, PI3Kp110α, Akt, ROCK-1, and 
ROCK-2, respectively. OXTA antagonized these effects of oxytocin. Flow cytometric 
measurements indicated that oxytocin-induced apoptosis and necrosis. IL-6 assay and ROS 
assay results displayed that oxytocin increased IL-6 and ROS, respectively. Oxytocin’s 
pre-treatment with Ang II in Wistar and SHR VSMCs caused: decreased cell proliferation; 
reduced phospho-ERK1/2, phospho-PI3Kp110α, phospho-Akt, ROCK-1, and ROCK-2; 
decreased IL-6; increased ROS. Comparison between Wistar and SHR VSMCs illustrated 
that oxytocin greatly reduced PI3Kp110α phosphorylation in Wistar VSMCs than SHR 
VSMCs (P < 0.01). Oxytocin caused higher IL-6 secretion in SHR VSMCs (P < 0.01) and 
higher ROS production in Wistar VSMCs (P < 0.001). Oxytocin’s pre-treatment with Ang 
II showed: higher reduction in ERK1/2 phosphorylation in SHR VSMCs (P < 0.001); 
higher reduction in PI3Kp110α phosphorylation (P < 0.05) and higher increase in ROS in 
Wistar VSMCs (P < 0.001). Conclusion. Oxytocin showed an anti-proliferative effect on 
aortic VSMCs, likely through inhibition of ERK1/2 and PI3K/Akt phosphorylation. 
Oxytocin-mediated decreased phosphorylation of ROCK-1 and ROCK-2 suggest 
oxytocin’s anti-vasoconstrictive action in VSMCs. Oxytocin’s antagonistic actions against 
Ang II indicate that oxytocin may exert beneficial vascular effects in conditions associated 
with high levels of Ang II. 
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Chapter 1: Introduction 
1.1. Background 
At the dawn of the 19th century, Sir Henry Dale achieved a breakthrough 
that would herald a new era in endocrinology. He discovered that a chemical 
extracted from the human posterior pituitary gland caused uterine contractions in 
pregnant cats, dogs and guinea pigs. He called this chemical ‘oxytocin,’ derived 
from the Greek words ‘ωχνξ,’ ‘τoχoxξ,’ meaning ‘swift birth.’ Over the next 100 
years, oxytocin became a subject for extensive research.1  
It is now established that oxytocin is a neurohypophysial nonapeptide 
secreted by magnocellular cells in the paraventricular and supraoptic nuclei of the 
hypothalamus. It is stored in the posterior lobe of the pituitary gland. A wide range 
of stimuli including sucking (milk ejection reflex), pre- (labor induction) and post-
parturition, and stress trigger oxytocin release from the posterior pituitary into the 
blood circulation. There is an extensive projection of oxytocinergic neurons in the 
central nervous system (CNS) — brain and spinal cord including amygdala, 
ventromedial hypothalamus, nucleus acumben, septum, and brainstem.2 Besides, 
oxytocin is also synthesized peripherally in tissues such as placenta, uterus, testis, 
kidney, heart, and blood vessels in both vascular endothelial cells (ECs) and 
vascular smooth muscle cells (VSMCs).3 
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The oxytocin receptor gene (OXTRG) has been mapped in the human 
chromosome at the locus 3p25-3p26.2 alongside a gene that encodes the 
vasopressin receptor. The distance between the two genes is 500-kilo bases (kb). 
The human OXTRG spreading over 17 kb consists of three introns and four exons. 
The third intron, being the largest spanning 12 kb, separates the transmembrane 
domain 6 from the coding region. Exons 1 and 2 frame the 5’ prime non-coding 
domain, while the exons 3 and 4 code for the amino acids sequence for oxytocin 
receptors. Exon 4, in particular, codes for the seven transmembrane domain, 
carboxyl terminal and the 3’ non-coding region.3  
Both oxytocin and vasopressin are the neurohypophysial peptides, with 
each having a sequence of nine amino acids, and are stored in the posterior lobe of 
the pituitary gland. The point of difference between the structure of oxytocin and 
vasopressin is the amino acid at position 8. In oxytocin, leucine is present at number 
8. Whereas, in vasopressin, either lysine or arginine is present at this position. The 
sequence of amino acid in oxytocin is as follows: Cysteine (1) – Tyrosine (2) – 
Phenylalanine (3) – Glutamine (4) – Asparagine (5) – Cysteine (6) – Proline (7) – 
Leucine (8) – Glycine (9). Importantly, the presence of isoleucine at position 3 in 
the oxytocin family is required for the activation of oxytocin receptors.4 
Oxytocin receptors belong to the class I G-protein coupled receptors 
(GPCRs) that predominantly bind to Gq/α11 class of guanosine triphosphate (GTP) 
binding proteins that activate phospholipase C (PLC). This brings about the 
formation of the two important secondary messengers: inositol-3-phosphate (IP3) 
and 1, 2-diacylglycerol (DAG). IP3 sparks the release of intracellular calcium 
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(Ca2+); DAG activates protein kinase C (PKC) that triggers the phosphorylation of 
targets leading to a further downstream signaling. The activation of these second 
messengers result in oxytocin-mediated physiological effects at different locations. 
When bound with Gi protein, oxytocin receptors inhibit the adenylyl cyclase (AC), 
leading to inhibition of the production of cyclic adenosine monophosphate (cAMP) 
from adenosine triphosphate (ATP). This inhibits cAMP pathway-dependent 
phosphorylation of targets and attenuates further downstream signaling. The effects 
of oxytocin varies widely and depends upon the target tissue(s), gland(s), organ(s) 
or system(s). 3,5,6 
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1.2.     Traditional roles of oxytocin 
Oxytocin is often referred to as a ‘female reproductive hormone.’ It is 
known to contract pregnant uterus assisting parturition1. It also affects lactating 
breasts by initiating milk ejection reflex7, promotes maternal-fetal bonding8 and 
plays a role in reproduction and in reaching an orgasm.9  
Oxytocin became commercially available in 1980. Its agonist and 
antagonists have found applications in both clinical research and pre-clinical 
studies.10,11,12  
It has become common in medical practice to employ pharmacological 
interventions such as intravenous administration of Pitocin (a commercial brand 
name oxytocin), along with other mechanical methods (for example extra-amniotic 
Foley catheter) to induce labor.13,14  
Oxytocin has emerged as a versatile hormone affecting social bonding, 
trust, memory, learning, empathy, and depression.15,16,17,18 
From as recent as the year 2012, the intranasal administration of oxytocin 
has found an application in clinical behavioral studies.19,20,21   
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1.3. Emerging role of oxytocin in the cardiovascular system (CVS) 
In the last decade, the dynamics in oxytocin research have been completely 
shifted. A new role for oxytocin has now evolved in cardiovascular regulation.22,23 
Oxytocin being considered initially as a female hormone is now gaining consensus 
as a ‘cardiovascular hormone.’24 The present study is an endeavor to develop a 
deeper understanding of the role that oxytocin plays in cardiovascular physiology 
and pathophysiological conditions. 
1.3.1. Effect of oxytocin on heart 
Several studies in rats and humans have reported that oxytocin is 
synthesized locally in the heart. The studies demonstrating competition binding 
curves have revealed only one receptor subtype for oxytocin in the heart. All the 
chambers of the heart and the large blood vessels have oxytocin and its 
receptors.25,26  
The equilibrium dissociation constant (KD) values are slightly different in 
rat heart (KD ~ 1.00 nM), hypothalamus (KD ~ 0.02 nM), and uterus (KD ~ 0.76 
nM). However, in the blood vessels there are no significant difference between the 
KD values of rat vena cava (KD ~ 0.78 nM) and aorta (KD ~ 0.59 nM). The right 
atrium and the left ventricle have the highest and lowest concentrations of oxytocin, 
respectively. The right atrium’s oxytocin levels are equivalent to hypothalamic 
oxytocin levels.25  
Studies have shown that oxytocin can reduce the rate of cardiac blood flow 
and induce bradycardia.  In isolated dog atriums, oxytocin produced negative 
inotropic and chronotropic effects via its receptors in the heart.27,28 
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1.3.2. Effect of oxytocin on cardiomyocytes 
Oxytocin plays a role in the regulation of atrial natriuretic peptide 
(ANP).29,30 The ANP is a peptide hormone consisting of 28-amino acids. It is 
synthesized, stored and released locally in cardiomyocytes. The factors that cause 
the secretion of ANP include atrial wall distension, increased blood volume (in 
pathological conditions such as congestive heart failure), angiotensin II (Ang II), 
endothelin, and sympathetic activation (norepinephrine). The ANP elicits a 
cardioprotective effect by decreasing the central venous pressure, thereby reducing 
blood volume and decreasing ventricular pre-load, and thus decreasing cardiac 
output. Besides, ANP also inhibits renin release and aldosterone synthesis.31  
One previous study has demonstrated the functional relevance of oxytocin 
and its receptors in rat heart and cultured cardiomyocytes. The study has evidenced 
that oxytocin (10-6 M, a physiologically relevant concentration) stimulates ANP 
release from isolated perfused female rat hearts and cultured cardiomyocytes. In 
this study, not only had the oxytocin antagonist (10-6 M and 10-7 M) , in a 
concentration-dependent manner, inhibited the oxytocin-stimulated ANP release in 
the heart perfusion medium, but also inhibited the basal release.29  
The research findings of these studies indicate that oxytocin, via ANP 
release, reduces cardiac contraction - force and rate, and decreases circulating blood 
volume.  This illustrates the protective effect of oxytocin in cardiovascular 
physiology, and its benefits can be further explored in cardiovascular 
pathophysiological conditions, for instance, congestive heart failure. 
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In recent years, oxytocin has also found relevance in stem cell research on 
cardiogenesis.  A few studies have indicated that oxytocin has the potential to 
induce differentiation of embryonic stem cells (P-19ECs) to cardiomyocytes 
(CMs). Studies have brought to light that nitric oxide (NO) signaling is involved in 
oxytocin-induced differentiation of P-19ECs to CMs.32 There is also an 
upregulation of oxytocin receptors and Gata-4 (a protein required for the atria-
ventricular formation and its functions) that are considered crucial to the oxytocin-
mediated cardiomyocytes differentiation process.33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8 
1.3.3. Effect of oxytocin on blood vessels (endothelial cells and VSMCs) 
Several pre-clinical studies have demonstrated that oxytocin has shown 
anti-oxidant and anti-inflammatory effects in vascular endothelial cells (derived 
from the aorta), THP-1 monocyte, and macrophages. The physiological levels of 
oxytocin have shown significant reduction in nicotinamide adenine dinucleotide 
phosphate (NADPH) superoxide production, and also decreased the levels of the 
interleukin-6 (IL-6) in monocytes, macrophages, and aortic endothelial cells.34  
It has been reported that in diabetes, an independent risk factor for many 
cardiovascular diseases (CVD),35 neovascularization is significantly impaired after 
ischemia.36 The endothelial cells lose the ability to recover significant blood flow 
due to endothelial dysfunction. Besides, the progenitor endothelial cells suffer 
reduced angiogenic functions.37 Oxytocin has been shown to restore angiogenic 
functions in a streptozocin-induced diabetes rat model. The pre-treatment of 
cultured bone marrow-mesenchymal stem cells (MSCs) with oxytocin has shown 
significant restoration of kruppel-like factor 2 (KLF2) which is a crucial angiogenic 
factor.38  
Many in vitro studies have shown that oxytocin, in endothelial cells derived 
from the human dermal microvasculature, umbilical vein and breast cancer cells, 
induces an overexpression of vascular endothelial growth factor (VEGF), matrix 
metalloproteinases (MMP-11, MMP-17 and MMP-26), integrin β6 genes, and 
cathepsin D.39,40 Thereby, stimulating migration and proliferation (which are the 
crucial steps in angiogenesis) of endothelial cells.  
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These studies have suggested that oxytocin induces angiogenic effects via 
an oxytocin receptor stimulation of the phosphatidylinositol-3-kinases 
(PI3K)/Akt/endothelial nitric oxide synthase (eNOS) pathway. It has been 
determined that the ability of oxytocin to phosphorylate Akt and eNOS depends on 
the PLC activity.39 A subsequent study has revealed that it is through the 
stimulation of PLC and calcium mobilization, oxytocin phosphorylates the tyrosine 
kinases: proline-rich tyrosine kinase-2 (Pyk-2) and Src. This activates the 
PI3K/Akt/eNOS pathway.41   
It is interesting to note that most of the cardiovascular effects of oxytocin 
have been studied in vascular endothelial cells and cardiomyocytes. However, in 
VSMCs, only the presence of oxytocin receptors has been established thus far. 
There is very little information regarding oxytocin effects in VSMCs.42,43 
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1.3.4. Effect of oxytocin in various pathophysiological cardiovascular 
conditions  
Inflammation and  oxidative stress are the two critical pathophysiological 
events in atherosclerosis.44 In a rat model of atherosclerosis, the administration of 
oxytocin showed an improvement in the lipid profile and decreased the plasma 
levels of IL-6, monocyte chemoattractant protein-1 (MCP-1) and C reactive protein 
(CRP). It also improved the plasma levels of reduced glutathione (GSH) and nitric 
oxide (NO). Besides, oxytocin treatment significantly improved the histological 
structure of the aorta detected by a significantly decreased expression of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) in a rat model of 
atherosclerosis.45  
The ability of oxytocin to counteract oxidative stress and reduce 
inflammation underscores the importance of oxytocin in many other cardiovascular 
pathophysiological conditions including atherosclerosis.45  
In myocardial infarction (MI), oxytocin has displayed a cardioprotective 
role. In a rabbit model of MI, oxytocin has been reported to protect against 
myocardial injury through the phosphorylation of kinases such as extracellular 
signal-regulated kinase (ERK), signal transducer and activator of transcription 3 
(STAT3), Akt, MMP and eNOS. Akt, ERK, and STAT3 are all pro-survival signals 
that may play an important role in cardiac ischemic preconditioning, thereby 
reducing ischemic damage to the heart.46  
In a rat model, oxytocin has mediated improvement in myocardial injury 
immediately after heart transplant by downregulating the chemotactic agents: 
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chemokine (C-X-C motif) ligand 1 (CXCL1), and macrophage inflammatory 
protein-2 alpha (MIP-2α)/Chemokine (C-X-C motif) ligand 2 (CXCL2). These 
agents are known to recruit neutrophils in the myocardium.47  In ovariectomized 
rats, the oxytocin pre-treatment protected from injury after MI by reducing 
plasminogen activator inhibitor-1 (PAI-1) concentrations.48  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
1.4. Role of angiotensin II (Ang II) in the CVS and its pathophysiology 
 
The emergence of the different functional aspects of oxytocin in the CVS 
continues to fascinate the scientific community. It is noteworthy that a central 
component of the CVS is the renin-angiotensin-aldosterone system (RAAS). The 
principal effector hormone of the RAAS is Ang II. It is an octapeptide, and an 
enzyme known as the angiotensin converting enzyme (ACE) catalyzes the 
conversion of angiotensin I (Ang I) into Ang II. Ang II affects all major organs of 
the body – heart, kidney, vasculature, and brain. In particular, Ang II has a diverse 
range of effects in the CVS.49  
Ang II causes vasoconstriction and maintains the blood pressure in the 
normal physiological conditions.50 Besides, it is also involved in many CVD such 
as atherosclerosis, congestive heart failure, diabetes, hypertension, inflammation 
and MI.51 It mainly binds to the angiotensin type 1 receptors (AT-1R) in the CVS 
and execute its actions via stimulation of the mitogen-activated protein kinases 
(MAPKs) pathways, PI3K/Akt/mammalian target of rapamycin (mTOR) pathways, 
and Rho kinase pathways.51,52 These signaling pathways and kinases are involved 
in Ang II-mediated contraction of VSMCs, hypertrophy, hyperplasia, endothelial 
dysfunction, vascular diseases, and their progression.53,54  
In pathological conditions such as hypertension and atherosclerosis, Ang II 
significantly impacts the repair and the remodeling of VSMCs in large blood 
vessels. It phosphorylates ERK1/2 and p38 MAPKs, thereby inducing expression 
of immediate early response genes: c-fos, c-myc and c-jun. Thus, Ang II mediates 
cell proliferation, migration, and hypertrophy in VSMCs.55,56 Besides, Ang II 
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causes the migration of VSMCs on receiving pathogenic stimuli by inducing 
STAT3 phosphorylation, and its subsequent nuclear translocation induces 
expression of the genes specific to cell proliferation, hypertrophy, and migration of 
VSMCs.57,58   
Ang II is also a known pro-oxidant.59 It causes production of reactive 
oxygen species (ROS) via the activation of NADPH oxidase, leading to increased 
oxidative stress. The Ang II-induced oxidative stress causes endothelial  
dysfunction and vascular inflammation by the activation of NF-kB, a redox-
sensitive nuclear transcription factor, and upregulation of adhesion molecules: 
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1), selectin, integrin, cytokines [IL-6, IL-12, IL-1, tumor necrosis factor-
alpha (TNF-α)], and chemokines (MCP-1, IL-8, osteopontin).60 It has been reported 
that glutathione s-transferase (GST) attenuates Ang II-induced STAT3 
phosphorylation and exerts a protective effect in VSMCs. GST conjugates the 
reduced form of glutathione (a cellular antioxidant) with reactive oxygen species 
(ROS) and detoxifies it.58  
Ang II has been shown to influence fibrinolysis activity.51,61 A key regulator 
of endogenous fibrinolytic activity and thrombolysis resistance is PAI-1. It 
physiologically inhibits plasminogen activation.  In response to vascular injury, 
PAI inhibits cellular migration and matrix degradation.62,63 Ang II infusion in 
normotensive and hypertensive patients showed increased circulating levels of 
PAI-1.64 In a rat model, Ang II via interactions with AT1R, increased the expression 
of PAI in VSMCs from isolated aorta, thereby influencing endogenous fibrinolytic 
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activity.65,66 PAI-1 is an important cardiovascular risk factor in atherosclerosis. 
Besides, an increased PAI-1 also manifests amongst the metabolic abnormalities 
associated with hypertension.67,68    
The antagonizing of Ang II effects by employing ACE inhibitors is a well-
established therapy commonly used in CVD. The ACE inhibitors are in clinical 
practice in the management of hypertension, coronary artery disease, heart failure, 
diabetes, and chronic kidney diseases.69 They are one of the few treatment options 
that we have currently for these diseases.  However, there are many side effects 
attributed to ACE inhibitors’ use in CVD.70 Despite the long clinical use of these 
agents, treatment of hypertension has not been all that successful. The need of the 
present times is to identify alternative targets and unveil better therapeutic 
approaches to better treat CVD.  
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1.5. The gap in the literature, research hypotheses, and study aims  
As mentioned earlier in the background, oxytocin has demonstrated 
cardioprotective effects in various in-vitro and in-vivo studies performed on 
vascular endothelial cells and cardiomyocytes.23 However, there is a gap in the 
literature. Even though previous researches have established that oxytocin receptors 
are found in VSMCs, interestingly, oxytocin effects in VSMCs have not been fully 
characterized. On the contrary, the effects of Ang II, another crucial cardiovascular 
peptide, have been well established in VSMCs and the CVS to a significant extent. 
As stated before, Ang II is known to induce vascular oxidative stress, phosphorylate 
ERKs, PI3Ks, and Rho kinases, leading to marked VSMCs proliferation, 
hypertrophy, hyper-contraction, inflammation, and increased oxidative stress.51 
Therefore, to fill in the gap regarding the lack of research on the effect of oxytocin 
on VSMCs and its interaction with Ang II, the present study was conducted.  
In the context of the protective effects of oxytocin in the cardiovascular 
system and from the results of the preliminary experiments, the following research 
hypotheses were proposed:    
1.5.1. Hypothesis 1 
By its ability to reduce proliferation, inflammation, oxidative stress, and 
vasocontraction pathway, oxytocin antagonizes Ang II-induced proliferation, 
inflammation, and oxidative stress and dysregulates Ang II-induced 
vasocontraction pathway in primary Wistar aortic VSMCs. 
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1.5.2. Hypothesis 2 
Oxytocin signaling pathways in aortic VSMCs are altered in hypertensive 
conditions.  
The hypotheses mentioned above were tested by pursuing the following 
specific aims:  
1.5.3. Specific Aim 1 
To characterize the effect of oxytocin on proliferation, inflammation, 
oxidative stress and vasocontraction in primary aortic VSMCs obtained from 
normotensive Wistar rats. The VSMCs proliferation was determined by 
employing cell proliferation, cell viability, and cell growth assays. To further 
understand the mechanism of how oxytocin reduces aortic VSMC proliferation, the 
two critical signaling pathways involved in VSMCs proliferation were investigated: 
ERK1/2 pathway and PI3K/Akt pathway. The oxidative stress was measured as the 
function of the ROS levels, and inflammation was assessed by measuring IL-6 
levels. The effect of oxytocin on vasocontraction was assessed indirectly by 
investigating oxytocin’s effect on the Rho-kinase pathway [Rho-associated coiled-
coil kinase-1 (ROCK-1) and -2 (ROCK-2)] involved in the vasocontraction of 
VSMCs.  
1.5.4. Specific Aim 2 
To determine of the interaction between oxytocin and Ang II in 
primary aortic VSMCs obtained from normotensive Wistar rats. The 
interaction of oxytocin with Ang II was investigated by studying the effect of 
pretreatment of oxytocin on Ang II-induced cell proliferation and proliferation 
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pathways (the ERK1/2 pathway and PI3K/Akt pathway), inflammation, oxidative 
stress, and the Rho-kinase pathway in aortic VSMCs obtained from normotensive 
Wistar rats. 
1.5.5. Specific Aim 3 
To characterize the effect of oxytocin on proliferation, inflammation, 
oxidative stress and vasocontraction in primary aortic VSMCs obtained from 
spontaneously hypertensive rats (SHRs). The effects of oxytocin on VSMC 
proliferation (ERK1/2, PI3K, Akt), oxidative stress (ROS), inflammation (IL-6) 
and vasocontraction (ROCK-1 and ROCK-2) were characterized on VSMCs 
isolated from SHRs. The comparison was made, and the analysis was carried out 
between the effects of oxytocin on its own and its pre-treatment with Ang II in 
aortic VSMCs Wistar rats and SHRs.  
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1.6. Role of VSMCs in the CVS and its pathophysiology 
VSMCs constitute tunica media, the middle layer of blood vessels, with 
endothelial cells and connective tissues making tunica intima and tunica externa, 
respectively (Figure 1). VSMCs are the stromal cells which perform a variety of 
functions and play a crucial role in the CVS.71  
 
Figure 1. Histology of a blood vessel. VSMCs form the middle layer (tunica media) 
of a blood vessel. Adapted from Muscle cell and Tissue, Intech Open. 2018;230. 
VSMCs maintain the contractile tone of the arterial wall via intracellular 
calcium release causing the myosin-actin interactions, regulating blood pressure 
and flow to meet the metabolic demands of the body. They secrete molecules that 
comprise the extracellular matrix (ECM) which enable arteries to withstand the 
high pressure of the circulating blood.72   
In normal physiological conditions, VSMCs remain quiescent and adhere 
to their phenotype essential in regulating contractile tone of arteries. Molecules 
such as laminin, perlecan, heparan sulfate proteoglycan (HSPG), and collagen type 
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IV, composing the basement of VSMCs are attributed to keeping VSMCs 
quiescent.73  
However, in the event(s) of pathological or pathophysiological condition(s) 
such as arterial injury, an excessive overload of lipids, pressure-related stress, 
hyperglycemic conditions, VSMCs undergo a variety of adaptations and 
remodeling. They become active and transition into mitogen-responsive 
phenotypes in the presence of fibronectin.74 They start interacting with the 
intracellular signaling pathways, involving the ERKs, PI3Ks, and Rho kinases.75,76 
The activation of these pathways leads to hypercontraction, proliferation 
and migration of VSMCs often leading to the thickening of the tunica intima, 
hyperplasia, precipitating aneurysm, hemorrhage, and restenosis, and worsening 
the other cardiovascular diseases including atherosclerosis, hypertension and 
increasing the complications post-vascular surgical procedures. 72,77 
The activated phenotype of VSMCs also produce ROS which play a role in 
the vascular pathology through its redox potential.78, The principal enzymatic 
source of the production of ROS in VSMCs is NOX. In hypertension, vasoactive 
agents such as Ang II activate the NOX, leading to the increased production of 
ROS, ultimately resulting in increased oxidative stress and increased expression of 
inflammatory mediators such as cytokines (example IL-6).79 
The functions of VSMCs in physiology and their role in the 
pathophysiology of the CVS are crucial and render them a potential target of 
therapeutic approaches in cardiovascular research.  Anti-proliferative therapies 
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such as rapamycin and paclitaxel targeting VSMCs’ hyperplasia in animal models 
have failed to show similar effects in patients.80   
Therefore, there is a need to develop therapies that are not only targeting 
the most notable pathophysiological features of CVD such as proliferation, 
migration, hypercontraction, oxidative stress, and inflammation of VSMCs but are 
also maintaining contractile phenotype of VSMCs. 
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1.7. Study significance  
It was envisioned that this study would be a step towards the long-term goal 
of identifying oxytocin as an alternative therapeutic target in the treatment of CVD. 
The present study was an attempt to determine the potential role of oxytocin with 
regards to its cardioprotective effects against Ang II-induced deleterious effects. 
Previous studies have established that at sustained high levels, Ang II acts as the 
‘aggressor’ in the cardiovascular system.53  On the contrary, pre-clinical evidence 
have, so far, indicated a ‘protective’ role of oxytocin in the cardiovascular system.23  
This in vitro study was the first of its kind to investigate and understand the 
protective effects of oxytocin against the harmful actions of Ang II, with relation 
to VSMCs, on the cardiovascular system. The study findings contributed towards a 
better understanding of oxytocin actions on blood vessels (VSMCs), and 
identification of secondary messenger pathways involved in this oxytocin effect.  
The research findings demonstrated that oxytocin blocked Ang II-mediated 
hyperproliferation of VSMCs and proliferation and vasocontraction pathways in 
VSMCs from SHRs, thus providing evidence of oxytocin’s vital role in 
cardiovascular pathophysiology and it shows the potential therapeutic benefits it 
might have in the management of hypertension. The study generated significant 
pre-clinical evidence regarding the beneficial effects of oxytocin in a hypertensive 
rat model, laying a platform foundation for future mechanistic in vivo studies and 
pilot clinical studies. 
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1.8. Barriers, issues, limitations, and delimitations  
The present study involved the use of primary rat aortic VSMCs. The 
advantage of using laboratory-cultured primary VSMCs is that they retain many 
cellular functions and markers quite similar to the ones observed in vivo. Whereas, 
commercially available VSMCs cell lines may differ phenotypically and 
genetically from their origin. However, there were specific challenges that occurred 
during the course of this study. 
Firstly, the procurement of significant yield of high purity VSMCs was 
challenging. The techniques utilized in this research to harvest primary cells was 
the ‘explant method.’81 Although this technique is cost-effective and routinely 
applied to obtain a high yield of VSMCs, its major drawback is the purity of 
primary cells obtained. That VSMCs are prone to natural contamination with 
intimal endothelial or adventitial fibroblasts, the VSMCs isolation protocol was 
optimized, and the cells were used from passages between 3-15 for maintaining the 
phenotypical uniformity and the purity of cells.81 The endothelial cells and 
fibroblast eventually die out by the time VSMCs underwent the third passage.  
Secondly, the effect of many cell passages was a challenge. For avoiding 
this, care was taken to make sure that all the experiments in both Wistar rats and 
SHRs were conducted using the same passage number. For example, if a cell 
proliferation experiment was carried out with VSMCs in the passage 4 in Wistar 
rats, the VSMCs from the similar passage number was utilized to perform a cell 
proliferation experiment in SHRs.  
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Lastly, the magnitude of the response of cells to the treatments obtained 
from one rat was different from the other rat. Therefore, to reduce the variation in 
data and increase the reproducibility of the data, the experiments were repeated 
numerous times using multiple rats to increase the number of replicates. However, 
the repetition of all the experiments was tough, time-consuming and challenging.   
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Chapter 2: Literature Review 
2.1. MAPK/ERK1/2 pathway in the CVS  
MAPKs belong to the serine-threonine specific class of kinases. They 
constitute a signal transduction pathway known as the MAPK pathway. The 
MAPK pathway is a cascade that converts signals from external mechanical 
stimuli and growth factors into signal transduction, leading to the regulation of 
genes involved primarily in protein synthesis.82 It occurs in sequential 
phosphorylation of the three core protein kinases from cytosol: mitogen-
activated protein kinase kinase kinase (MAPKKK), mitogen-activated protein 
kinase kinase (MAPKK), and mitogen-activated protein kinase (MAPK).83 A 
schematic representation of the activation of MAPK signaling pathway is 
shown in the Figure 2.1.84 
It is the MAPKs which carry out intracellular signal transduction 
through three distinct pathways. The first one is through the phosphorylation 
and activation of extracellular signal-regulated kinase (ERK), which has two 
isoforms: ERK1 and ERK2. The phosphorylated ERK1 and 2 (active form) lead 
to the phosphorylation and activation of various regulatory proteins in the 
cytosol as well as in the nucleus, which is critical for protein synthesis and cell 
survival.83  
The second MAPK pathway involves the phosphorylation and 
activation of stress-activated protein kinases (SAPK). This cascade of MAPK 
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is triggered in response to external stimuli such as ultraviolet rays, stress (heat 
shock), altered osmolarity, hypoxia, and exposure to reactive oxygen species.85  
The triggering of the second MAPK pathway causes the 
phosphorylation and activation of c-Jun N-terminal kinases (JNK) which is 
critical in proliferation, apoptosis, inflammation, and in response to 
deoxyribonucleic acid (DNA) damage.86–88  
 
 
Figure 2.1. Activation of mitogen-activated protein kinase (MAPK) signaling 
pathway in the cardiovascular system. Adapted from Physiol Rev. 
2010;90(4);1508. GPCR indicates G-protein coupled receptor; RTK, receptor 
tyrosine kinase; ERK, extracellular signal-regulated kinase; JNK, c-Jun N-
terminal kinase; RAF, rapidly accelerated fibrosarcoma ; MLK, mixed-lineage 
kinases; ASK-1, apoptosis signal-regulating kinase 1; TAK-1, transforming growth 
factor-β-activated kinase 1; MAPKKK/MEKK, mitogen-activated protein kinase 
kinase kinase; MAPKK/MEK/MKK, mitogen-activated protein kinase kinase; 
MAPK, mitogen-activated protein kinase.  
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The third pathway consists of p38 MAPK. Like the JNK pathway, this 
pathway can also be triggered in response to stress induced by a change in 
cellular osmolarity, exposure to free radicals, heat shock, and inflammation.89 
The p38 MAPK signaling is involved in cellular processes such as proliferation, 
differentiation, migration and immune response.90–92  
The ERK1/2 pathway is one of the first MAPK pathways to be 
characterized in mammals. In VSMCs, the stimulation of AT1R by Ang II, 
causes the phosphorylation of ERK1/2. The phosphorylated ERK1/2 (active 
form) then translocate to the nucleus, and subsequently result in the 
phosphorylation of transcription factors including c-Fos, c-Jun, and activator 
protein-1 transcription factors, ultimately carrying out cell synthesis, 
proliferation, differentiation and migration of VSMCs. In addition, ERK1/2 
targets the ribosomal S6 kinase (RSK). Once phosphorylated, the activated 
ERK1/2, in turn, phosphorylates RSK via the transfer of ribonucleic acid 
(RNA)-binding factor. This is a key step in the initiation of translation, leading 
to protein synthesis, regulation, and progression of the cell cycle of VSMCs.93–
95  
Phosphorylated ERK1/2 is also known to be involved in the regulation 
of vascular tone of VSMCs. It has been established that h-Caldesmon (h-CD) 
is a downstream target of the phosphorylated ERK1/2.96 An h-CD is a high 
molecular weight contractile regulatory protein involved in the contractile 
responses of vascular walls.97 
Numerous studies have implicated ERK1/2 signaling in the 
pathophysiology of CVDs such as hypertension.98,99 In an in vivo study, 
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increased activity of ERK1/2 was reported after transient elevation of blood 
pressure with Ang II in femoral arteries and rat aortas.100  
The pharmacological inhibition of ERK1/2 signaling was shown to 
improve endothelial function, and significantly reduced Ang II-induced  
contraction of mesenteric resistance arteries in spontaneously hypertensive rats 
(SHRs).100  In transgenic mice models, ERK1/2 signaling was shown to 
stimulate hypertrophy in cardiomyocytes via phosphorylation of factors such 
as elk-1, necessary for the activation of the c-Fos gene.101 
Oxytocin was demonstrated to exert differential effects on the ERK1/2 
signaling pathway. For example, oxytocin-induced phosphorylation of ERK1/2 
increased the proliferation of cardiomyocytes and vascular endothelial 
cells.40,102 In other instances, such as in human embryonic kidney (HEK293) 
cells, oxytocin exhibited proliferative as well as anti-proliferative actions. The 
dual action of oxytocin on the proliferation of HEK293 cells was determined 
by the location of the oxytocin receptors. Oxytocin reduced the phosphorylation 
of ERK1/2, and as a result, inhibited cell proliferation when the oxytocin 
receptors were present outside the caveolin-1-enriched microdomains. And, 
oxytocin augmented phosphorylation of ERK1/2, resulting in stimulated cell 
proliferation when the oxytocin receptors were inside caveolin-1-enriched 
microdomains.103  
It is imperative to understand the role of caveolins. Caveolins are 
scaffolding proteins involved in the regulation of GPCR signaling. They 
facilitate GPCR regulation via scaffolding and partitioning of different 
receptors, G-proteins trafficking, and signaling.104 
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As stated earlier, oxytocin’s effect on cell proliferation and ERK1/2 
activity has been studied in cardiomyocytes and vascular endothelial cells. 
However, little to no information is available on the effects of oxytocin on 
ERK1/2 signaling pathway and on its effects on the proliferation of VSMCs.  
The present study characterized the effect of oxytocin and its impact on 
Ang II (known for stimulating cell proliferation via the ERK1/2 signaling55) on 
cell proliferation in aortic VSMCs from normotensive rats (Wistar rats). 
Further, oxytocin’s impact on aortic VSMCs proliferation and on ERK1/2 
signaling, and oxytocin’s effect on Ang II-mediated cell proliferation and Ang 
II-stimulated ERK1/2 signaling were also investigated in aortic VSMCs from 
SHRs.  
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2.2. PI3K/Akt signaling in the CVS  
The phosphoinositide-3-kinase (PI3K)/Akt pathway is an essential 
intracellular signaling transduction pathway involved in the regulation of the 
CVS.105 It is crucial in the proliferation of VSMCs,106 control of the vascular 
myogenic tone, and inflammation.107,108 Over the last decade, the PI3K/Akt 
signaling has been implicated in various pathological conditions of the CVS 109 
such as cardiac hypertrophy (a critical risk factor of heart failure),110 and 
hypertension. 107  
Phosphoinositide-3-kinases (PI3Ks) are intracellular enzymes which 
catalyze the phosphorylation of phosphatidylinositol (PI). PI are lipids 
(phosphatidyl glycerides).111 PI3Ks phosphorylate PI at the 3-hydroxyl group of the 
inositol ring. Based on the products of the catalysis, PI3Ks have been grouped into 
three classes: Class I PI3Ks, which form phosphatidylinositol-3,4-biphosphate (PI-
3,4-P2); Class II PI3Ks, which form phosphatidylinositol-3-phosphate (PI-3-P), PI-
3,4-P2, and phosphatidylinositol triphosphate (PIP3); and Class III PI3Ks, which 
generate PI-3-P. All classes of PI3Ks are present in cardiomyocytes, vascular 
endothelial cells, and VSMCs.112 
A general structure of a PI3K includes three domains: C-2 domain, helical 
domain, and a catalytic domain. The C-2 domain binds to the membranes, the 
helical domain serves regulatory functions, and the catalytic domain carries out the 
kinase activity of PI3Ks. Based on the regulatory domain, the Class I PI3Ks are 
further subdivided into two categories: Class I A PI3Ks which bind to receptor 
tyrosine kinases (RTKs), and Class I B PI3Ks which bind to GPCRs. The Class I 
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A PI3Ks exist as heterodimers of different isoforms of α, β, and δ of the p110 
catalytic domain. Whereas, the Class I B PI3Ks exist as heterodimers of p110𝛾 and 
p101 catalytic domains.113 All Class I PI3Ks are significant in the CVS and its 
pathophysiology.114 Their actions are antagonized by phosphatase and tensin 
homolog deleted on chromosome ten (PTEN).115  
Akt is a serine-threonine kinase and also known as protein kinase B (PKB). 
Akt is a downstream signaling target of PI3Ks. There are three isoforms of Akt: 
Akt 1 (PKBα), Akt 2 (PKBβ), Akt 3 (PKB𝛾). All forms of Akt are present 
throughout blood vessels, heart, lungs, and brain.116 The stimulation of GPCRs by 
peptides such as Ang II or growth factors results in the activation of PI3Ks. The 
activated PI3Ks lead to the formation of PI-3,4-P2 and PIP3, which in turn 
phosphorylate Akt (active form).117  
The phosphorylated form of Akt triggers downstream signaling via the 
phosphorylation of downstream signaling molecules such as mTOR. mTOR is a 
serine-threonine kinase. The phosphorylation of mTOR by phosphorylated Akt is 
vital to protein synthesis by the PI3K/Akt signaling pathway. mTOR has two 
isoforms: mTORC1 and mTORC2. The phosphorylated mTORC1 stimulates cell 
proliferation via the phosphorylation of p70S6 kinase, eukaryotic initiation factor 
4E (elF4E), and 4E-binding protein 1 (4E-BP1). The activated p70S6 kinase 
phosphorylates and activates S6 ribosomal protein. The activated elF4E acts as 
translator initiator. It phosphorylates 4E-BP1. A phosphorylated 4E-BP1 is 
required for protein translation. The phosphorylated mTORC2 stimulates the 
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phosphorylation of Akt and is involved in the autoregulation of mTOR.118 The 
PI3K/Akt signaling pathway is illustrated in the following figure (Figure 2.2): 
 
Figure 2.2. The PI3K/Akt signaling pathway in the cardiovascular system. A 
schematic representation of the PI3K/Akt signaling pathway in cardiomyocytes, 
vascular endothelial cells, and vascular smooth muscle cells (VSMCs). Adapted 
from Curr Pharm Des. 2011;17(18):1819. FKBP indicates FK506-binding protein; 
GLUT, glucose transporter; GPCR, G-protein coupled receptor; GSK, glycogen 
synthase kinase; IGF, insulin-like growth factor; PDK, phosphoinositide-
dependent kinase; PI3K, phosphoinositide 3-kinase; PtdIns, phosphatidylinositol; 
PTEN, phosphatase and tensin homolog deleted on chromosome ten; p70S6K, 
p70S6 kinase; TSC, tuberous sclerosis complex; eIF4, eukaryotic initiation factor 
4.  
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The implication of PI3K/Akt signaling cascade in many cardiovascular 
pathophysiological conditions has been reported by previous studies.119 In 
hypertension, it has been shown that the PI3K/Akt pathway alters vascular function 
mainly by increasing the myogenic tone of resistance arteries and by enhancing the 
constricting activity of VSMCs. A myogenic tone can be described as the functional 
behavior of resistance arteries in response to perfusion pressure.107 On the 
activation of GPCRs by cardiovascular peptides such as Ang II, the PI3K/Akt 
signaling results in an increased intracellular level of calcium via the L-type 
voltage-gated calcium channel (L-VGCC).120,121 
It is noteworthy that L-VGCC dysfunction is an important characteristic 
feature of CVDs such as hypertension and cardiac arrhythmia, and its targeting by 
the compounds known as calcium channel blockers has been a long-standing 
clinical practice in the management of hypertension and arrhythmia.122,123  
Several studies have documented the relevance of PI3Ks in 
hypertension.107,124,125 A study conducted using a transgenic mice model revealed 
that the chronic administration of Ang II did not produce hypertension in mice 
lacking PI3K𝛾. The lack of PI3K𝛾 not only reduced the L-VGCC-mediated 
intracellular calcium reflux but also decreased VSMCs contractility when 
stimulated with Ang II.121  
Another relevant aspect of the PI3K/Akt signaling in the physiology and 
pathophysiology of the CVS is its role in cardiac hypertrophy.110 It is pertinent to 
highlight that cardiac hypertrophy can be both beneficial and harmful. Beneficial 
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cardiac hypertrophy is called ‘physiological cardiac hypertrophy,’ whereas the 
harmful hypertrophy is known as ‘pathological cardiac hypertrophy.’126  
Physiological cardiac hypertrophy is usually seen and is associated with 
natural post-natal development, pregnancy, and exercise. Thus, this is an adaptive 
growth of cardiomyocytes. The characteristic features of physiological cardiac 
hypertrophy are the preservation of contractile functions of the sarcomere (the 
contractile unit of cardiomyocytes) and a lack of interstitial fibrosis.127,128 On the 
other hand, pathological cardiac hypertrophy is ‘maladaptive hypertrophy.’ It is 
characterized by increased cell volume of cardiomyocytes, the new formation of 
sarcomeres, interstitial fibrosis and inflammation.129  
Several studies have demonstrated PI3K/Akt-mediated cell signaling in 
both physiological and pathological cardiac hypertrophy.130,131 In a study 
employing a transgenic mice model, mice with dominant negative PI3K showed a 
significant reduction in exercise-induced physiological cardiac hypertrophy 
compared to wild type mice (control).132 In another study employing a similar 
transgenic mice model, mice deficient in PI3K showed protection against 
isoproterenol-induced pathological cardiac hypertrophy and thus protection from 
heart failure.133   
It is thought-provoking that oxytocin is being touted as a ‘cardioprotective’ 
hormone,23 yet it has not been investigated for its effects on PI3K/Akt signaling in 
cardiomyocytes, vascular endothelial cells, and VSMCs. To partially address this 
gap in the scientific literature, the present study used an in vitro model to investigate 
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the effects of oxytocin alone and its pre-treatment with Ang II on the PI3K/Akt 
signaling pathway in VSMCs in both normotensive and hypertensive conditions.   
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2.3. Rho kinases (ROCK-1 and ROCK-2) signaling in the CVS 
Rho-associated coiled-coil kinases (ROCK) -1 and -2 belong to the 
serine/threonine category of kinases. They are the targets of small GTPases (that 
bind and hydrolyze the guanosine triphosphates) : Rho A, Rho B, and Rho C.134 
These GTPases are found abundantly in VSMCs and are rapidly activated by 
vasoconstricting peptides such as Ang II.135 Both ROCK-1 and ROCK-2 are 
involved in the organization and remodeling of actin cytoskeleton, extracellular 
matrix, and in the contraction of VSMCs.136,137 They are also critical in cell 
adhesion, motility, and proliferation.138,139 Pre-clinical research and clinical 
evidence have implicated ROCK signaling in the pathogenesis of various diseases 
of the CVS including angina pectoris, hypertension, pulmonary arterial 
hypertension, heart failure, and stroke.140–144   
The structural features of ROCKs include phosphorylation and cleavage 
sites. The structure of both ROCK-1 and ROCK-2 has an N-terminal containing a 
kinase domain, coiled-coil region, Rho-binding domain (RBD), and a C-terminal 
comprising of a PH-domain containing a cysteine-rich C1 domain. An RBD 
possesses three zones known as a ‘switch’: Switch I, Switch II, and Switch III, with 
each having a strong binding affinity for Rho A, Rho B, and Rho C, respectively. 
The C1-domain of C-terminal is involved in the autoinhibition of ROCKs. The two 
isoforms of ROCK have the highest homology in their kinase domain (about 92 
percent) and the least homology in their coiled-coil domain (about 55 percent). 
145,146   
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The activation of ROCKs depends on the catalytic activity of both the N-
terminal and C-terminal regions. The ROCKs form homodimers, and dimerization 
depends upon kinase domains, an extension of N-terminals, and coiled-coil regions. 
Following an interaction of RBD with guanosine-5'-triphosphate (GTP)-loaded 
Rho proteins (Rho-A, -B, -C), the phosphorylation of the hydrophobic motif near 
the C-terminal region occurs, causing the kinase domain to undergo conformational 
changes from a closed (inactive) to an open (active) state.147,148 The active state of 
ROCKs is essential in carrying out the downstream cell signaling in the following 
three different ways: 
First, the activated form of ROCKs directly augments the phosphorylation 
of myosin phosphatase target subunit-1 (MYPT-1). Second, it stimulates the 
phosphorylation of zipper-interacting protein kinase (ZIPK) which in turn 
phosphorylates MYPT-1.149,150 Third, activated ROCKs phosphorylate C-kinases 
potentiated protein phosphatase 1 inhibitor -17 (CPI-17). A CPI-17 is a direct 
inhibitor of MYPT-1.151,152 
The phosphorylation of MYPT-1 prevents the binding of myosin light chain 
phosphatases (MLCP) with myosin light chain (MLC), thus boosting myosin light 
chain kinase (MLCK)-induced phosphorylation of actin leading to sustained 
contraction of VSMCs. The stimulation of the ROCK signaling results in decreased 
activation of MLCP, and increased contraction of VSMCs which ultimately leads 
to elevated blood pressure.151,152 The ROCK-mediated contraction of VSMCs is 
depicted in the  Figure 2.3. 
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In animal models of hypertension, an increased ROCK signaling has been 
observed which is further enhanced by the intake of a high-salt diet.153 An increased 
ROCK signaling in hypertension has been attributed to the dysregulation of Rho 
guanine nucleotide exchange factors (Rho-GEFs).154,155 In clinical studies, an 
elevated phosphorylation level of MYPT-1 has been reported in patients diagnosed 
with essential hypertension. Ang II-induced hypertension and cardiac hypertrophy 
have also been linked with hyper-ROCKs signaling.156,157  
In samples of heart-tissues obtained from patients with heart failure, 
truncated ROCKs have been found. A cleavage of C-terminal of ROCKs by the 
activation of pro-apoptotic enzymes such as caspases abolishes the autoinhibitory 
capability of ROCKs. This leads to constitutive activation of ROCKs, resulting in 
a sustained hypercontraction of blood vessels, fibrotic cardiomyopathy, and 
diastolic dysfunction.158  
These detrimental effects of truncated ROCKs were further supported by 
findings from a study carried out on cardiomyocytes from mice. The 
cardiomyocytes showed an increased expression of C-terminally nicked ROCK-1, 
and the histopathological findings presented the characteristics of fibrotic 
cardiomyopathy.159  
Over the years many compounds have been developed to target the ROCK 
signaling. A wide range of those compounds are often non-selective ROCK 
inhibitors (i.e., they are non-specific in their binding to the two ROCK isoforms). 
They compete for ATP in the kinase domain of ROCKs, thus acting as competitive 
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inhibitors.160 Fasudil is the only ROCK inhibitor that has been approved for clinical 
use for the treatment of various CVD including hypertension. 161 
Medical interventions employing fasudil in patients with hypertension, 
pulmonary arterial hypertension (PAH), angina pectoris, and heart failure have 
shown significant improvement in their medical conditions.142,162–164 The 
administration of fasudil in patients with congenital heart defects significantly 
reduced pulmonary artery pressure and pulmonary vascular resistance.165 
Evidence presenting an increased expression of ROCK-2 in the pulmonary 
arteries and pulmonary VSMCs in patients with idiopathic PAH has demonstrated 
the role of ROCK signaling in PAH.166 This was further strengthened by another 
study in which patients with PAH treated with fasudil resulted in acute pulmonary 
vasodilation.167 Chronic treatment with fasudil not only resulted in an improvement 
in pulmonary hypertension, but also reduced right ventricular hypertrophy, and 
prevented further remodeling in the pulmonary vasculature, along with significant 
decrease in VSMCs proliferation and hypercontraction, and lower endothelial 
dysfunction.168 
Previous studies have highlighted enhanced activity of ROCK in patients 
with acute and chronic heart failure.169 ROCK activity measured in terms of 
phosphorylated levels of total MYPT-1 in circulating leukocytes indicates the 
involvement of ROCK signaling in heart failure.170 Also, stimulated ROCK activity 
has been found in patients with myocardial infarction. A study in which fasudil was 
administered to patients with heart failure showed a significant decrease in vascular 
resistance in the forearm and a noticeable increase in forearm vasodilation.171 
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Another clinical study showed the beneficial effect of ROCK inhibitors in 
patients with angina. The treatment with fasudil resulted in reduced number of 
angina attacks per week in patients with stable angina and also increased their 
maximum exercise time.162,164  
The literature presented above underlines a crucial role of ROCK signaling 
pathway in physiological and pathophysiological conditions of CVS. Interestingly, 
oxytocin effect on ROCKs’ signaling has not been previously studied. The present 
study endeavored to investigate the effect oxytocin, and its impact on Ang II-
stimulated ROCK signaling in aortic VSMCs isolated from normotensive and 
hypertensive rats. 
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Figure 2.3. ROCK signaling pathway in the contraction of VSMCs. Adapted from 
Cardiovasc Res. 2018;114(4):534. Ang II indicates angiotensin II; ET-1, 
endothelin-1; GPCR, G-protein coupled receptor; RTK, receptor tyrosine kinase; 
GDP, guanosine diphosphate; GTP, guanosine triphosphate; GEF; guanine 
nucleotide exchange factor; GDI, guanine nucleotide dissociation inhibitor; PI3K, 
phosphoinositide-3-kinase; ROCK, rho-associated coiled-coil kinase; CPI-17, C-
kinases potentiated protein phosphatase 1 inhibitor-17; MLCP, myosin light chain 
phosphatases; ZIPK, zipper-interacting protein kinase; MLCK,  myosin light chain 
kinase. 
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2.4. Interleukin-6 in the CVS  
IL-6 is a cytokine which has pleiotropic effects.172 It is crucial in the CVS 
and its diseases.173 IL-6 is involved in the process of inflammation eliciting a 
myriad of immunological responses such as activation of thymocytes, stimulation 
and activation of T-cells and B-cell differentiation, differentiation and 
galvanization of macrophages, activation of natural killer (NK) cells, and 
stimulation of hepatocytes for the production of  inflammatory proteins such as the 
CRP.174–181 
IL-6 binds to the IL-6 receptor complex to induce the signal transduction. 
The IL-6 receptor complex is comprised of two membrane-bound glycoproteins: 
IL-6R and glycoprotein 130 (gp130). The IL-6R is an 80 Kilo dalton (KD) 
component which binds to a ligand. The gp130 is the signal transducing part of the 
IL-6 receptor complex with an atomic mass of 130 KD.182 Also, there is a soluble 
form of IL-6R (termed sIL-6R). The binding of IL-6 to the membrane-bound IL-
6R has been attributed to normal physiological immune responses of IL-6.183 
However, the binding of IL-6 to the soluble form (IL-6/sIL-6R) has been 
implicated in various pathological conditions,184,185 and has been clinically targeted 
by anti-IL-6 agents such as tocilizumab in severe cases of rheumatoid arthritis 
(RA).186,187,188, The IL-6 and its receptors both soluble and membrane-bound are 
present ubiquitously in all tissues, and abundantly in endothelial cells, VSMCs, and 
cardiomyocytes in particular.189–191 
The effects of IL-6 are both protective and detrimental.192 The duration of 
pathogenic stimuli or conditions determines these actions whether they would be 
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beneficial or deleterious.193,194 Short-term exposure to pathogenic stimuli results in 
protective effects of IL-6, whereas, a long-term exposure culminates in IL-6 driven 
harmful effects. A classic example of such consequences is the effects of IL-6 on 
the heart. IL-6 signaling in cardiomyocytes is cardioprotective in response to a 
short-term pathophysiological condition.194–196 However, when that 
pathophysiological condition remains for a long time, then the IL-6 signaling 
induces pathological cardiac hypertrophy, reduces cardiac contractility, ultimately 
leading to decreased cardiac function.193,197,198 Studies have highlighted IL-6 
mediated decreased cardiac contractility is associated with the JAK/STAT pathway 
and not the ERK pathway.199  
IL-6 has been implicated in the pathogenesis of coronary artery disease such 
as atherosclerosis.200 Previous studies have shown the IL-6-mediated upregulation 
of MMPs contribute to vascular remodeling and atherosclerotic plaque 
disruption.201 Many studies have demonstrated higher serum levels of IL-6 in 
patients diagnosed with and hospitalized for unstable angina.202  
The increased expression of myocardial IL-6 has been associated with the 
progression of heart disease.203,204–206 Studies have established elevated levels of 
IL-6 in patients with heart failure. More specifically, the concentrations of IL-6 
were directly related to the severity of left ventricular dysfunction and to the extent 
of the activation of the sympathetic system and RAAS.207  
Ang II, an effector hormone of the RAAS, is known to induce inflammation 
in VSMCs via stimulation of IL-6 signaling.208 Oxytocin, on the other hand, has 
shown anti-inflammatory actions via decreasing IL-6 signaling in vascular 
 43 
endothelial cells.34 The effects of oxytocin on inflammation in VSMCs have not 
been studied. Interestingly, its interaction with Ang II with regards to inflammation 
has also not been investigated. This study undertook the investigation of oxytocin’s 
effect on inflammation, and its interaction with Ang II in aortic VSMCs isolated 
from both normotensive rats and hypertensive rats. 
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2.5. Reactive oxygen species (ROS) in the CVS 
The ability of a living organism to convert oxygen into water through 
aerobic phosphorylation forms the core of the metabolism and production of 
energy. This very process of the metabolism of oxygen yields a byproduct known 
as ‘ROS.’209 These toxic species are extremely deleterious in nature. They cause 
severe damage to cellular DNA, RNA, lipids, and proteins, resulting in cellular 
apoptosis, necrosis, and inflammation.210–212 ROS play a significant role in the 
development of various pathological condition of the CVS including hypertension, 
cardiac hypertrophy, heart failure, diabetes, and atherosclerosis.78,213–216   
The primary source of ROS in cells in general, and in vascular endothelial 
cells, VSMCs, and cardiomyocytes, in particular, is an enzyme called ‘nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase.’217  
The catalytic component of NADPH oxidase is NOX. There are seven 
isoforms of NOX that have been identified, and five of them are found in human: 
NOX1, NOX2, NOX3, NOX4, and NOX5.79,218  
In cardiovascular cells, the generation of ROS is stimulated by 
neurohumoral vasoconstrictor peptides such as Ang II and Endothelin -1 (ET-1), 
and by norepinephrine (NE). It is well known that activation of AT-1R by Ang II, 
triggers the production of superoxide (O2−) by NADPH oxidase. Studies have 
demonstrated the production of O2−, by NADPH oxidase, resulting in vasopressor 
action in response to Ang II infusion in normotensive conditions (Wistar rats).219,220  
The reaction of NADPH oxidase-mediated  production of highly reactive 
superoxide is as follows: 
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2O2 + NADPH → 2·O2− + NAD(P)+ + H+ 
ET-1 is also known to induce ROS production via the activation of NADPH 
oxidase. ET-1 is a potent vasoconstrictor of the endothelium layer of blood vessels. 
There are two isoforms of ET receptors: ETA and ETB. The stimulation of ETA 
receptors induces ROS production via NADPH oxidase activation and results in 
vasoconstriction of endothelium. The ETB receptors have the opposite effect. They 
mediate vasorelaxation of endothelium.221  
ROS production in VSMCs and cardiomyocytes is also induced through the 
stimulation of alpha-1 adrenergic receptors (⍺1-ADR) by NE.222 The AT-1R, ET-
1, and ⍺1-ADR activate NADPH oxidase via interaction with G-proteins and thus 
generate ROS.223 
The other sources of ROS production are mitochondrial transport chain and 
eNOS uncoupling. In addition to ROS production by NADPH oxidase, ROS 
generated via NOS uncoupling and in mitochondria contribute to pathogenesis of 
the CVDs such as hypertension.224–227  
Under normal physiological conditions, the production of NO occurs via the 
coupling of L-arginine, in the presence of tetrahydrobiopterin (BH4) acting as a co-
factor, with eNOS. On stimulation by pathogenic stimuli, the levels of BH4 are 
reduced, leading to the uncoupling of eNOS. eNOS uncoupling results in the release 
of O2− from the oxygenase domain of eNOS. The increased production of O2− 
causes endothelial dysfunction and eventually precipitates vascular 
damage.224,228,229 
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The dysfunction of the mitochondrial respiratory chain due to vascular 
damage under pathophysiological conditions causes the transfer of electrons to 
molecular oxygen and bring about the formation of ROS such as O2− and hydrogen 
peroxide (H2O2).230–232 Increased mitochondrial ROS production damages 
mitochondrial antioxidants such as manganese superoxide dismutase (MnSOD), in 
turn, further initiating ROS production.233 The imbalance between ROS and 
antioxidants creates oxidative stress which is at the core of the pathogenesis of 
many CVD including hypertension.234  Redox signaling in the CVS is elucidated in 
the following figure: 
 
Figure 2.4. Redox signaling in the cardiovascular system. Adapted from J Biomed 
Sci.2013;20(69):4. AT-1 indicates angiotensin-1 receptors; α-AR, alpha-
adrenergic receptors; ET-1, endothelin-1; Ang II, angiotensin II; NE, 
norepinephrine; ROS, reactive oxygen species;  HO-1, heme oxygenase-1; Cat, 
catalase; AP-1, activator protein-1; NF-κB, nuclear factor kappa-light-chain-
enhancer of activated B cells; Nrf2, nuclear factor (erythroid-derived 2)-like 2; 
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MAPK, mitogen-activated protein kinase; PI3K, phosphoinositide-3-kinase; eNOS, 
endothelial nitric oxide synthase.  
 
Oxidative stress is known to induce activation of MAPKs (ERK1/2, JNK, 
and p-38 MAPK).235,236 Many studies have demonstrated that the induction of 
oxidative stress under pathophysiological conditions increases ROS production, 
which in turn activates various MAPKs, leading to activation of several 
transcription factors, for example, activator protein-1 (AP-1), NF-κB, and nuclear 
factor (erythroid-derived 2)-like 2 (Nrf2). These transcription factors are involved 
in hypertrophy of cardiomyocytes, endothelial cells and VSMCs, necrosis, 
apoptosis, and inflammation which are characteristic features of many CVD.237,238  
Previous research has shed light on the effect of oxytocin on oxidative stress 
in cardiomyocytes and vascular endothelial cells. However, the impact of oxytocin 
on oxidative stress in VSMCs has not been investigated thus far.  The present study 
examined oxytocin’s effect on oxidative stress in VSMCs via ROS measurement. 
Also, the interaction of oxytocin with Ang II, a known pro-oxidant, was studied in 
aortic VSMCs isolated from normotensive rats and hypertensive rats. 
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2.6. Summary  
The present study was conducted to address the gap in the literature regarding 
oxytocin’s effect on proliferation, proliferation pathways (ERK1/s and PI3K/Akt 
signaling pathways), and vasocontraction pathways (ROCK pathway) in VSMCs. 
The study also evaluated the impact of oxytocin on oxidative address (assessed by 
measuring ROS levels) and inflammation (analyzed by measuring IL-6 levels). To 
characterize these effects of oxytocin on VSMCs, this study employed aortic 
VSMCs isolated from Wistar rats (normotensive) and SHRs (hypertensive rats). 
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Chapter 3: Methodology 
3.1. Wistar rats and SHRs 
The present study employed aortic VSMCs isolated from Wistar rats and 
SHRs. Hypertension has been extensively studied pre-clinically in SHRs models, 
often using normotensive Wistar rats as control.239,240 The SHR is a well-
established genetic animal model of primary hypertension. The major advantage of 
the SHR model is the lack of inter-individual variation. Similar to the progression 
of hypertension in humans, SHRs have pre-hypertensive, developing and sustained 
hypertensive phases.241,239  
3.2. Isolation and culture of primary rat aortic VSMCs 
The study protocol was approved by the Nova Southeastern University 
Institutional Animal Care and Use Committee (NSU-IACUC).  Adult male Wistar 
rats (300-350g) and spontaneously hypertensive rats [(SHRs) 300-350g] were 
euthanized in a carbon dioxide (CO2) chamber as per the established guidelines. 
VSMCs were isolated and cultured as per the previously established explant 
method. 242  
The thoracic cavity was cut-open, the aorta was isolated, and placed in a 
sterile 100 mm Petri dish containing sterile phosphate-buffered saline (PBS). 
Sterile forceps were utilized to clean the aorta by removing adjacent fat layers and 
coagulated blood.  
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Once cleaned, the aorta was slit from top to bottom and cut into two pieces 
using sterile scissors. Each piece was then cut into a 1 mm strip and each strip was 
placed in a sterile 100 mm Petri dish containing Dulbecco’s Modification of Eagle’s 
Medium (DMEM) [(Corning Cellgro, NY)], supplemented with 10% (v/v) fetal 
bovine serum (FBS) glutamine (2 mM/L), streptomycin (100 1g/mL) and penicillin 
(VWR Life Science, GA). Petri dishes containing strips of freshly isolated aortic 
VSMCs were incubated at 37°C under standard humidified conditions (95% air and 
5% CO2) to allow VSMCs to grow out from strips onto the surface of petri-dish. 
Once VSMCs were outgrown, strips were removed, and VSMCs were allowed to 
grow in petri-dish. On reaching confluency, VSMCs were passaged in T-75 flasks 
so that enough number of cells were obtained to be able to conduct experiments 
using 100-mm Petri dishes, 6-well plates, 24-well plates, and 96-well plates.   
Before every experiment, VSMCs were subjected to trypsinization 
(Corning™ 0.25% Trypsin, Fischer Scientific, FL), counted using the 
Hemocytometer method, and were seeded in either 100 mm Petri dishes, 6-, 24-, or 
96-well plates depending on the experimental design. They were incubated at 37°C 
under previously described standard humidified conditions. After every 48 hours, 
the culture medium was replenished until VSMCs were about 90% confluent. Once 
confluent, VSMCs were washed with sterile PBS. VSMCs were made quiescent by 
replenishing with the serum-free media (SFM) for 24 hours before commencing 
with the experimental treatments. Cell passages from 3-15 were used for all 
experiments. All experiments were performed using the primary aortic VSMCs 
isolated from at least three rats or more. 81               
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3.3. VSMCs proliferation assessment by the Hemocytometer method 
3.3.1. The principle of the Hemocytometer method 
The Hemocytometer method is the most widely used technique used to 
determine the number of cells per unit volume of a suspension.243 It is a valuable 
research tool utilized to count cells in cell proliferation studies. It consists of a 
microscopic slide which is divided into two chambers. Each chamber has grid lines 
which make nine large squares. Each large square has an area of 1mm². The large 
squares are demarcated from each other by compact grid lines. The volume of the 
entire counting grid lines is 0.9 mm3 in each chamber. A glass cover-slip is placed 
over a chamber following which a suspension of cells is introduced into the 
chamber, and the cells are counted under the microscope. The cells are excluded 
from counting if they are touching the right-side and the bottom (Figure 3.1).  
 
Figure 3.1. Hemocytometer and the grid lines of a chamber in a hemocytometer 
microscopic slide. Adapted from https://www.hemocytometer.org/wp-
content/uploads/2013/06/hemocytometer-squares-to-count.png?w=551. 
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The hemocytometer technique employs the staining of cells with dyes such 
as trypan blue to identify live and dead cells. The cytoplasm of dead cells readily 
absorbs trypan blue and turns the appearance of dead cells to blue, making it easy 
to distinguish from live cells which have intact cytoplasm that does not take up 
trypan blue.243 
3.3.2. The procedure of the cell counting by the hemocytometer method 
Aortic VSMCs were seeded at 1×106 cells/well in 6-well plates and cultured 
as mentioned before. The cells were made quiescent by replacing serum-media with 
SFM, 24 hours prior to treatment. Post-treatment, the cells in each well were 
subjected to trypsinization and centrifuged at 1,500 rpm at 21°C for 10 minutes. 
The pellet was used to make the cell suspension with 1000 µL SFM, of which 100 
µL was pipetted out and transferred in an Eppendorf tube, and stained with 900 µL 
0.4% trypan blue. From the trypan blue-stained cell suspension, 10 µL was applied 
to the hemocytometer (Bright-Line Hemocytometer Set, Hausser Scientific, VWR 
Life Science, GA).  
The cover-slip was placed on top to allow the complete and gentle filling of 
both chambers of the hemocytometer. The grid lines of the hemocytometer were 
focused under a microscope with a 10X objective. The cells were counted in all the 
4 sets of large squares in the four corners of a chamber of the hemocytometer. The 
cells were excluded from counting when present on the right-hand boundary line or 
touching the bottom. The stained cells (dead cells), and unstained cells (live cells) 
were calculated and  the dilution factor was corrected as per the manufacturer’s 
protocol.243,244 
 53 
3.4. VSMCs viability determination by the MTT assay 
3.4.1. The principle of the MTT assay 
The MTT assay measures cell viability as a function of the mitochondrial 
activity. It is a colorimetric assay which relies on the reduction of the yellow 
colored 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by 
mitochondrial enzymes such NADPH oxidase and mitochondrial succinate, into an 
insoluble purple colored formazan. Organic solvents such as isopropanol and 
dimethyl sulfoxide (DMSO) are employed to solubilize the insoluble formazan, and 
the color change is measured as ‘optical density’ by a microplate reader. The optical 
density is a function of the mitochondrial activity. The higher optical density is 
indicative of higher mitochondrial activity, and the higher mitochondrial activity 
relates to the higher number of metabolically active cells.245 
3.4.2. The procedure of the MTT assay 
Aortic VSMCs were seeded at 1×104 cells/well in 96-well plates. The 
serum-media was replaced with SFM 24 hours prior to treatment. After carrying 
out the treatments with different groups, the SFM-containing the different 
treatments was aspirated, and 50 µL of MTT (ACROS Organics, NJ) was added to 
each 96-well. The 96-well plates were incubated at 37°C under standard humidified 
conditions for 45 minutes. Following the incubation, 100 µL of DMSO (Merc 
KGaA, Germany) was added to each well. The plates were read at 570 nm using a 
Biotek microplate reader (Biotek-Synergy H1 Hybrid Reader, VT).244  
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3.5. VSMCs growth measurement by the 3H-Thymidine incorporation assay 
3.5.1. The principle of the 3H-Thymidine incorporation assay 
The tritiated-Thymidine (3H-Thymidine) incorporation assay is considered 
as the gold-standard method to assess cell proliferation. This assay involves the 
direct measurement of cell proliferation by determining the synthesis of DNA. It 
employs the incorporation of the radioactive nucleoside tritiated (3H)-Thymidine 
into strands of chromosomal DNA of the actively dividing cells, during the mitotic 
phase of cell division. The radioactivity recovered from the cells is measured using 
a liquid scintillation counter as ‘counts per minute.’ The cell growth is assessed as 
the function counts per minute (cpm).  
A higher radioactivity count reflects higher cell growth. The cells 
undergoing active division resulting in higher cell growth will have more 
incorporation of 3H-Thymidine into their DNA strands and consequently will have 
higher radioactivity count than those that are undergoing lesser cell division. Hence, 
a higher reading of cpm reflects a higher cell growth, and a lower reading of cpm 
represents a lower cell growth.246   
3.5.2. The procedure of 3H-Thymidine incorporation assay 
Aortic VSMCs were seeded at 5×104 cells/well in 24-well plates, cultured 
and made quiescent, as described previously, 24 hours before starting the 
treatments. Quiescent cells were subjected to different treatments. After the first 24 
hours of treatment, 5 µL of 3H-thymidine (1 µCi/mL) [Thymidine (Methyl-3H), MP 
Biomedicals, LLC, CA], was added to each well. The plates were incubated at 37°C 
under standard humidified conditions for another 24 hours. In the end, the SFM 
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containing the treatments and 3H-thymidine was aspirated and washed with sterile 
cold-PBS (1,000 µL), and 500 µL of cold 10% trichloroacetic acid (TCA) was 
added to each well (this was done to precipitate out remnants of any radioactive 
material present outside cells). The 24-well plates were incubated overnight at 4°C.  
TCA was removed and 500 µL of 0.1 N sodium hydroxide (NaOH) − 2% 
sodium dodecyl sulfate [(SDS), NaOH-SDS] solution, previously maintained at 
room temperature (25°C), was added to each well and incubated for one hour at 
4°C. This step was carried out to cause alkaline lysis of cells resulting in protein 
denaturation (breaking of double-stranded DNA into a single-stranded DNA). SDS 
solubilizes the cell membrane, and NaOH disrupts the hydrogen bonding between 
the DNA bases and thus causing protein denaturation). 
The samples were collected in vials (20 mL). To each sample, 6 mL of 
liquid scintillation cocktail (Ultima Gold™, PerkinElmer Inc., CA) was added, and 
the samples were quantified by a PerkinElmer liquid scintillation counter (Tri-
Carb® 2810TR Liquid Scintillation Analyzer, PerkinElmer Inc., CA) as per the 
manufacturer’s protocol.247 
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3.6. VSMCs apoptosis and necrosis assessment by flow cytometery 
3.6.1. The principle of flow cytometery  
Flow cytometry is a technique commonly used in determining the 
characteristics of a single cell in suspension. It involves the measurement of the 
optical and fluorescence properties of cells including their nuclei and 
chromosomes. The technique relies on the use of fluorescent dyes, for example 
Annexin V and propidium iodide, that are specific in their binding to cellular 
components such as membrane phospholipids, DNA, and RNA. When cells in a 
suspension labeled with fluorescent dyes are passed through a light (laser) source, 
they rise to a higher energy state. When cells return to their resting state, they emit 
light energy at higher wavelengths. Multiple fluorochromes with similar excitation 
and different emission wavelengths enable the simultaneous determination of 
several properties of cells.248 
This technique is also valuable in cell sorting and is widely utilized in 
clinical hematology. When cells continue to move straight in the direction of the 
light source, the process is called ‘forward-scatter,’ and when they deviate from the 
direction of the light source, it is referred to as ‘side-scatter.’ The larger cells 
demonstrate forward-scatter whereas, the smaller cells show side-scatter.249 A flow 
diagram of a typical flow cytometer is shown in Figure 3.2. 
Flow cytometry has profound applications in cell viability studies. It is used 
in the detection of apoptosis and necrosis.250 Apoptosis is defined as ‘programmed 
cell death’ whereas necrosis is 'premature cell death' due to external factors 
including injury and acute infection.251 Apoptosis is characterized by specific 
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morphological changes such as loss of plasma membrane asymmetry, membrane 
blebbing, shrinking of cytoplasm and nucleus, and DNA cleavage in the 
nucleosome. One of the earliest features of a cell undergoing apoptosis is the loss 
of plasma membrane asymmetry. It is characterized by the translocation of 
phosphatidylserine (PS), a membrane phospholipid, from the inside to the outside 
of the plasma membrane (Figure 3.3).252 
A fluorochrome-labeled dye such as Annexin V binds to the PS of plasma 
membranes of an apoptotic cell and is detected by flow cytometer. Similarly, a 
fluorescent 7-amino actinomycin D dye (7-AAD) binds to broken fragments of 
DNA, the hallmark of necrosis, and thus enable the detection of cells undergoing 
necrosis by flow cytometer.253 
 
Figure 3.2. Flow cytometer. A flow diagram of a typical flow cytometer analyzing 
a single cell suspension. The sample containing a single suspension is projected 
with a sheath fluid. The argon-ion laser intersects the cells and causes the forward-
scatter and the side-scatter. The signals are detected, amplified, registered, and 
digitally analyzed in a computer. Adapted from Clin Chem. 2000;46(8 Pt 2):1222. 
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Figure 3.3. Presentation of markers for detection by healthy, apoptotic, late-
apoptotic and necrotic cells. Adapted from BD Biosci. 2011; 8:2. 
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3.6.2. The procedure of apoptosis and necrosis assessment using flow 
cytometer 
The present study utilized flow cytometry to study the effect of oxytocin on 
cell viability, apoptosis, and necrosis in aortic VSMCs from Wistar rats and SHRs. 
Aortic VSMCs were made quiescent 24 hours before the treatments. On the day of 
the assay after replenishing with the serum-free media (SFM), the treatment was 
performed, and cells were placed under standard incubation conditions for 24 hours. 
Post-treatment, the supernatant was removed. The cells were washed with 1,000 
µL of sterilized PBS (previously maintained at the room temperature). The PBS 
was then removed, and 400 µL of Accutase cell detachment solution (# A6964 
Sigma-Aldrich®, MO) was added to each well. The cells were then incubated under 
standard incubation conditions for about 5 -7 minutes. 
Following the incubation, 1,000 µL of fluorescent-activated cell sorting 
(FACS) buffer (# MB-086-0500 RocklandTM antibody & assays) was added to each 
well, and the samples were collected in Eppendorf tubes (1.5 mL). The samples 
were then subjected to centrifugation at 1,500 rpm at 21°C for 10 minutes. The 
supernatant was discarded via decantation (the vacuum was not used to remove the 
supernatant in an effort to prevent cell loss). The pellet was re-suspended with the 
cold PBS (1,000 µL), and samples were re-centrifuged at 10,000 rpm for 5 minutes.  
The supernatant was discarded, and the pellet was re-suspended with 100 
µL Annexin V binding buffer and vortexed. To each prepared sample, 4 µL of 
Annexin V and 4 µL of 7-AAD (# 640922, FITC Annexin V Apoptosis Detection 
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Kit with 7-AAD, BioLegend®, CA) was added, and gently mixed and allowed to 
stand for 30 minutes.  
Subsequently, 400 µL of binding buffer was added to each sample, and the 
samples were run at the medium speed (with the limit set at 10,000 events) using 
the BD LSRFortessa™ X-20 cell analyzer as per the manufacturer’s protocol.254 
The data generated represents four sections: percentage of live cells; 
percentage of cells positive for Annexin V; percentage of cells positive for 7-AAD; 
and percentage of cells positive for both Annexin V and 7-AAD. The cells positive 
for Annexin V indicate the percentage of cells undergoing apoptosis. The cells 
positive for 7-AAD reflect the percentage of cells undergoing necrosis. And, the 
cells that were double positive for both Annexin-V and 7-AAD represent the cells 
undergoing both apoptosis and necrosis.  
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3.7. IL-6 measurement by the enzyme-linked immunosorbent assay (ELISA) 
3.7.1. The principle of IL-6 ELISA 
ELISA is an immunological assay used for the detection and quantification 
of peptides, antibodies, cytokines, and hormones in biological samples. The general 
principle of ELISA is based on the interaction of antigen present in the biological 
sample with the specific antibody immobilized to a solid surface, and then its 
interaction with a secondary antibody conjugated with an enzyme. The detection is 
carried out by measuring the activity of the enzyme-linked by incubating it with a 
substrate, yielding a quantifiable product.255  
The present study employed ELISA to measure IL-6 levels secreted by 
VSMCs in the culture media. For this purpose, rat IL-6 ELISA kits were purchased 
(Rat IL-6 Immunoassay, # R6000B Quantikine® ELISA, R&D Inc., MN). The 
package comprised of microplates previously coated with monoclonal antibodies 
for rat IL-6. The samples were loaded into the microplates. A secondary antibody 
(specific to rat Il-6) was then added making a sandwich of immobilized antibody 
specific for rat IL-6, samples (containing IL-6 antigen), and secondary antibody. 
The secondary antibody conjugated with horseradish peroxidase (HRP) 
produced a colored or fluorescent reaction when a chemical substrate was added. 
The fluorescent signals were detected by a Biotek microplate reader (Biotek-
Synergy H1 Hybrid Reader, VT), thus determining the presence and the quantity of 
IL-6 antigen in the samples. A typical ELISA sandwich is depicted in the following 
figure: 
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Figure 3.4. A typical enzyme-linked immunosorbent assay (ELISA) sandwich. 
Adapted from https://www.immunology.org/public-information/bitesized-
immunology/experimental-techniques/enzyme-linked-immunosorbent-assay. 
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3.7.2. The procedure of IL-6 ELISA  
The reagents contained in the rat IL-6 ELISA kit (Rat IL-6 Immunoassay, 
# R6000B Quantikine® ELISA, R&D Inc., MN) were prepared as per the 
manufacturer's protocol.  
First, 50μL of assay diluent was added to each well in the assay plate, and 
then 50μL of standards, 50μL of each sample, and 50μL of assay control were 
added in their designated wells in the plate. Subsequently, the plate was incubated 
at room temperature (25°C) for 2 hours.  
After incubation, the plate was washed five times with wash buffer and 
10μL of rat IL-6 conjugate was added to each well.  
The plate was incubated again for 2 hours at room temperature. After 
incubation, the rat IL-6 conjugate was aspirated, and each well was washed five 
times with wash buffer. 100μL of substrate solution was added to each well, and 
the plate was incubated under darkness for 30 minutes.  
At the end of the 30 minutes, the stop solution was added to each well, and 
the plate was read by a Biotek microplate reader (Biotek-Synergy H1 Hybrid 
Reader, VT) at 450 nm.256   
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3.8. ROS assay 
3.8.1. The principle of ROS assay 
The ROS assay employs a fluorogenic dye named 2’,7’– 
dichlorofluorescein diacetate (DCFDA).257 It measures the free radicals such as 
hydroxy, peroxyl and other ROS within a cell. The assay principle is based on the 
process of deacetylation of DCFDA. The dye readily diffuses into cells and gets 
deacetylated into a ‘non-fluorescent’ compound by cellular esterase enzymes 
present in cells. The so formed non-fluorescent compound later gets oxidized by 
ROS present in cells into a ‘highly fluorescent’ compound called 2’,7’–
dichlorofluorescein (DCF) which is detected by fluorescence spectroscopy with 
maximum excitation at 485 nm and emission at 535 nm.258 
3.8.2. ROS assay procedure 
The ROS assay was carried out as per the manufacturer’s protocol (# 
ab113851, DCFDA Cellular ROS Detection Assay Kit, Abcam®, MA). Aortic 
VSMCs were seeded at 1×104 cells/well in 96-well plates, cultured and made 
quiescent by replacing serum media with SFM 24 hours prior to treatment. On the 
day of the experiment, cells were first washed with sterile PBS and then stained 
with 100 µL of DCFDA (concentration of 25 µM/well) for 45 minutes under 
standard incubation conditions. 
After incubation, the cells were re-washed with sterile PBS, and 100 µl of 
SFM was added to each well, and the treatment was carried out as per the 
experimental protocol. Post-treatment, the 96-well plates were read using a Biotek 
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microplate reader [(excitation at 485 nm and Emission at 535 nm), Biotek-Synergy 
H1 Hybrid Reader, VT]. 
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3.9. Western blotting 
3.9.1. The principle of Western blotting  
Western blotting is also known as immunoblotting. It is a reliable and 
sensitive technique routinely employed in research for the detection and 
characterization of proteins. It is a qualitative and semi-quantitative method. 
Western blotting involves the electrophoretic separation of protein samples based 
on their size and molecular weight in a polyacrylamide gel. The proteins are 
electrically transferred from a gel to a nitrocellulose membrane. The electrical 
transfer of proteins from gel-to-membrane is called ‘blotting.’  
Following the transfer, membranes are probed with a specific primary 
antibody and a secondary antibody conjugated with an enzyme (horseradish 
peroxidase) for the chemiluminescence detection of protein(s).259 The various steps 
in Western blotting is shown schematically in Figure 3.5. 
3.9.2. Preparation of cell lysate and procedure of Western blotting  
Cultured aortic VSMCs were lysed on ice with lysis buffer [sodium chloride 
(NaCl) 137 mM; Tris- hydrochloric acid (HCl) 20 mM; glycerol 10% v/v; Triton 
X-100 1% v/v; protease inhibitor cocktail―1 tablet per10 mL (PierceTM Protease 
Inhibitor, Thermo Scientific, IL)], and centrifuged at 10,000 rpm for 10 minutes at 
4°C. The supernatants were collected, and the bicinchoninic acid (BCA) assay 
(PierceTM BCA Protein Assay Kit, Thermo Scientific, IL) was carried out for 
estimating total protein content.  
Subsequently, samples were diluted with a modified laemmli sample buffer 
[2.5% SDS, 20% glycerol, 10% beta-mercaptoethanol, 0.004% bromphenol blue, 
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0.125 M Tris HCl, and pH 6.8 (Bio-Rad, CA)]. The preheated protein samples 
(equivalent to 20 µg proteins off each sample) were loaded in each well in 10% 
polyacrylamide gel and were subjected to sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE).  
Nitrocellulose membranes were used to transfer the proteins from the gels. 
The membranes were blocked with 5% w/v non-fat milk (Blotting-Grade Blocker, 
Bio-Rad, CA) solution [in 0.1% Tween in Tris-buffer saline (TBST)] for one hour 
at room temperature (25°C).  
The membranes were washed three times for five minutes with 0.1% TBST 
solution and were incubated with primary antibodies overnight at 4°C. After that, 
the membranes were probed with secondary antibodies conjugated with horseradish 
peroxidase for one hour at room temperature (25°C). The enhanced 
chemiluminescence (ECL) reagents (ECL Femto Max, Thermo Scientific, IL) were 
utilized for visualizing the membranes under chemiluminescence.  
The bands were quantified with the Image J Software (National Institutes 
of Health, MD). The membranes were stripped with the stripping buffer (RestoreTM 
Western Blot Stripping Buffer, VWR Life Science, GA), washed, and blocked in a 
similar manner as described above, and were incubated with primary antibodies for 
the housekeeping protein [glyceraldehyde-3-phosphate dehydrogenase (GAPDH)], 
probed with secondary antibodies, and visualized under chemiluminescence and 
quantified as stated previously.260,261   
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Figure 3.5. A schematic representation of the various steps in Western blotting. 
Adapted from https://microbeonline.com/western-blot-technique-principle-
procedures-advantages-and-disadvantages/ 
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The primary and secondary antibodies employed in Western blotting are 
mentioned in the following table: 
Table 3.1: Primary and secondary antibodies used in Western blotting 
# Antibody Code # Manufacturer 
1 p44/42 MAPK (ERK1/2) 
(137F5) Rabbit mAb 
4695 Cell Signaling Technology®, 
Inc., MA 
2 Phospho-p44/42 MAPK 
(ERK1/2) (Thr202/Tyr204) 
9101 Cell Signaling Technology®, 
Inc., MA 
3 ROCK-1 (C8F7) Rabbit 
mAb 
4035 Cell Signaling Technology®, 
Inc., MA 
4 ROCK-2 Antibody 8236 Cell Signaling Technology®, 
Inc., MA 
5 PI3-Kinase Flour® 680 p110 
Antibody (D-4) Mouse 
sc-8010 
AF 680 
Santa Cruz Biotechnology 
Inc., TX 
6 Phospho-AKT (Ser473) 
587F11 Mouse mAb 
4051 Cell Signaling Technology®, 
Inc., MA 
7 GAPDH (D16H11) XP® 
Rabbit mAb HRP conjugate 
8884 Cell Signaling Technology®, 
Inc., MA 
8 Anti-Rabbit IgG HRP-linked 
Antibody 
7074 Cell Signaling Technology®, 
Inc., MA 
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9 Anti-Mouse IgG (Fab 
specific)-Peroxidase 
Conjugate 
A3682 Sigma-Aldrich®, MO 
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The concentrations of primary and secondary antibodies used in Western 
blotting are mentioned in the following table: 
Table 3.2. Concentrations of primary and secondary antibodies used in Western 
blotting 
# Antibody Dilution Function 
1 p44/42 MAPK (ERK1/2) 1:1000 in TBST Proliferation marker 
2 
Phospho-p44/42 MAPK 
(ERK1/2) 
1: 1000 in TBST Proliferation marker 
3 ROCK-1 1: 1000 in TBST 
Vasocontraction 
marker 
4 ROCK-2 1: 1000 in TBST 
Vasocontraction 
marker 
5 PI3-Kinase p110α 1:200 in TBST Proliferation marker 
6 Phospho-AKT 
1: 1000 in 5% 
w/v non-fat dry 
milk, 1x	TBS, and 
0.1% Tween-20 
Proliferation marker 
7 GAPDH 1: 1000 in TBST 
Loading control 
(housekeeping) 
8 
Anti-Rabbit IgG HRP-
linked Antibody 
1: 10000 in TBST Secondary antibody 
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The compositions of buffers and polyacrylamide gels: separating and 
stacking gels used in Western blotting are mentioned in Table 3.3, Table 3.4, and 
Table 3.5, respectively. 
Table 3.3: Composition of buffers used in Western blotting 
Buffers 10X 
Running buffer 
(for gel electrophoresis) 
Tris: 15.20 g 
Glycine: 72.02 g 
Sodium dodecyl sulfate (SDS): 5.00 g 
Make the volume up to 1,000 mL with distilled water. 
Transfer buffer 
(for blotting) 
Tris: 15.20 g 
Glycine: 72.02 g 
Make the volume up to 1,000 mL with distilled water. 
Tris-buffered saline 
(TBS) 
Tris: 60.57g  
Sodium chloride (NaCl): 87.66 g 
Make the volume up to 1,000 mL with distilled water. 
Phosphate-buffered 
saline (PBS) 
Sodium chloride (NaCl): 82.00 g 
Potassium chloride (KCl): 2.00 g 
Disodium hydrogen phosphate (Na2HPO4): 29.00 g 
Potassium dihydrogen phosphate (KH2PO4): 2.00 g 
9 
Anti-Mouse IgG (Fab 
specific)-Peroxidase 
Conjugate 
1: 10000 in TBST Secondary antibody 
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Make the volume up to 1,000 mL with distilled water. 
 
Table 3.4: Composition of 10% resolving (separating) gel used in Western 
blotting 
Ingredients 2 gels 4 gels 
Acrylamide (30%) 3.75 mL 7.50 mL 
SDS (10%) 112.50 μL 225.00 μL 
Tris-HCl (1.5 M, pH 8.8) 2.85 mL 5.70 mL 
Distilled water 4.65 mL 9.3 mL 
Ammonium per sulfate 
[(APS), 10%] 
37.50 μL 75 μL 
Tetramethylethylenediamine 
 (TEMED) 
7.50 μL 15 μL 
 
Table 5: Composition of 5% stacking gel used in Western blotting  
Ingredients 2 gels 4 gels 
Acrylamide (30%) 487.50 μL 975.00 μL 
SDS (10%) 37.50 μL 75.00 μL 
Tris-HCl (1.5 M, pH 8.8) 937.50 μL 1875.00 μL 
Distilled water 2.25 mL 4.50 mL 
Ammonium per sulfate 
[(APS), 10%] 
19.00 μL 38.00 μL 
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Tetramethylethylenediamine  4.00 μL 8.00 μL 
 
3.10. Statistical Analysis  
The analysis of variance (ANOVA) was used for comparison between 
Wistar rats and SHRs. The unpaired Student t-test was applied to determine whether 
differences between the two individual treatment groups were significant. The 
difference between the treatment groups was considered statistically significant if 
the probability value (P value) was less than 0.05.262  
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3.11. Specific aims 1 and 2, strategies, and experimental design 
Specific aim 1: To characterize the effect of oxytocin on proliferation, 
inflammation, oxidative stress, and on vasocontraction pathway in primary aortic 
VSMCs obtained from normotensive Wistar rats.  
Specific aim 2: To determine the interaction between oxytocin and Ang II with 
regards to proliferation, inflammation, oxidative stress, and on vasocontraction 
pathway in primary aortic VSMCs obtained from normotensive Wistar rats. 
Strategies and experimental design for specific aims 1 and 2: 
The following four strategies and experimental designs were devised for 
specific aims 1 and 2: 
Strategy 1a: 
To investigate the effect of oxytocin, and its interaction with Ang II on the 
proliferation of aortic VSMCs obtained from normotensive Wistar rats, the 
following techniques were utilized: 
1.    Cells were counted directly by employing the Hemocytometer method.  
2.    Cell viability was assessed using the MTT assay. 
3.  Cell growth was determined using the 3H-Thymidine incorporation 
assay. 
4.    Cell apoptosis and necrosis were detected by Flow Cytometry. 
Experimental design for the strategy 1a: 
VSMCs were seeded in 6-well plates, 24-well plates, and 96-well plates in 
the hemocytometer experiments, 3H-Thymidine incorporation assays, and MTT 
assays, respectively. For the hemocytometer method, MTT-assay, and 3H-
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Thymidine incorporation assay, the treatment groups were identical and are stated 
in the following table: 
Table 3.6: Treatment groups in Hemocytometer method, MTT, and 3H- 
Thymidine incorporation assays 
# Treatment Groups 
1 The control group (only SFM and no treatment) 
2 Oxytocin 100 nM 
3 Ang II 100 nM 
4 Oxytocin (100 nM) + Ang II (100 nM) 
5 L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM 
6 OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM) 
7 OXTA 1 μM + Oxytocin (100 nM) 
 
Cells were pre-treated with oxytocin (VWR Life Science, GA) ten minutes 
before treatment with Ang II (VWR Life Science, GA). OXTA (Santa Cruz 
Biotechnology Inc., TX) was added 30 minutes before the treatment with oxytocin. 
In both the hemocytometer method and MTT assay, the treatment was carried out 
every 24 hours through 72 hours. In the 3H-Thymidine incorporation assay, the 
treatment was carried out at 24 and 48 hours, respectively. The SFM was 
replenished (every 24 hours) before the start of treatments. 
For the flow cytometer assay, 6-well plates were used to seed cells. There 
were three experimental groups: control (only SFM and no treatment), oxytocin (10 
nM), and oxytocin (100 nM). The treatment was carried out only for 24 hours.  
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Strategy 1b: 
To further understand the mechanism of oxytocin, and its interaction with 
Ang II on the proliferation of aortic VSMCs in Wistar rats, the two critical signaling 
pathways involved in VSMCs proliferation were investigated: ERK1/2 pathway 
and PI3K/Akt pathway. Western blotting technique was utilized as a part of strategy 
1b.  
Experimental design for Strategy 1b: 
Cells were seeded in 6-well plates. The experimental design consisted of 
the following treatment groups mentioned in Table 3.7: 
Table 3.7: Treatment groups for ERK1/2 and PI3K/Akt pathway experiments  
# Treatment Groups 
1 The control group (only SFM and no treatment) 
2 Oxytocin 100 nM 
3 Ang II 100 nM 
4 Oxytocin (100 nM) + Ang II (100 nM) 
5 L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM 
6 OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM) 
 
For investigating the effect of oxytocin, and its interaction with Ang II on 
the phosphorylation of ERK1/2, PI3K p110α, and Akt, cells were treated with 
oxytocin for ten minutes, and also with Ang II also for ten minutes. In the 
combination group, cells were pre-treated with oxytocin for ten minutes before the 
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treatment with Ang II. OXTA was added 30 minutes before the treatment with 
oxytocin.  
Strategy 2: 
To investigate the effect of oxytocin, and its interaction with Ang II on 
oxidative stress in aortic VSMCs (Wistar rats), ROS levels were measured. A ROS 
assay was carried out to determine ROS levels.  
Experimental design for strategy 2: 
Cells were seeded in 96-well plates. The experimental design for the ROS 
assay comprised of the following treatment groups (Table 3.8): 
Table 3.8: Treatment groups for the ROS assay 
# Treatment Groups 
1 The control group (SFM and no treatment) 
2 Oxytocin 100 nM 
3 Ang II 100 nM 
4 Oxytocin (100 nM) + Ang II (100 nM) 
5 L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM 
6 OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM) 
7 OXTA 1 μM + Oxytocin (100 nM) 
8 OXTA 1 μM + Ang II (100 nM) 
 
Cells were treated for ten minutes with oxytocin and Ang II. In the 
combination group, cells were pre-treated with oxytocin ten minutes before the 
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treatment with Ang II. OXTA was added 30 minutes before the treatment with 
oxytocin and Ang II.  
Strategy 3: 
To investigate the effect of oxytocin, and its interaction with Ang II on 
inflammation in aortic VSMCs (Wistar rats), the levels of IL-6, a critical 
inflammatory mediator, were measured. An IL-6 ELISA was utilized to measure 
IL-6 levels. 
Experimental design for strategy 3: 
Cells were seeded in 6-well plates. The experimental design for the IL-6 
assay included the following treatment groups (Table 3.9): 
Table 3.9: Treatment groups for the IL-6 assay 
# Treatment Groups 
1 The control group (only SFM and no treatment) 
2 Oxytocin (10 nM) 
3 Oxytocin (100 nM) 
4 Oxytocin (1000 nM) 
5 Ang II (100 nM) 
6 Oxytocin (10 nM) + Ang II (100 nM) 
7 Oxytocin (100 nM) + Ang II (100 nM) 
8 Oxytocin (1000 nM) + Ang II (100 nM) 
9 L-371,257 [oxytocin receptor antagonist (OXTA)] + Oxytocin 
(100 nM) + Ang II (100 nM) 
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Cells were treated with different concentrations of oxytocin for ten minutes, 
and with Ang II for ten minutes. In the combination group, cells were pre-treated 
with oxytocin ten minutes before the treatment with Ang II. OXTA was added 30 
minutes before the treatment with oxytocin and Ang II. Post-treatment, IL-6 
secreted in the media (supernatant) was collected, and IL-6 ELISA was carried out 
as per the manufacturer’s protocol. 
Strategy 4: 
The effect of oxytocin, and its interaction with Ang II on vasocontraction in 
aortic VSMCs in Wistar rats was assessed indirectly by investigating the Rho-
kinase pathway (ROCK-1 and ROCK-2) a critical pathway implicated in 
vasocontraction of VSMCs. The Western blotting method was employed as part of 
strategy 4.  
Experimental design for strategy 4: 
Cells were seeded in 6-well plates. The experimental design to pursue 
strategy 4 incorporated the following treatment groups (Table 3.10): 
Table 3.10: Treatment groups for Rho kinase pathway experiments  
# Treatment Groups 
1 The control group (only SFM and no treatment) 
2 Oxytocin 100 nM 
3 Ang II 100 nM 
4 Oxytocin (100 nM) + Ang II (100 nM) 
5 L-371,257 [oxytocin receptor antagonist (OXTA)] 1 μM 
6 OXTA 1 μM + Oxytocin (100 nM) + Ang II (100 nM) 
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 To determine the effect of oxytocin, and its interaction with Ang II on the 
phosphorylation of ROCK-1 and ROCK-2, cells were treated with oxytocin for ten 
minutes, and with Ang II also for ten minutes. In the combination group, cells were 
pre-treated with oxytocin for ten minutes before the treatment with Ang II. OXTA 
was added 30 minutes before the treatment with oxytocin.  
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3.12. Specific aim 3, strategy, and experimental design 
Specific aim 3: To characterize the effect of oxytocin and its interaction with Ang 
II on proliferation, inflammation, oxidative, and vasocontraction pathway in 
primary aortic VSMCs obtained from SHRs.  
Strategies and experimental design for specific aim 3: 
To pursue specific aim 3, the approaches similar to specific aims 1 and 2 
were adopted, and identical experimental designs were employed in aortic VSMCs 
obtained from hypertensive rats (SHRs). 
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Chapter 4: Results 
4.1.  Normotensive Wistar rats  
(Specific aims 1 and 2)  
4.1.1. Effects of oxytocin and Ang II on proliferation of aortic VSMCs 
isolated from normotensive Wistar rats 
4.1.1.1.   Cell counting by Hemocytometer method in Wistar VSMCs 
Oxytocin (100 nM) significantly reduced the proliferation of aortic VSMCs 
compared to the control group in normotensive Wistar rats. Oxytocin-induced 
reduction of VSMCs proliferation rate of VSMCs was time-dependent, with a 
50.9% ± 8.3% (P < 0.05) reduction in proliferation at 24 hours, 89.2% ± 1.2 % (P 
< 0.001) reduction at 48 hours and 94.7% ± 5.3%  (P < 0.001) at 72 hours compared 
to control (Figures 4.1 and 4.2). 
Contrary to oxytocin, Ang II (100 nM) significantly increased the 
proliferation of VSMCs by 354% ± 46% (P < 0.001) at 24 hours, 217% ± 13% (P 
< 0.001) at 48 hours, and 118% ± 73% (P < 0.001) at 72 hours when compared to 
control (Figures 4.1 and 4.2). 
Pre-treatment with oxytocin (100 nM) for ten minutes remarkably reduced 
the Ang II-induced increase in VSMCs proliferation by 62.9% ± 8.8% (P < 0.01) 
at 24 hours, 82.9% ± 21.5% (P < 0.001) at 48 hours and 86.9% ± 5.5% (P < 0.001) 
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at 72 hours compared to Ang II alone. These effects of oxytocin were prevented by 
pre-treatment with the OXTA– L-371,257 (1µM), (Figures 4.1 and 4.2).
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Figure 4.1. The effect of oxytocin and different treatment groups on aortic 
VSMCs proliferation in Wistar rats as assessed by the Hemocytometer method. 
Cells were seeded at 1×106 cells/well in 6-well plates. Cell proliferation was 
measured by counting the number of cells per milliliter (mL). The data are 
represented as the mean ± SEM from three independent experiments performed in 
duplicates using aortic VSMCs from three Wistar rats. Ang II indicates Angiotensin 
II; OXTA, Oxytocin receptor antagonist. 
* P < 0.05 and  *** P < 0.001 : All groups versus Control 
 P < 0.05,  P < 0.01, and P < 0.001 : Oxytocin versus (OXTA + Oxytocin); 
and Oxytocin versus Ang II 
## P < 0.01 and  ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and 
(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II) 
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Figure 4.2. The effect of oxytocin and different treatment groups on the 
proliferation rate of aortic VSMCs in Wistar rats as assessed by the 
Hemocytometer method. Cells were seeded at 1×106 cells/well in 6-well plates. 
Cell proliferation rate was assessed as percent (%) change of control. The data are 
represented as the mean ± SEM from three independent experiments performed 
using aortic VSMCs from three Wistar rats. Ang II indicates Angiotensin II; OXTA, 
Oxytocin receptor antagonist. 
* P < 0.05 and *** P < 0.001 : All groups versus Control 
 P < 0.05,  P < 0.01, and P < 0.001 : Oxytocin versus (OXTA + Oxytocin); 
and Oxytocin versus Ang II 
## P < 0.01 and ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and 
(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II) 
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4.1.1.2.   Assessment of cell viability with the MTT-assay in Wistar 
VSMCs 
The effect of oxytocin on cell viability in aortic VSMCs was evaluated with 
the MTT assay. Oxytocin (100 nM) induced a significant decrease in cell viability 
of VSMCs in a time-dependent manner with 4.4% ± 3% (P < 0.001), 22.6% ± 7% 
(P < 0.001), and 21.4% ± 6% (P < 0.001) reduction at 24, 48 and 72 hours, 
respectively compared to control (Figures 4.3 and 4.4).  
Contrary to oxytocin’s effect, Ang II (100 nM) treatment showed a 
significant increase in cell viability of VSMCs with 112% ± 15% (P < 0.001), 119% 
± 15% (P < 0.001), and 79.6% ± 10% (P < 0.001) increases in proliferation of 
VSMCs at 24, 48, and 72 hours, respectively compared to control (Figures 4.3 and 
4.4). 
The pre-treatment with oxytocin (100 nM) also significantly reduced Ang 
II-induced VSMCs viability with 53.8% ± 4.5% (P < 0.001) decrease at 24 hours, 
63.8% ± 7.7% (P < 0.001) decrease at 48 hours and a 51.6% ± 5.8% (P < 0.001) 
decrease at 72 hours compared to Ang II alone. Both these effects of oxytocin were 
significantly antagonized by the OXTA (Figures 4.3 and 4.4). 
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Figure 4.3. The effect of oxytocin and different treatment groups on Wistar aortic 
VSMCs viability as assessed by the MTT assay. Cells were seeded at 1×104 
cells/well in 96-well plates. Cell viability was determined as the function of an 
optical density (OD) measured at 570 nm. The data are shown as the mean ± SEM 
of three independent experiments performed using aortic VSMCs isolated from 
three Wistar rats. Each experiment was performed with 12 replicates. Ang II 
indicates Angiotensin II; OXTA, Oxytocin receptor antagonist. 
*** P < 0.001 : All groups versus Control 
 P < 0.05, P < 0.01, and P < 0.001 :  Oxytocin versus (OXTA + Oxytocin); 
and Oxytocin versus Ang II 
 ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II) 
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Figure 4.4. The effect of oxytocin and different treatment groups on Wistar aortic 
VSMCs viability rate as assessed by the MTT assay. Cells were seeded at 1×104 
cells/well in 96-well plates. Cell viability was measured as the percent (%) change 
of control. The data are the shown as the mean ± SEM of three independent 
experiments performed using aortic VSMCs isolated from three Wistar rats. Each 
experiment was performed with 12 replicates. Ang II indicates Angiotensin II; 
OXTA, Oxytocin receptor antagonist. 
 *** P < 0.001 : All groups versus Control 
 P < 0.05, P < 0.01, and P < 0.001 :  Oxytocin versus (OXTA + Oxytocin); 
and Oxytocin versus Ang II 
 ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II) 
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4.1.1.3. Assessment of cell growth with 3H-Thymidine incorporation 
assay in Wistar VSMCs 
The growth assay allowed an indirect measurement of cell division/growth 
– as the function of the incorporation of the radioisotope 3H-Thymidine into 
deoxyribonucleic acid (DNA) of the rapidly dividing cells. The radioactivity 
recovered from the cells was measured in terms of counts per minute (cpm). A 
higher count indicated a higher growth rate and vice-versa. 
 Growth assay results validated that oxytocin (100 nM) significantly 
reduced the 3H-Thymidine incorporation in aortic VSMCs from 5,857 ± 3,825 cpm 
(control) to 2,171 ± 1,446 cpm [44% ± 12% decrease (P < 0.01), Figure 4.5].  
On the other hand, treatment with Ang II (100 nM) significantly increased 
3H-Thymidine incorporation in VSMCs from 5,857 ± 3,825 cpm (control) to 11,194 
± 7,874 cpm [70% ± 15% increase (P < 0.01), Figure 4.5].  
Ang II-induced growth of VSMCs was significantly decreased by pre-
treatment with oxytocin [4,092 cpm ± 2,257 cpm (43% ± 15% decrease), P < 0.01] 
compared to Ang II alone (11,194 cpm ± 7,874 cpm). Both these effects of oxytocin 
were antagonized by OXTA (Figure 4.5). 
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Figure 4.5. The effect of oxytocin and various treatment groups on aortic Wistar 
VSMCs growth as assessed by the 3H-Thymidine incorporation assay. VSMCs 
were seeded at 5×104 cells/well in 24-well plates. Cell growth was measured as the 
function of the intake of the radioisotope 3H-Thymidine into the deoxyribonucleic 
acid (DNA) of the rapidly dividing cells and counted by the scintillation counter. 
The data are represented as the counts per minute (cpm) and are shown as the 
mean ± SEM of four independent experiments, each performed with triplicates, 
using aortic VSMCs from four Wistar rats.  Ang II indicates Angiotensin II; OXTA, 
Oxytocin receptor antagonist. 
* P < 0.05 and ** P < 0.01 :  versus Control 
  P < 0.01 and P < 0.001 : Oxytocin versus (OXTA + Oxytocin);   and 
Oxytocin versus Ang II 
 # P < 0.05 and ## P < 0.01 : (Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang 
II);and (Oxytocin + Ang II) versus and Ang II alone  
 
 92 
4.1.1.4.   Assessment of cell viability by flow cytometry in Wistar 
VSMCs 
The outcomes of the flow cytometry experiments revealed that treatment 
with oxytocin decreased cell viability, and induced apoptosis and necrosis in aortic 
VSMCs isolated from Wistar rats. 
The flow experiments utilized two different concentrations of oxytocin: 10 
nM and 100 nM. When compared to the control group (95.5% ± 0.7%), the live cell 
percentage in aortic VSMCs significantly decreased to 91.7 % ± 0.4% (P < 0.05) in 
the 10 nM oxytocin group and further plummeted to 67.5% ± 2.3% (P < 0.01) in 
the 100 nM oxytocin group, respectively (Figure 4.6). 
Oxytocin significantly induced apoptosis in aortic VSMCs. The treatment 
with 100 nM oxytocin significantly increased apoptosis up to 26.1% ± 3% (P < 
0.05) compared to apoptosis in the control group (2.6% ± 1.1%). However, there 
were no significant differences in the percentage of apoptotic cells between the 10 
nM oxytocin group (4.2% ± 1.6%) and the control group [2.7% ± 1.1% (Figure 
4.6)]. 
In addition to inducing apoptosis, the flow results demonstrated that 
oxytocin considerably induced necrosis in aortic VSMCs. When compared to 
control (0.7% ± 0.1%), the percentage of cells undergoing necrosis significantly 
increased to 3.6% ± 1.4% (P < 0.05) and 3.9% ± 0.3% (P < 0.01) in the10 nM 
oxytocin group and the 100 nM oxytocin group, respectively. However, there was 
no statistically significant difference between the percentage of necrotic cells 
between oxytocin 10 nM an oxytocin 100 nM treatment groups (Figure 4.6). 
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The percentage of aortic VSMCs double positive for both necrosis and 
apoptosis significantly increased from 0.9% ± 0.1% (in control group) to 2.5% ± 
0.1% [in 100 nM oxytocin group (P < 0.01)]. Conversely, there were no significant 
differences between the 10 nM oxytocin group (0.5% ± 0.1%) and the control group 
[0.9% ± 0.1% (Figure 4.6)]. 
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Figure 4.6. The effect of oxytocin on apoptosis and necrosis in aortic Wistar 
VSMCs as assessed by flow cytometry. VSMCs were seeded at 1×106 cells/well in 
6-well plates. The data are shown as the percentage of cells positive for apoptosis, 
necrosis and apoptosis + necrosis across different treatment groups. The data are 
represented as the mean ± SEM from three independent experiments performed 
using aortic VSMCs from three Wistar rats. The treatment was carried out for 24 
hours with the two different concentrations of oxytocin: 10 nM and 100 nM. Cells 
in the control group were not treated with oxytocin (only SFM). Cells were stained 
with fluorescent dyes: Annexin V (for apoptosis) and 7-amino actinomycin D [(7-
AAD) for necrosis] and assessed with the flow cytometer. 
* P < 0.05 :  Live cells in Oxytocin 10 nM group versus Live cells in Control group 
 ** P < 0.01 : Live cells in Oxytocin 100 nM group versus Live cells in Control 
group 
  P < 0.05 : Apoptotic cells in Oxytocin 100 nM group versus Apoptotic cells in 
Control group 
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 # P < 0.05 : Necrotic cells in Oxytocin 10 nM group versus Necrotic cells in Control 
group 
## P < 0.01 : Necrotic cells in Oxytocin 100 nM group versus Necrotic cells in 
Control group 
  P < 0.01 : (Apoptotic + Necrotic cells) in Oxytocin 100 nM group versus 
(Apoptotic + Necrotic cells) in Control group 
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4.1.2. Effect of oxytocin and its pre-treatment with Ang II on the 
phosphorylation of ERK1/2 in aortic Wistar VSMCs  
In aortic Wistar VSMCs, oxytocin (100 nM) significantly decreased the 
active phosphorylated form of ERK1/2 (pERK1/2) after ten minutes of treatment 
compared to the control group (basal levels). While the treatment with Ang II (100 
nM) significantly increased pERK1/2 after ten minutes of treatment compared to 
control (Figure 4.7). 
The pre-treatment with oxytocin (100 nM) significantly reduced Ang II-
induced activation of pERK1/2, and pre-treatment with OXTA (1 μM) for 30 
minutes significantly abrogated these effects of oxytocin (Figure 4.7). 
The densitometric analysis of the western blot images showed that oxytocin 
significantly decreased pERK1/2 by 57.9% ± 14.2% (P < 0.001) compared to 
control, Ang II significantly increased pERK1/2 by 223% ± 11% (P < 0.001) 
compared to control, and the oxytocin pre-treatment significantly decreased 
pERK1/2 by 76.6% ± 1.4% (P < 0.01) compared to Ang II alone (Figure 4.7). 
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Figure 4.7. The effect of oxytocin and different treatment groups on the 
phosphorylation of ERK1/2 in aortic Wistar VSMCs. Western blotting was utilized 
to measure phospho-ERK1/2 levels, and the data were normalized with total 
ERK1/2. The effect of oxytocin and its combination with different treatment groups 
on the phosphorylation of ERK1/2 is shown as the percent (%) of control, with 
control as 100%. The data are shown as the mean ± SEM of five independent 
experiments, performed using aortic VSMCs isolated from five Wistar rats. ** 
indicates P < 0.01 versus control; *** P < 0.001 versus control;  P < 0.01 
Oxytocin versus Ang II; ## P < 0.01 (Oxytocin + Ang II) versus Ang II alone; and 
(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II). Ang II indicates 
Angiotensin II; OXTA, Oxytocin receptor antagonist.  
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4.1.3. Effect of oxytocin and its pre-treatment with Ang II on the 
phosphorylation of PI3K p110𝒂 and Akt in aortic Wistar VSMCs  
In primary aortic VSMCs obtained from Wistar rats, the densitometric 
analysis of the western blot images showed that the treatment with oxytocin (100 
nM) significantly decreased the active phosphorylated form of PI3K p110alpha 
(phospho-PI3K p110a) by 64.8% ± 2.8% (P < 0.01) and the active phosphorylated 
form of Akt (phospho-Akt) by 46.2% ± 9.5%  (P < 0.05) compared to controls, 
respectively (Figures 4.8 and 4.9). 
One the other hand, treatment with Ang II (100 nM) significantly increased 
the levels of phospho-PI3K p110a by 184% ± 17% (P < 0.05) and phospho-Akt by 
44.4% ± 3.5% (P < 0.001) compared to control respectively (Figures 4.8 and 4.9). 
Pre-treatment with oxytocin (100 nM) significantly reduced Ang II-
mediated increased levels of phospho-PI3K p110a by 83.8% ± 8.6% (P < 0.01) and 
phospho-Akt by 62.1% ± 10.9% (P < 0.001) compared to Ang II alone, 
respectively. These effects of oxytocin were significantly abated by pre-treatment 
with OXTA (1 μM) for 30 minutes (Figures 4.8 and 4.9). 
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Figure 4.8. The effect of oxytocin and different treatment groups on the 
phosphorylation of PI3K p110α in aortic Wistar VSMCs. Western blotting was 
utilized to measure the phosphorylation of PI3K p110α, and the data were 
normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect 
of oxytocin and its combination with different treatment groups on the 
phosphorylation of PI3K p110α is shown as the percent (%) of control, with control 
as 100 %. The data are shown as the mean ± SEM of three independent 
experiments, performed using aortic VSMCs isolated from three Wistar rats. * 
indicates P < 0.05 versus control; ** P < 0.01 versus control;  P < 0.01 Oxytocin 
versus Ang II; ## P < 0.01 (Oxytocin + Ang II) versus Ang II alone; ### P < 0.001 
(Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II). Ang II indicates 
Angiotensin II; OXTA, Oxytocin receptor antagonist. 
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Figure 4.9. The effect of oxytocin and different treatment groups on the 
phosphorylation of Akt in aortic Wistar VSMCs. Western blotting was utilized to 
measure the phosphorylation of Akt, and the data were normalized with 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect of oxytocin and 
its combination with different treatment groups on the phosphorylation of Akt is 
shown as the percent (%) of control, with control as 100%. The data are shown as 
the mean ± SEM of four independent experiments, performed using aortic VSMCs 
isolated from four Wistar rats. ** indicates P < 0.01 versus control; *** P < 0.001 
versus control; P < 0.001 Oxytocin versus Ang II; ### P < 0.001 (Oxytocin + 
Ang II) versus Ang II alone, and (Oxytocin + Ang II) versus (OXTA + Oxytocin + 
Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin receptor antagonist. 
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4.1.4. Effect of oxytocin and its pre-treatment with Ang II on the activation 
of ROCK -1 and ROCK-2 in aortic Wistar VSMCs  
Densitometric analysis of the western blot images showed that in Wistar 
rats, oxytocin (100 nM) significantly reduced the activation of ROCK-1 by 60.4% 
± 7.6% (P < 0.001) and ROCK-2 by 38.7%  ± 13.1% (P < 0.01) compared to 
controls, respectively (Figures 4.10 and 4.11). 
Ang II (100 nM) significantly enhanced the activation of ROCK-1 by 147% 
± 50% (P < 0.05) and ROCK-2 by 83.2% ± 14.6% (P < 0.001) compared to controls, 
respectively (Figures 4.10 and 4.11).  
Pre-treatment with oxytocin (100 nM) significantly reduced Ang II-induced 
activation of ROCK-1 by 85.2% ± 10.6% (P < 0.01) and ROCK-2 by 65.9% ± 
13.2% (P < 0.001) compared to Ang II alone, respectively. These effects of 
oxytocin were significantly reduced by pre-treatment with OXTA (1µM) (Figures 
4.10 and 4.11). 
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Figure 4.10. The effect of oxytocin and different treatment groups on the 
activation of ROCK- 1 in aortic Wistar VSMCs. Western blotting was utilized to 
measure the ROCK-1 levels, and the data were normalized with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination 
with different treatment groups on the activation of ROCK- 1 is shown as the 
percent (%) of control, with control as 100%. The data are shown as the mean ± 
SEM of four independent experiments, performed using aortic VSMCs isolated 
from four Wistar rats. * indicates P < 0.05 versus control; *** P < 0.001 versus 
control;  P < 0.01 Oxytocin versus Ang II; ## P < 0.01 (Oxytocin + Ang II) versus 
Ang II alone, and (Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II). Ang II 
indicates Angiotensin II; OXTA, Oxytocin receptor antagonist; ROCK, Rho-
associated coiled-coil containing protein kinase. 
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Figure 4.11. The effect of oxytocin and different treatment groups on the 
activation of ROCK-2 in aortic Wistar VSMCs. Western blotting was utilized to 
measure the ROCK-2 levels, and the data were normalized with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination 
with different treatment groups on the activation of ROCK-2 is shown as the percent 
(%) of control, with control as 100%. The data are shown as the mean ± SEM of 
five independent experiments, performed using aortic VSMCs isolated from five 
Wistar rats. * indicates P < 0.05 versus control; ** P < 0.01 versus control; *** 
P < 0.001 versus control; P < 0.001 Oxytocin versus Ang II; ### P < 0.001 
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(Oxytocin + Ang II) versus Ang II alone; ## P < 0.01 (Oxytocin + Ang II) versus 
(OXTA + Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin 
receptor antagonist; ROCK, Rho-associated coiled-coil containing protein kinase. 
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4.1.5. Effect of oxytocin and its pre-treatment with Ang II on IL-6 secretion 
in aortic Wistar VSMCs  
The IL-6 ELISA assay was carried out as per the manufacturer’s protocol. 
The concentration of IL-6 secreted by aortic VSMCs in the culture media was 
measured in ‘picogram per milliliter’ (pg/mL). In Wistar rats, the outcomes of the 
IL-6 assay showed that oxytocin treatment resulted in a significant increase in IL-
6 secretion compared to the control group. Three different concentrations of 
oxytocin were used: 10 nM, 100 nM, 1,000 nM. The treatment with oxytocin at 100 
nM and 1,000 nM resulted in significant increases in IL-6 with 1,033 ± 24 pg/mL 
(P < 0.01) at 100 nM and 959 ± 52 pg/mL (P < 0.05) at 1,000 nM, respectively 
compared to control group [614 ± 104 pg/mL (Figure 4.12)]. 
However, there was no significant difference between oxytocin 10 nM (695 
± 101 pg/mL) and control group (614 ± 104 pg/mL). There was no significant 
difference between oxytocin 100 nM (1,033 ± 24 pg/mL) and oxytocin 1,000 nM 
[959 ± 52 pg/mL (Figure 4.12)]. 
Ang II (100 nM) treatment showed a significant increase in IL-6 [1,481 ± 
91 pg/mL (P < 0.01)] compared to control group (614 ± 104 pg/mL). Ang II (100 
nM) treatment resulted in more IL-6 secretion (1,481 ± 91 pg/mL) compared to 
treatment with oxytocin [100 nM (1,033 ± 24 pg/mL), P < 0.01] when compared to 
control [614 ± 104 pg/mL (Figure 4.12)]. 
Interestingly, in contrast to its singular effect, oxytocin’s pre-treatment (100 
nM) with Ang II (100 nM) significantly decreased IL-6 secretion (735 ± 77 pg/mL) 
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compared to Ang II 100 nM alone [1,481 ± 91 pg/mL (P < 0.01)] and oxytocin 100 
nM alone [1,033 ± 24  pg/mL (P < 0.01)], respectively (Figure 4.12).  
The effect of oxytocin pre-treatment (100 nM) on Ang II (100 nM) was 
significantly abolished by pre-treatment with 1µM OXTA. IL-6 secretion was 
significantly higher [1,487 ± 64 pg/mL (P < 0.001] in the OXTA-pre-treatment 
group [OXTA (1µM) + Oxytocin (100 nM) + Ang II (100 nM)] than Oxytocin 100 
nM + Ang II 100 nM group [735 ± 77 pg/mL (Figure 4.12)].  
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Figure 4.12. The effect of oxytocin and different treatment groups on IL-6 
secretion in aortic Wistar VSMCs. The concentration of IL-6 secreted by aortic 
VSMCs in the culture media was measured in picogram per milliliter (pg/mL). The 
data are represented as the mean ± SEM from three independent experiments 
performed using aortic VSMCs from three Wistar rats. In each experiment each 
treatment group had duplicates. * indicates P < 0.05 versus Control group; ** P 
< 0.01 versus Control group;  P < 0.05 Oxytocin 10 nM versus Oxytocin 100 nM 
and Oxytocin 1000 nM respectively. # P < 0.05 (Oxytocin 100 nM + Ang II 100 nM) 
versus Oxytocin 100 nM alone; ## P < 0.01 (Oxytocin 100 nM + Ang II 100 nM) 
versus Ang II 100 nM alone; ### P < 0.001 (Oxytocin 100 nM + Ang II 100 nM) 
versus (OXTA 1µM + Oxytocin 100 nM + Ang II 100 nM);  P < 0.01 Oxytocin 
100 nM versus Ang II 100 nM. Ang II indicates Angiotensin II; OXTA, Oxytocin 
receptor antagonist. 
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4.1.6. Effect of oxytocin and its pre-treatment with Ang II on ROS in aortic 
Wistar VSMCs  
ROS was assessed as the function of fluorescent units. The outcomes of the 
ROS assay in aortic Wistar VSMCs demonstrated that the treatment with oxytocin 
(100 nM) significantly increased ROS production [8,584 ± 114 (P < 0.001)] 
compared to the control group (7,542 ± 128). Ang II (100 nM) significantly 
increased ROS production [8,336 ± 204 (P < 0.001)] compared to the control group 
(7,542 ± 128). There was no significant difference in the ROS production between 
oxytocin [100 nM (8,584 ± 114)] and Ang II [100 nM (8,336 ± 204)] treatment 
groups (Figure 4.13). 
The pre-treatment of oxytocin (100 nM) with Ang II (100 nM) significantly 
increased ROS production [9,346 ± 143 (P < 0.001)] compared to the control group 
[7,542 ± 128 (Figure 4.13)]. 
Interestingly, the pre-treatment of oxytocin (100 nM) followed by Ang II 
(100 nM) resulted in significantly higher (P < 0.001) ROS production (9,346 ± 143) 
than oxytocin (100 nM) alone (8,584 ± 114) and Ang II (100 nM) alone (8,336 ± 
204), respectively, indicating an additive effect (Figure 4.13). 
OXTA (1 µM) on its own significantly increased ROS production [8,530 ± 
267 (P < 0.001)] compared to the control group (7,542 ± 128). In addition, pre-
treatment of OXTA (1 µM) with oxytocin (100 nM) resulted in significantly 
increased ROS production [9,594 ± 177 (P < 0.001)] when compared with oxytocin 
(100 nM) alone (8,584 ± 114). This suggests an additive effect of OXTA on 
oxytocin-stimulated ROS production (Figure 4.13). 
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The combination of OXTA (1 µM), oxytocin (100 nM), and Ang II (100 
nM) significantly increased ROS production [10,511 ± 179 (P < 0.001)] compared 
to control (7,542 ± 128) in aortic Wistar VSMCs (Figure 4.13). 
ROS production in the combination group of OXTA (1 µM), oxytocin (100 
nM), and Ang II (100 nM) was significantly higher [10,511 ± 179 (P < 0.001)] than 
Oxytocin (100 nM) alone (8,584 ± 114), Ang II (100 nM) alone (8,336 ± 204), and 
OXTA (1 µM) alone (8,530 ± 267), respectively, thus indicating an additive effect 
(Figure 4.13). 
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Figure 4.13. The effect of oxytocin and different treatment groups on ROS 
production in aortic Wistar VSMCs. VSMCs were seeded at 1×104 cells/well in 
96-well plates. The ROS levels were measured as the function of the fluorescent 
unit. The data are represented as the mean ± SEM from three independent 
experiments performed using aortic VSMCs from three Wistar rats. In each 
experiment each treatment group had 12 replicates. *** indicates P < 0.001 versus 
Control group; ### P < 0.01 (Oxytocin + Ang II) versus Oxytocin alone, Ang II 
alone, and (OXTA + Oxytocin + Ang II);  P < 0.001 (OXTA + Oxytocin + Ang 
II) versus Oxytocin alone, Ang II alone, and OXTA alone;    P < 0.001 Oxytocin 
versus (OXTA + Oxytocin). Ang II indicates Angiotensin II; OXTA, Oxytocin 
receptor antagonist. 
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4.2. Spontaneously hypertensive rats [Specific Aim 3] 
4.2.1. Effect of oxytocin and its pre-treatment with Ang II on aortic SHR 
VSMCs proliferation  
4.2.1.1.   Cell counting by Hemocytometer method in SHR VSMCs 
Similar to its effects on VSMCs proliferation from the normotensive rats, 
oxytocin (100 nM) significantly reduced aortic VSMCs proliferation in SHRs 
compared to the control group (Figures 4.14 and 4.15). 
The hemocytometer cell counting revealed that oxytocin-induced reduction 
in SHR VSMCs proliferation rate was time-dependent, with 44.8% ± 3% reduction 
(P < 0.001) in proliferation at 24 hours, 84.4% ± 0.9% reduction (P < 0.001) 
reduction at 48 hours and 88.2% ± 4.0% reduction (P < 0.001) reduction at 72 hours 
compared to control (Figures 4.14 and 4.15). 
On the other hand, the treatment with Ang II (100 nM) significantly 
increased SHR VSMCs proliferation, with 190% ± 18% (P < 0.001) increase in 
proliferation rate at 24 hours, 112% ± 15% (P < 0.001) increase at 48 hours, and 
207 % ± 56% (P < 0.001) increase at 72 hours compared to control (Figures 4.14 
and 4.15).  
It is noteworthy that even in the SHRs, the oxytocin (100 nM) pre-treatment 
significantly reduced Ang II-induced VSMCs proliferation in a time-dependent 
manner, with 66% ± 24% (P < 0.001) decrease at 24 hours, 93% ± 3% (P < 0.001) 
decrease at 48 hours and 97% ± 4 % (P < 0.001) decrease at 72 hours compared to 
Ang II alone (Figures 4.14 and 4.15). Pre-treatment with OXTA (1 µM) 
significantly diminished these effects of oxytocin (Figures 4.14 and 4.15). 
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Figure 4.14. The effect of oxytocin and different treatment groups on aortic 
VSMCs proliferation in SHRs as assessed by the Hemocytometer method. SHR 
VSMCs were seeded at 1×106 cells/well in 6-well plates. Cell proliferation was 
measured by counting the number of cells per milliliter (mL). The data are 
represented as the mean ± SEM from three independent experiments performed 
using aortic VSMCs from three SHRs. Ang II indicates Angiotensin II; OXTA, 
Oxytocin receptor antagonist. 
*** P < 0.001 : All groups versus Control 
 P < 0.01 and P < 0.001 :  Oxytocin versus (OXTA + Oxytocin); and 
Oxytocin versus Ang II 
 ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II) 
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Figure 4.15. The effect of oxytocin and different treatment groups on aortic 
VSMCs proliferation rate in SHRs assessed by the Hemocytometer method. SHR 
VSMCs were seeded at 1×106 cells/well in 6-well plates. Cell proliferation rate was 
assessed as the percent (%) change of control. The data are represented as the 
mean ± SEM from three independent experiments performed using aortic VSMCs 
from three SHRs. Ang II indicates Angiotensin II; OXTA, Oxytocin receptor 
antagonist. 
*** P < 0.001 : All groups versus Control 
 P < 0.01 and P < 0.001 :  Oxytocin versus (OXTA + Oxytocin); and 
Oxytocin versus Ang II 
 ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II) 
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4.2.1.2.   Assessment of cell viability with MTT-assay in SHR VSMCs 
The findings from the MTT assay in aortic SHRs VSMCs were similar to 
those in Wistar rats. Oxytocin (100 nM) significantly reduced cell viability of aortic 
SHR VSMCs (Figures 4.16 and 4.17).   
The MTT assay demonstrated that oxytocin caused a reduction in the cell 
viability of SHR VSMCs by 37.5% ± 3.9% (P < 0.001) and 32 % ± 3.8% (P < 
0.001) at 48 hours and 72 hours, respectively compared to control. However, at 24 
hours oxytocin did not show any significant reduction in VSMCs viability rate 
(Figures 4.16 and 4.17).  
The treatment with Ang II (100 nM) showed an increase in the VSMCs 
viability with 145% ± 20% (P < 0.001), 121% ± 14% (P < 0.001), and 166% ± 13% 
(P < 0.001) increase at 24, 48 and 72 hours, respectively compared to control 
(Figures 4.16 and 4.17).  
The pre-treatment with oxytocin (100 nM) prominently reduced Ang II-
induced VSMC viability by 51.8% ± 8.3% (P < 0.001) at 24 hours, 63.7% ± 5.7% 
(P < 0.001) at 48 hours, and 71.9% ± 3.9% (P < 0.001) at 72 hours compared to 
Ang II alone, and the pre-treatment with OXTA (1 µM) significantly blocked the 
effects of oxytocin (Figures 4.16 and 4.17).  
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Figure 4.16. The effect of oxytocin and different treatment groups on aortic SHR 
VSMCs viability as assessed by the MTT assay. SHR VSMCs were seeded at 1×104 
cells/well in 96-well plates. Cell viability was determined as the function of an 
optical density (OD) measured at 570nm. The data are shown as the mean ± SEM 
of three independent experiments performed using aortic VSMCs isolated from 
three SHRs. Each experiment was performed with 12 replicates. Ang II indicates 
Angiotensin II; OXTA, Oxytocin receptor antagonist. 
 *** P < 0.001 : All groups versus Control 
 P < 0.001 : Oxytocin versus Ang II; and Oxytocin versus (OXTA + Oxytocin) 
 ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II) 
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Figure 4.17. The effect of oxytocin and different treatment groups on aortic SHR 
VSMCs viability rate as assessed by the MTT assay. SHR VSMCs were seeded at 
1×104 cells/well in 96-well plates. Cell viability was measured as the percent (%) 
change of control. The data are shown as the mean ± SEM of three independent 
experiments performed using aortic VSMCs isolated from three SHRs. Each 
experiment was performed with 12 replicates. Ang II indicates Angiotensin II; 
OXTA, Oxytocin receptor antagonist. 
 *** P < 0.001 : All groups versus Control 
 P < 0.001 : Oxytocin versus Ang II; and Oxytocin versus (OXTA + Oxytocin) 
 ### P < 0.001 : (Oxytocin + Ang II) versus Ang II alone; and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II) 
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4.2.1.3. Assessment of cell growth with 3H-Thymidine incorporation 
assay in SHR VSMCs 
The growth assay results corroborated that oxytocin (100 nM) significantly 
reduced 3H-Thymidine incorporation in aortic SHR VSMCs from 2,668 ± 1,419 
cpm (control) to 1,958 ± 2,473 cpm [36% ± 6% decrease (P < 0.01), Figure 4.18]. 
In contrast, treatment with Ang II (100 nM) significantly increased the 3H-
Thymidine incorporation into aortic SHR VSMCs from 2,668 ± 1,419 cpm 
(control) to 5,245 cpm ± 1,108 cpm [46% ± 71% increase (P < 0.001), Figure 4.18]. 
Pre-treatment with oxytocin (100 nM) followed by Ang II (100 nM) 
significantly decreased Ang II-induced growth of SHR VSMCs [1,385 cpm ± 1,170 
cpm (73% ± 25% decrease), P < 0.001] compared to Ang II alone (5,245 ± 1,108 
cpm), and these effects were antagonized by OXTA [1 µM (Figure 4.18)]. 
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Figure 4.18. The effect of oxytocin and various treatments groups on aortic SHR 
VSMCs growth as assessed by the 3H-Thymidine incorporation assay. SHR 
VSMCs were seeded at 5×104 cells/well in 24-well plates. Cell growth was 
measured as the function of the uptake of the radioisotope 3H-Thymidine into the 
deoxyribonucleic acid (DNA) of the rapidly dividing cells and counted by the 
scintillation counter. The data are represented as the count per minute (cpm) and 
are shown as the mean ± SEM of four independent experiments, each performed 
with triplicates, using aortic VSMCs isolated from four SHRs. Ang II indicates 
Angiotensin II; OXTA, Oxytocin receptor antagonist. 
** P < 0.01 and *** P < 0.001 : versus Control 
 P < 0.05 and P < 0.001 : Oxytocin versus (OXTA + Oxytocin); and   
Oxytocin versus Ang II 
 ### P < 0.01 : (Oxytocin + Ang II) versus (OXTA + Oxytocin + Ang II); and 
(Oxytocin + Ang II) versus Ang II alone 
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4.2.1.4.   Assessment of cell viability by flow cytometry in SHR VSMCs 
In aortic SHR VSMCs, the flow cytometry results showed oxytocin 
treatment decreased the cell viability and induced apoptosis in a concentration-
dependent manner, also caused necrosis (Figure 4.19).  
The flow experiments utilized two different concentrations of oxytocin: 10 
nM and 100 nM. When compared to the control group (93.4% ± 1.10%), the live 
cell percentage in aortic VSMCs significantly decreased to 80.9% ±0.7% (P < 0.01) 
in 10 nM oxytocin group and further declined to 65% ± 0.9% (P < 0.01) in 100 nM 
oxytocin group, respectively (Figure 4.19). 
Oxytocin significantly induced apoptosis in aortic SHR VSMCs. The 
treatment with 10 nM and 100 nM oxytocin significantly increased apoptosis up to 
13.9% ± 0.4% (P < 0.001) and 23.9% ± 0.1% (P < 0.001), respectively compared 
to apoptosis in the control group [2.6% ± 1.1% (Figure 4.19)]. 
In addition to inducing apoptosis, oxytocin considerably induced necrosis 
in aortic VSMCs. The percentage of aortic VSMCs undergoing necrosis 
significantly increased from 2.2% ± 0% (in control group) to 8.6% ± 1.3% (P < 
0.05) in 100 nM oxytocin group. However, there was no significant difference 
between 10 nM oxytocin group (2.6% ± 0.3%) and the control group [2.2% ± 0% 
(Figure 4.19)]. 
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Figure 4.19. The effect of oxytocin on apoptosis and necrosis in aortic SHR 
VSMCs as assessed by flow cytometry. SHR VSMCs were seeded at 1×106 
cells/well in 6-well plates. The data are shown as the percentage of cells positive 
for apoptosis, necrosis and apoptosis + necrosis across different treatment groups. 
The data are represented as the mean ± SEM from three independent experiments 
performed using aortic VSMCs from three SHRs. The treatment was carried out for 
24 hours with the two different concentrations of oxytocin: 10 nM and 100 nM. The 
cells in the control group were not treated with oxytocin (only SFM). The cells were 
stained with fluorescent dyes: Annexin V (for apoptosis) and 7-amino actinomycin 
D [(7-AAD) for necrosis] and assessed with flow cytometer. 
** P < 0.01 : Live cells in Oxytocin 10 nM group versus Live cells in Control group 
** P < 0.01 Live cells in Oxytocin 100 nM group versus Live cells in Control group  
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 P < 0.001 Apoptotic cells in Oxytocin 10 nM group versus Apoptotic cells in 
Control group 
  P < 0.001 Apoptotic cells in Oxytocin 100 nM group versus Apoptotic cells in 
Control group 
 # P < 0.05 Necrotic cells in Oxytocin 100 nM group versus Necrotic cells in Control 
group. 
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4.2.2. Effect of oxytocin and its pre-treatment with Ang II on the 
phosphorylation of ERK1/2 in aortic SHR VSMCs  
In aortic VSMCs isolated and cultured from SHRs, the densitometric 
analysis of the western blot images showed that treatment with oxytocin (100 nM) 
significantly decreased the active phosphorylated form of ERK1/2 (pERK1/2) by 
35.4% ± 4% (P < 0.001) compared to control (Figure 4.20). 
Contrary to oxytocin’s effect on pERK1/2 in SHR VSMCs, treatment with 
Ang II (100 nM) significantly increased phosphorylation of ERK1/2 by 157% ± 
21% (P < 0.001) compared to control (Figure 4.20). 
Interestingly, the oxytocin (100 nM) pre-treatment significantly reduced 
Ang II-induced pERK1/2 levels by 93.3% ± 1.4% (P < 0.001) compared to Ang II 
alone. The effects of oxytocin were significantly antagonized by the pre-treatment 
with 1 µM OXTA (Figure 4.20). 
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Figure 4.20. The effect of oxytocin and different treatment groups on the 
phosphorylation of ERK1/2 in aortic SHR VSMCs. Western blotting was utilized 
to measure phospho-ERK1/2 levels, and the data were normalized with total 
ERK1/2. The effect of oxytocin and its combination with different treatment groups 
on the phosphorylation of ERK1/2 is shown as the percent (%) of control, with 
control as 100%. The data are represented as the mean ± SEM of five independent 
experiments, performed using aortic VSMCs isolated from five SHRs. *** indicates 
P < 0.001 versus control; P < 0.001 Oxytocin versus Ang II; ### P < 0.001 
(Oxytocin + Ang II) versus Ang II alone, and (Oxytocin + Ang II) versus (OXTA + 
Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin receptor 
antagonist.  
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4.2.3. Effect of oxytocin and its pre-treatment with Ang II on the 
phosphorylation of PI3K p110α and Akt in aortic SHRs VSMCs   
In aortic VSMCs cultured from SHRs, the densitometric analysis of western 
blot images showed that treatment with oxytocin (100 nM) significantly decreased 
the phosphorylated forms of PI3K p110a by 31% ± 5.1% (P < 0.01)  and Akt by 
45.5% ± 8.6% (P < 0.01) compared to control, respectively (Figures 4.21 and 4.22). 
On the other hand, treatment with Ang II (100 nM) increased 
phosphorylated forms of PI3K p110a by 79.8% ± 10.3% (P < 0.001) and Akt by 
70.2% ± 20.4% (P < 0.05) compared to control, respectively (Figures 4.21 and 
4.22). 
It is noteworthy that the oxytocin (100 nM) pre-treatment significantly 
reduced Ang II-induced higher levels of phospho-PI3K p110a by 61.3% ± 4.8% (P 
< 0.01) and phospho-Akt by 60.4% ± 2.6% (P < 0.001) compared to Ang II alone, 
respectively. And these effects of oxytocin were antagonized by pre-treatment with 
1 µM OXTA (Figures 4.21 and 4.22). 
Western blots depicting effect of oxytocin and various treatments on the 
phosphorylation of PI3K p110a and Akt in SHR VSMCs are shown in Figures 
4.21 and 4.22, respectively.  
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Figure 4.21. The effect of oxytocin and different treatment groups on the 
phosphorylation of PI3K p110α in aortic SHR VSMCs. Western blotting was 
utilized to measure the phosphorylation of PI3K p110α, and the data were 
normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect 
of oxytocin and its combination with different treatment groups on the 
phosphorylation of PI3K p110α is shown as the percent (%) of control, with control 
as 100%. The data are shown as the mean ± SEM of three independent experiments, 
performed using aortic VSMCs isolated from three SHRs. ** indicates P < 0.01 
versus control; *** P < 0.001 versus control;  P < 0.001 Oxytocin versus Ang 
II; ### P < 0.001 (Oxytocin + Ang II) versus Ang II alone, and (Oxytocin + Ang II) 
versus (OXTA + Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, 
Oxytocin receptor antagonist. 
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Figure 4.22. The effect of oxytocin and different treatment groups on the 
phosphorylation of Akt in aortic SHR VSMCs. Western blotting was utilized to 
measure the phosphorylation of Akt, and the data were normalized with 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The effect of oxytocin and 
its combination with different treatment groups on the phosphorylation of Akt is 
shown as the percent (%) of control, with control as 100%. The data are shown as 
the mean ± SEM of four independent experiments, performed using aortic VSMCs 
isolated from four SHRs. * indicates P < 0.05 versus control; ** P < 0.01 versus 
control; *** P < 0.001 versus control; P < 0.01 Oxytocin versus Ang II; ## P < 
0.01 (Oxytocin + Ang II) versus Ang II alone, and (Oxytocin + Ang II) versus 
(OXTA + Oxytocin + Ang II). Ang II indicates Angiotensin II; OXTA, Oxytocin 
receptor antagonist. 
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4.2.4. Effect of oxytocin and its pre-treatment with Ang II on the activation 
of ROCK -1 and ROCK-2 in aortic SHR VSMCs 
In aortic SHR VSMCs, the densitometric analysis of western blot images 
showed treatment with oxytocin (100 nM) significantly reduced the activation of 
ROCK-1 by 58.9% ± 5.4% (P < 0.001) and ROCK-2 by 41.5% ± 12.8% (P < 0.01) 
compared to control, respectively (Figures 4.23 and 4.24). 
Treatment with Ang II (100 nM) prominently increased the activation of 
ROCK-1 by 102% ± 43% (P < 0.05) and ROCK-2 by 81.2% ± 14.8% (P < 0.001) 
compared to control, respectively (Figures 4.23 and 4.24). 
Pre-treatment with oxytocin (100 nM) significantly reduced Ang II-induced 
activation of ROCK-1 by 79%  ±  6.9% (P < 0.01) and ROCK-2 by 69.5% ± 13.2% 
(P < 0.001) compared to Ang II alone, respectively. These effects of oxytocin were 
significantly blocked by pre-treatment with 1µM OXTA (Figures 4.23 and 4.24). 
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Figure 4.23. The effect of oxytocin and different treatment groups on the 
activation of ROCK-1 in aortic SHR VSMCs. Western blotting was utilized to 
measure the ROCK-1 levels, and the data were normalized with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination 
with different treatment groups on the activation of ROCK-1 is shown as the percent 
(%) of control, with control as 100%. The data are shown as the mean ± SEM of 
four independent experiments, performed using aortic VSMCs isolated from four 
SHRs. * indicates P < 0.05 versus control; *** P < 0.001 versus control; P < 
0.01 Oxytocin versus Ang II; ## P < 0.01 Oxytocin + Ang II versus Ang II alone; # 
P < 0.05 Oxytocin + Ang II versus OXTA + Oxytocin + Ang II. Ang II indicates 
Angiotensin II; OXTA, Oxytocin receptor antagonist; ROCK, Rho-associated 
coiled-coil-containing protein kinase. 
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Figure 4.24. The effect of oxytocin and different treatment groups on the 
activation of ROCK-2 in aortic SHR VSMCs. Western blotting was utilized to 
measure the ROCK-2 levels, and the data were normalized with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The effect of oxytocin and its combination 
with different treatment groups on the activation of ROCK-2 as the percent (%) of 
control, with control as 100%. The data are shown as the mean ± SEM of five 
independent experiments, performed using aortic VSMCs isolated from five SHRs. 
** indicates P < 0.01 versus control; *** P < 0.001 versus control; P < 0.01 
Oxytocin versus Ang II; ### P < 0.01 Oxytocin + Ang II versus Ang II alone, and 
Oxytocin + Ang II versus OXTA + Oxytocin + Ang II. Ang II indicates Angiotensin 
II; OXTA, Oxytocin receptor antagonist; ROCK, Rho-associated coiled-coil 
containing protein kinase. 
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4.2.5. Effect of oxytocin and its pre-treatment with Ang II on IL-6 secretion 
in aortic SHR VSMCs 
As per the manufacturer’s protocol, the IL-6ELISA assay was carried out 
and the concentration of IL-6 secreted by the aortic VSMCs in the culture media 
was measured as ‘picogram per milliliter’ (pg/mL). In spontaneously hypertensive 
rats (SHRs), the findings of the IL-6 assay demonstrated that oxytocin significantly 
increased IL-6 secretion in culture media compared to the control group (Figure 
4.25). 
The assay employed three different concentrations of oxytocin: 10 nM, 100 
nM, 1,000 nM. When compared with control group (848 ± 9 pg/mL), oxytocin 
significantly increased IL-6 secretion in a concentration-dependent manner: 985 ± 
25 pg/mL (P < 0.01) at 10 nM; 1,289 ± 8 pg/mL (P < 0.001) at 100 nM; and 1,468 
± 19 pg/mL (P < 0.01) at 1,000 nM, respectively (Figure 4.25). 
The treatment with Ang II (100 nM) showed a significant increase in IL-6 
secretion [1,620 ± 66 pg/mL (P < 0.001)] compared to the control group [(848 ± 9 
pg/mL), Figure 4.25]. 
When oxytocin (100 nM) and Ang II (100 nM) groups were compared to 
the control group,  Ang II (100 nM) showed significantly more IL-6 [1,620 ± 66 
pg/mL (P < 0.01)] than oxytocin [100 nM (1,289 ± 8 pg/mL)] compared  to the 
control group [(848 ± 9 pg/mL), Figure 4.25]. 
Although oxytocin on its own significantly increased IL-6 secretion, 
interestingly, oxytocin’s pre-treatment (100 nM) with Ang II (100 nM) 
significantly decreased IL-6 secretion [891 ± 59 pg/mL (P < 0.001)] compared to 
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Ang II 100 nM alone (1,620 ± 66 pg/mL) and oxytocin 100 nM alone [1,289 ± 8 
pg/mL (P < 0.001)], respectively (Figure 4.25). 
The effect of oxytocin’s pre-treatment (100 nM) on Ang II (100 nM) was 
significantly inhibited by pre-treatment with 1µM OXTA. IL-6 secretion was 
significantly higher [1,476 ± 58 pg/mL (P < 0.01)] in the OXTA-pre-treatment 
group [OXTA (1µM) + Oxytocin (100 nM) + Ang II (100 nM)] than Oxytocin 100 
nM + Ang II 100 nM group [(891 ± 59 pg/mL), Figure 4.25]. 
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Figure 4.25. The effect of oxytocin and different treatment groups on IL-6 
secretion in aortic SHR VSMCs. The concentration of IL-6 secreted by aortic SHR 
VSMCs in culture media was measured in picogram per mL (pg/mL). The data are 
represented as the mean ± SEM from three independent experiments performed 
using aortic VSMCs from three SHRs. In each experiment each treatment group 
had duplicates. ** indicates P < 0.01 versus Control group; *** P < 0.001 versus 
Control group;  P < 0.001 Oxytocin 10 nM versus Oxytocin 100 nM and 
Oxytocin 1000 nM respectively, and Oxytocin 100 nM versus Oxytocin 1000 nM. ## 
P < 0.01 Oxytocin 100 nM + Ang II 100 nM versus Oxytocin 100 nM alone and 
OXTA 1µM + Oxytocin 100 nM + Ang II 100 nM; ### P < 0.001 Oxytocin 100 nM 
+ Ang II 100 nM versus Ang II 100 nM alone;  P < 0.01 Oxytocin 100 nM versus 
Ang II 100 nM. Ang II indicates Angiotensin II; OXTA, Oxytocin receptor 
antagonist. 
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4.2.6. Effect of oxytocin and its pre-treatment with Ang II on ROS production 
in aortic SHR VSMCs   
The outcomes of the ROS assay in aortic SHR VSMCs revealed that 
oxytocin significantly increased ROS production and its pre-treatment with Ang II 
also considerably increased ROS production (Figure 4.26). 
Measured as the function of fluorescent units, the ROS assay findings 
showed that treatment with oxytocin (100 nM) significantly increased ROS 
production [6,657 ± 202 (P < 0.001)] compared to the control group (5,411 ± 259) 
in aortic SHR VSMCs. The treatment with Ang II (100 nM) significantly increased 
ROS production [6,286 ± 208 (P < 0.001)] compared to the control group (5,411 ± 
259) (Figure 4.26). 
There was no significant difference in ROS production between oxytocin 
[100 nM (6,657 ± 202)] and Ang II [100 nM (6,286 ± 208)] treatment groups 
(Figure 4.26). 
The pre-treatment of oxytocin (100 nM) followed by Ang II (100 nM) 
significantly increased ROS production [7,481 ± 162 (P < 0.001)] compared to the 
control group [5,411 ± 259 (Figure 4.26)]. 
Additionally, pre-treatment with Oxytocin (100 nM) followed by Ang II 
(100 nM) significantly increased the ROS production (7,481 ± 162) compared to 
oxytocin (100 nM) alone [6,657 ± 202 (P < 0.01)]  and Ang II (100 nM) alone 
[6,286 ± 208 (P < 0.001)], respectively, indicating an additive effect (Figure 4.26). 
Interestingly, OXTA (1 µM) on its own significantly increased the ROS 
production [6,703 ± 173 (P < 0.001)] compared to the control group (5,411 ± 259). 
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In addition, pre-treatment with OXTA (1 µM) followed by Oxytocin (100 nM) also 
significantly increased ROS production [6,978 ± 223 (P < 0.001)] compared to 
control group [5,411 ± 259 (Figure 4.26)]. 
There was no significant difference between Oxytocin (100 nM) group 
(6,657 ± 202) and OXTA (1 µM) + Oxytocin (100 nM) group [6,978 ± 223 (Figure 
4.26)]. 
The combination of OXTA (1 µM), Oxytocin (100 nM), and Ang II 
significantly increased ROS production [7,705 ± 211 (P < 0.001)] compared to 
control (5,411 ± 259) in aortic SHR VSMCs (Figure 4.26). 
The combination of OXTA, Oxytocin, and Ang II (100 nM) significantly 
increased ROS production [7,705 ± 211 (P < 0.001)]  compared to Oxytocin (100 
nM) alone (6,657 ± 202), Ang II (100 nM) alone (6,286 ± 208) and OXTA (1 µM) 
alone (6,703 ± 173), respectively, indicating an additive effect (Figure 4.26).  
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Figure 4.26. The effect of oxytocin and different treatment groups on ROS 
production in aortic SHR VSMCs. SHR VSMCs were seeded at 1×104 cells/well 
in 96-well plates. The ROS levels were measured as the function of the fluorescent 
unit. The data are represented as the mean ± SEM from three independent 
experiments performed using aortic VSMCs from three SHRs. In each experiment 
each treatment group had 12 replicates. ** indicates P < 0.01 Ang II versus 
Control; *** P < 0.001 versus Control group; ## P < 0.01 Oxytocin + Ang II versus 
Oxytocin alone; ### Oxytocin + Ang II versus Ang II alone; P < 0.001 OXTA + 
Oxytocin + Ang II versus Oxytocin alone, Ang II alone, and OXTA alone. Ang II 
indicates Angiotensin II; OXTA, Oxytocin receptor antagonist.  
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4.3. Comparison of the effects of oxytocin and its pre-treatment with Ang II on 
aortic Wistar VSMCs versus SHR VSMCs 
The effects of oxytocin on aortic Wistar VSMCs and SHR VSMCs alone 
and after pre-treatment with Ang II were analyzed and compared, and are explained 
under the following sub-headings:  
4.3.1. Comparison between Wistar VSMCs and SHR VSMCs regarding the 
effect of oxytocin and its pre-treatment with Ang II on aortic VSMCs 
proliferation  
In control group, the proliferation of Wistar VSMCs was significantly 
higher at 24 hours [6.37 × 106 cells/mL ± 9.20 × 105 cells/mL (P < 0.05)] and 48 
hours [1.50 × 107 cells/mL ± 1.47 × 106 cells/mL (P < 0.05)]  compared to SHR 
VSMCs (4.24 × 106 cells/mL ± 1.51 × 105 cells/mL at 24 hours and 1.10 × 107 
cells/mL ± 7.04 × 105 at 48 hours). However, at 72 hours there was no significant 
difference in proliferation between Wistar VSMCs (2.30 × 107 cells/mL ± 5.53 × 
106 cells/mL) and SHR VSMCs [1.59 × 107 cells/mL 2.72 × 106 cells/mL (Figure 
4.27)]. 
Oxytocin significantly decreased proliferation in Wistar VSMCs: 3.12 × 106 
cells/mL ± 4.14 × 105 cells/mL at 24 hours; 1.64 × 106 cells/mL ± 3.07 × 105 
cells/mL at 48 hours; and 1.23 × 106 cells/mL ± 4.45 × 105 cells/mL at 72 hours 
post-treatment compared to their respective control. Similar to the results in Wistar 
VSMCs, oxytocin remarkably decreased proliferation in SHR VSMCs: 2.34 × 106 
cells/mL ± 1.98 × 105 cells/mL at 24 hours; 1.72 × 106 cells/mL ± 1.04 × 105 
cells/mL at 48 hours; and 1.71 × 106 cells/mL ± 4.29 × 105 cells/mL at 72 hours 
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post-treatment compared to their respective control. It is noteworthy that there was 
no significant difference in the pattern and magnitude of oxytocin-induced 
inhibition of proliferation in Wistar VSMCs and SHR VSMCs (Figure 4.27).  
Ang II showed significantly more proliferation in Wistar VSMCs [2.88 × 
107 cells/mL ± 1.74 × 106 cells/mL (P < 0.001) at 24 hours; 4.73 × 107 cells/mL ± 
3.45 × 106 cells/mL  (P < 0.01) at 48 hours; and 5.03 × 107 cells/mL ± 1.82 × 106 
cells/mL (P < 0.05) at 72 hours post-treatment] than SHR VSMCs (1.22 × 107 
cells/mL ± 2.98 × 105 cells/mL at 24 hours; 2.33 × 107 cells/mL ± 1.03 × 106 
cells/mL  at 48 hours; and 4.88 × 107 cells/mL ± 9.99 × 105 cells/mL at 72 hours 
post-treatment) compared to their respective controls (Figure 4.27). 
Oxytocin pre-treatment with Ang II significantly reduced Ang II-mediated 
proliferation of VSMCs isolated from both Wistar rats (1.07 × 107 cells/mL ± 2.99 
× 106 cells/mL at 24 hours; 8.06 × 106 cells/mL ± 3.13 × 106 cells/mL  at 48 hours; 
and 6.55 × 106 cells/mL ± 2.23 × 106 cells/mL at 72 hours post-treatment) and SHRs 
(4.14 × 106 cells/mL ± 8.47 × 105 cells/mL at 24 hours; 1.60 × 106 cells/mL ± 2.80 
× 105 cells/mL  at 48 hours; and 1.37 × 106 cells/mL ± 2.32 × 105 cells/mL at 72 
hours post-treatment) compared to their respective Ang II (alone) groups. However, 
this effect was significantly higher in SHRs than Wistar Rats at 24 hours (P < 0.05), 
48 hours (P < 0.05), and 72 hours (P < 0.05) post-treatment (Figure 4.27).  
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Figure 4.27. The comparison of the effects of oxytocin, Ang II, and the pre-
treatment of oxytocin with Ang II on proliferation of aortic VSMCs between 
Wistar VSMCs and SHR VSMCs as assessed by the Hemocytometer method. 
VSMCs isolated from both Wistar rats and SHRs were seeded at 1×106 cells/well 
in 6-well plates. Cell proliferation was measured by counting the number of cells 
per milliliter (mL). The data are represented as the mean ± SEM from three 
independent experiments performed using aortic VSMCs from three Wistar rats and 
three SHRs, respectively. * indicates P < 0.05 versus Control Wistar rats versus 
Control SHRs;   P < 0.05 (Oxytocin + Ang II) Wistar rats versus (Oxytocin + Ang 
II) SHRs; ## P < 0.01 Ang II Wistar rats vs Ang II SHRs; ### P < 0.001 Ang II Wistar 
rats vs Ang II SHRs. Ang II indicates Angiotensin II; OXTA, Oxytocin receptor 
antagonist.  
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4.3.2. Comparison between Wistar VSMCs and SHR VSMCs regarding the 
effect of oxytocin and its pre-treatment with Ang II on aortic VSMCs 
viability 
In MTT assay, the cell viability was determined as the function of the 
optical density (OD) measured at 570 nm. On comparing the cell viability of aortic 
VSMCs isolated from both Wistar rats and SHRs, significantly higher cell viability 
was observed in the control group SHR VSMCs [0.4 OD ± 0.1 (P < 0.05)] OD at 
24 hours than Wistar VSMCs (0.3 OD ± 0.0 OD). However, at 48 hours and 72 
hours there was no significant difference in the cell viability between Wistar 
VSMCs  (0.5 OD ± 0.0 OD at 48 hours and 0.7 OD ± 0.0 OD and 72 hours) and 
SHR VSMCs [0.5 OD ± 0.0 OD at 48 hours and 0.8 OD ± 0.0 OD at 72 hours 
(Figure 4.28).  
Oxytocin significantly decreased the cell viability of aortic VSMCs isolated 
from both Wistar rats and SHRs compared to the control groups, respectively. At 
24 hours post-treatment, Oxytocin significantly decreased more cell viability of 
Wistar VSMCs [0.2 OD ± 0.0 OD (P < 0.05)] than SHR VSMCs (0.4 OD ± 0.1 
OD). However, at 48 hours and 72 hours there was no significant difference in the 
oxytocin-induced decrement in viability between the Wistar VSMCs  (0.3 OD ± 
0.0 OD at 48 hours and 0.6 OD ± 0.1 OD at 72 hours) and SHR VSMCs (0.3 OD ± 
0.0 OD at 48 hours and 0.5 OD ± 0.0 OD at 72 hours). Oxytocin showed a similar 
pattern and magnitude of inhibition in cell viability in both Wistar VSMCs and 
SHR VSMCs at 48 hours and 72 hours post-treatment (Figure 4.28). 
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Ang II significantly increased the cell viability of aortic VSMCs isolated 
from both Wistar rats (0.5 OD ± 0.1 OD at 24 hours, 1.0 OD ± 0.1 OD at 48 hours, 
and 1.3 OD ± 0.1 OD at 72 hours) and SHRs (0.7 OD ± 0.0 OD at 24 hours, 1.1 
OD ± 0.1 OD at 48 hours, and 2.0 OD ± 0.1 OD at 72 hours) compared to the 
respective control groups. However, at 72 hours post-treatment, Ang II showed a 
more significant increase in cell viability in SHR VSMCs [2.0 OD ± 0.1 OD (P < 
0.001)] than Wistar VSMCs [1.3 OD ± 0.1 OD (Figure 4.28)]. 
The pre-treatment of oxytocin with Ang II significantly decreased Ang II-
induced cell viability in both Wistar VSMCs  (0.2 OD ± 0.0 OD at 24 hours, 0.3 
OD ± 0.0 OD at 48 hours, and 0.6 OD ± 0.1 OD at 72 hours) and SHR VSMCs (0.4 
OD ± 0.1 OD at 24 hours, 0.3 OD ± 0.0 OD at 48 hours, and 0.6 OD ± 0.0 OD at 
72 hours) compared to the respective Ang II (alone) groups (Figure 4.28). 
At 24 hours post-treatment, the oxytocin-pretreatment showed more 
significant decrease viability in Wistar VSMCs [0.2 OD ± 0.0 OD (P < 0.01)] than 
SHR VSMCs (0.4 OD ± 0.1 OD). Although, at 48 and 72 hours, respectively, there 
was no significant difference in the cell viability between Wistar VSMCs and SHR 
VSMCs in the oxytocin-pre-treatment with Ang II group (Figure 4.28). 
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Figure 4.28. The comparison of the effects of oxytocin, Ang II, and the pre-
treatment of oxytocin with Ang II on viability of aortic Wistar VSMCs and SHR 
VSMCs as assessed by the MTT assay. VSMCs isolated from both Wistar rats and 
SHRs were seeded at 1×104 cells/well in 96-well plates. Cell viability was 
measured as the function of an optical density (OD) at 570 nm. The data are shown 
as the mean ± SEM from three independent experiments performed using aortic 
VSMCs from three Wistar rats and three SHRs, respectively. Each experiment was 
performed with 12 replicates. * indicates P < 0.05 Control Wistar rats versus 
Control SHRs; § P < 0.05 Oxytocin Wistar rats versus Oxytocin SHRs;  P < 0.01 
(Oxytocin + Ang II) Wistar rats versus (Oxytocin + Ang II) SHRs; ### P < 0.001 
Ang II Wistar rats versus Ang II SHRs. Ang II indicates Angiotensin II; OXTA, 
Oxytocin receptor antagonist. 
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4.3.3. Comparison of the effect of oxytocin on apoptosis and necrosis between 
Wistar VSMCs and SHR VSMCs 
In aortic VSMCs isolated from both Wistar rats and SHRs, the flow 
cytometry results showed that oxytocin significantly reduced live cells percentage, 
prominently induced apoptosis (in a concentration-dependent manner) and induced 
necrosis.  
The flow experiments employed two different concentrations of oxytocin: 
10 nM and 100 nM. In the control group, there was no significant difference 
between: live cells in Wistar VSMCs (95.5 ± 0.7%) and SHR VSMCs (93.4% ± 
1.1% in SHRs); and apoptotic cells in Wistar VSMCs (2.7% ± 1.1%) and SHR 
VSMCs (2.4% ± 0.3%). However, the SHR VSMCs control group showed a 
significantly higher percentage of necrotic cells [1.5% ± 0.0% (P < 0.01)] compared 
to the Wistar VSMCs control group [0.7% ± 0.1% (Figure 4.29)]. 
The treatment with oxytocin 10 nM resulted in a more significant reduction 
in live cells percentage in SHR VSMCs [80.9% ± 0.7% (P < 0.01)] than Wistar 
VSMCs (91.6% ± 0.4%) compared to their respective controls. In addition, 
oxytocin 10 nM induced significantly more apoptosis in SHR VSMCs [13.9% ± 
0.4% (P < 0.05)] than Wistar VSMCs (4.2% ± 1.6%) compared to their respective 
controls (Figure 4.29). 
Treatment with oxytocin 100 nM showed a similar pattern and magnitude 
in reduction of the percentage of live cells and induction of apoptosis in between 
Wistar VSMCs (67.5% ± 2.3% live cells and 26.1% ± 3.0% apoptotic cells) and 
SHR VSMCs (65.0% ± 0.9% live cells and 23.9% ± 0.1% apoptotic cells) compared 
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to their respective controls. Interestingly, oxytocin 100 nM resulted in a 
significantly higher percentage of cells undergoing necrosis [8.6% ± 1.3% (P < 
0.05)] in SHR VSMCs than Wistar VSMCs [3.9% ± 0.3% (Figure 4.29)].  
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Figure 4.29. The comparison of the effects of oxytocin on the live cells, apoptosis, 
and necrosis between Wistar VSMCs and SHR VSMCs as assessed by flow 
cytometry. Aortic VSMCs isolated from both Wistar rats and SHRs were seeded at 
1×106 cells/well in 6-well plates. The data are shown as the percentage of cells and 
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are represented as the mean ± SEM from three independent experiments performed 
using aortic VSMCs from three Wistar rats and three SHRs, respectively. The 
treatment was carried out 24 hours with two different concentrations of oxytocin: 
10nM and 100nM. The cells were stained with fluorescent dyes: Annexin V (for 
apoptosis) and 7-amino actinomycin D [(7-ADD) for necrosis]. ** indicates P < 
0.01 Live Cells in Oxytocin 10 nM group in Wistar rats versus Live Cells in 
Oxytocin 100 nM in group SHRs;  P < 0.05 Apoptotic cells in Oxytocin 10 nM 
group in Wistar rats versus Apoptotic cells in Oxytocin 10 nM group in SHRs; # P 
< 0.05 Necrotic cells in Oxytocin 100 nM group in Wistar rats vs Necrotic cells in 
Oxytocin 100 nM group in SHRs; ##P < 0.01 Necrotic cells in Control group in 
Wistar rats vs Necrotic cells in Control group in SHRs.  
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4.3.4. Comparison of the effect of oxytocin and its pre-treatment with Ang II 
on the phosphorylation of ERK1/2, PI3K p110𝑎, and AKT in aortic 
Wistar VSMCs and SHR VSMCs 
Western blotting was utilized to study the effect of oxytocin, Ang II, and its 
pre-treatment with Ang II on the phosphorylation of ERK1/2, PI3K p110α, and 
Akt. The densitometric analysis of western blot images demonstrated that oxytocin 
and its pre-treatment with Ang II significantly decreased the phosphorylation of 
ERK1/2, PI3K p110 α, and Akt in aortic Wistar VSMCs and SHR VSMCs. 
On the phosphorylation of ERK1/2 
There was no significant difference between Wistar VSMCs  and SHR 
VSMCs regarding oxytocin-mediated decrease in the levels of the phosphorylated 
forms of (active form) ERK1/2: oxytocin decreased the phosphorylation of ERK1/2 
by 57.9% ± 14.2% in Wistar VSMCs and by 35.4% ± 4% in SHR VSMCs compared 
to respective controls (Figure 4.30 b).  
Although, Ang II-induced phosphorylation of ERK1/2 was significantly 
higher in Wistar VSMCs (P < 0.05) than SHR VSMCs. In Wistar VSMCs, Ang II 
increased the phosphorylation of ERK1/2 by 223% ± 11% compared to control, 
whereas, in SHR VSMCs, Ang II increased the phosphorylation of ERK1/2 by 
157% ± 21% compared to control (Figure 4.30 a). 
The pre-treatment of oxytocin with Ang II caused more significant decrease 
in the phosphorylation of ERK1/2 in SHR VSMCs [93.3% ± 1.4% decrease (P < 
0.001) than in Wistar VSMCs (76.6% ± 1.4% decrease) compared to their 
respective Ang II (alone) groups (Figure 4.30 c). 
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On the phosphorylation of PI3K p110a 
There was a significant difference between oxytocin-mediated reduction in 
the phosphorylated form of (active form) of PI3K p110a between Wistar VSMCs 
and SHR VSMCs. Oxytocin showed a more substantial decrease of phospho-PI3K 
p110a in Wistar VSMCs (P < 0.01) than SHR VSMCs. In Wistar VSMCs, oxytocin 
reduced phospho-PI3K p110a by 64.8% ± 2.8% compared to control. On the other 
hand, in SHR VSMCs, oxytocin reduced phospho-PI3K p110a by 31% ± 5.1% 
compared to control (Figure 4.30 e).   
Ang II-induced phosphorylation of PI3K p110a was significantly higher in 
Wistar VSMCs (P < 0.01) than SHR VSMCs. In Wistar VSMCs, Ang II increased 
phospho-PI3K p110a by 184% ± 17% compared to control, whereas, in SHR 
VSMCs, Ang II increased phospho-PI3K p110a by 79.8% ± 10.3% compared to 
control (Figure 4.30 d). 
The oxytocin’s pre-treatment with Ang II showed significantly more 
decrease in phospho-PI3K p110a levels in Wistar VSMCs (P < 0.05) than SHR 
VSMCs. The oxytocin’s pre-treatment decreased the phosphorylation of PI3K 
p110a by 83.8% ± 8.6% in Wistar VSMCs and by 61.3% ± 4.8% in SHR VSMCs, 
respectively, compared to their respective Ang II (alone) groups (Figure 4.30 f). 
On the phosphorylation of Akt 
There was no significant difference in oxytocin-mediated decrease in the 
phosphorylation of Akt between Wistar VSMCs (46.2% ± 9.5% decrease) and SHR 
VSMCs (45.5% ± 8.6% decrease) compared to the respective control groups 
(Figure 4.30 h).  
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Similarly, Ang II-induced increase in the phosphorylation of Akt was not 
markedly different between Wistar VSMCs (44.4% ± 3.5%) rats and SHR VSMCs 
(70.2% ± 20.4% increase) compared to their respective control groups (Figure 4.30 
g). 
The pre-treatment of oxytocin with Ang II also didn’t show any significant 
difference in inhibiting phospho-Akt between Wistar VSMCs (62.1% ± 10.9% 
decrease) and SHR VSMCs (60.4% ± 2.6% decrease) compared to the respective 
Ang II (alone) groups (Figure 4.30 i). 
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Figure 4.30. The comparison of the effects of oxytocin, Ang II, and pre-treatment 
of oxytocin with Ang II on the phosphorylation of ERK1/2 (figure a, b, and c), 
PI3K p110⍺ (figure d, e, and f), and Akt (figure g, h, and i) in aortic Wistar and 
SHR VSMCs. The data are shown as the normalized relative intensity of the bands 
and are represented as percent (%) of control, with control as 100%. The data are 
shown as the mean ± SEM of five (five Wistar rats and five SHRs each), three (three 
Wistar rats and three SHRs each), and four (four Wistar rats and four SHRs each) 
independent experiments conducted for ERK1/2, PI3K p110⍺, and Akt, 
respectively. * indicates P < 0.05; ** P < 0.01; *** P < 0.001. Ang II indicates 
Angiotensin II; OXTA, oxytocin receptor antagonist; ERK, extracellular signal-
regulated kinase; PI3K, phosphatidylinositol-3-kinase.  
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4.3.5. Comparison of the effect of oxytocin and its pre-treatment with Ang II 
on vasocontraction pathway: ROCK-1 and ROCK-2 in aortic VSMCs 
isolated from Wistar rats and SHRs 
Western blotting was employed to investigate the effect of oxytocin, Ang 
II, and its pre-treatment with Ang II on the activation of ROCK-1 and ROCK-2. 
The densitometric analysis of western blot images demonstrated that oxytocin 
significantly decreased the activation of ROCK-1 and ROCK-2 in both aortic 
Wistar VSMCs and SHR VSMCs. 
On ROCK-1 
There was no significant difference between oxytocin-mediated reduced 
activation of ROCK-1 between Wistar VSMCs and SHR VSMCs, respectively 
(Figure 4.31).  
Oxytocin reduced the ROCK-1 activation by 60.4% ± 7.6% in Wistar 
VSMCs and by 58.9% ± 5.4% in SHR VSMCs compared to their respective control 
groups (Figure 4.31 b).  
Similarly, Ang II-induced activation of ROCK-1 was not markedly different 
between Wistar VSMCs (147 % ± 50 % increase) and SHR VSMCs (102% ± 43% 
increase) compared to their respective control groups (Figure 4.31 a).   
The pre-treatment of oxytocin with Ang II also didn’t show any significant 
difference in reducing the activation of ROCK-1 between Wistar VSMCs (85.2% 
± 10.6% decrease) and SHR VSMCs (79%  ±  6.9% decrease) compared to the 
respective Ang II (alone) groups (Figure 4.31 c). 
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On ROCK-2 
Similar to ROCK-1, the impact of oxytocin in reducing the activation of 
ROCK-2 was not markedly different between Wistar VSMCs and SHR VSMCs 
(Figure 4.31). 
Oxytocin-mediated reduced activation of ROCK-2 in Wistar VSMCs 
(38.7% ± 13.1% decrease) was not statistically different from that in SHR VSMCs 
[(41.5% ± 12.8% decrease (Figure 4.31 e)]. Ang II-induced increased activation of 
ROCK-1 in Wistar VSMCs (83.2% ± 14.6% increase) was not prominently 
different from SHR VSMCs (81.2% ± 14.8% increase) compared to their respective 
control groups (Figure 4.31 d). 
The pre-treatment of oxytocin with Ang II also didn’t show any substantial 
difference in reducing the activation of ROCK-1 between Wistar VSMCs (65.8% 
± 13.2% decrease) and SHR VSMCs (69.5%  ±  13.2% decrease) compared to their 
Ang II (alone) groups respectively (Figure 4.31 f). 
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Figure 4.31. The comparison of the effects of oxytocin, Ang II, and the 
pretreatment of oxytocin with Ang II on the phosphorylation of Rho kinases – 
ROCK-1 (figure a, b, and c) and ROCK-2 (figure d, e, and f) in aortic Wistar and 
SHR VSMCs. The data are shown as the normalized relative intensity of the bands 
and are represented as percent (%) of control, with control as 100%. The data are 
shown as the mean ± SEM of four (four Wistar rats and four SHRs each) and five 
(five Wistar rats and five SHRs each) independent experiments conducted for 
ROCK-1 and ROCK-2, respectively. Ang II indicates Angiotensin II; OXTA, 
oxytocin receptor antagonist; ROCK, rho-associated coiled-coil containing protein 
kinase. 
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4.3.6. Comparison of the effect of oxytocin and its pre-treatment with Ang II 
on IL-6 in aortic Wistar VSMCs and SHR VSMCs 
The ELISA based IL-6 assay involved the measurement of the 
concentration of IL-6 released in the culture media. The findings of IL-6 assay 
established that oxytocin significantly increased IL-6 secretion from aortic VSMCs, 
but its pre-treatment with Ang II significantly decreased IL-6 in both Wistar 
VSMCs and SHR VSMCs.  
There was a significant difference in IL-6 secretion levels in the control 
group between Wistar VSMCs and SHR VSMCs. The control group in SHR 
VSMCs showed more IL-6 [848 ± 9 pg/mL (P < 0.05)] than Wistar VSMCs [614 ± 
104 pg/mL (Figures 4.32 and 4.33)].  
The assay employed three different concentrations of oxytocin: 10 nM, 100 
nM, 1000 nM. In response to different concentrations of oxytocin, aortic SHRs 
VSMCs showed significantly more IL-6 secretion [985 ± 25 pg/mL (P < 0.05) at 
10 nM (Figure 4.32); 1,289 ± 8 pg/mL (P < 0.001) at 100 nM (Figures 4.32 and 
4.33); and 1,468 ± 19 pg/mL (P < 0.001) at 1,000 nM (Figure 4.32)] than Wistar 
VSMCs  (695 ± 101 pg/mL at 10 nM; 1033 ± 24 pg/mL at 100 nM; and 959 ± 52 
pg/mL at 1,000 nM) compared to their respective controls. 
There was no significant difference between Wistar VSMCs and SHR 
VSMCs with regards to Ang II-induced secretion of IL-6 (1,481 ± 91 pg/mL in 
Wistar VSMCs and 1,620 ± 66 pg/mL in SHR VSMCs) compared to their 
respective control groups (Figures 4.32 and 4.33).  
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Although oxytocin on its own significantly increased IL-6 in both Wistar 
VSMCs  and SHR VSMCs, interestingly, oxytocin’s pre-treatment (100 nM) 
followed by Ang II (100 nM) significantly decreased IL-6 secretion in both Wistar 
VSMCs (735 ± 77 pg/mL) and SHR VSMCs (891 ± 59 pg/mL) compared to their 
respective Ang II 100 nM (alone) groups (Figures 4.32 and 4.33).   
However, there was no significant difference between the Wistar VSMCs 
and SHR VSMCs concerning the effect of oxytocin’s pre-treatment on Ang II-
induced IL-6 secretion (Figures 4.32 and 4.33). The pattern and magnitude of the 
impact of oxytocin pre-treatment on Ang II-mediated IL-6 secretions were similar 
in both Wistar VSMCs and SHR VSMCs. 
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Figure 4.32. The comparison of the effect of oxytocin (10 nM, 100 nM, and 
1,000nM), Ang II (100 nM), pre-treatment of oxytocin with Ang II on IL-6 
secretion in aortic Wistar VSMCs and SHRs VSMCs. The concentration of IL-6 
secretion by the aortic VSMCs in the culture media was measured in picogram per 
mL (pg/mL). The data are represented as the mean ± SEM from three independent 
experiments performed using aortic VSMCs from three Wistar rats and three SHRs, 
respectively. In each experiment each treatment group had duplicates.  * indicates 
P < 0.05 Control Wistar rats versus Control SHRs; P < 0.05 Oxytocin 10 nM 
Wistar rats versus Oxytocin 10 nM SHRs;   P < 0.001 Oxytocin 100 nM Wistar 
rats versus Oxytocin 100 nM SHRs; ### P < 0.001 Oxytocin 1000 nM Wistar rats 
versus Oxytocin 1000 nM SHRs. Ang II indicates Angiotensin II.  
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Figure 4.33. The comparison of the effect of oxytocin (100 nM), Ang II (100 nM), 
pre-treatment of oxytocin (100 nM) with Ang II (100 nM) on IL-6 secretion in 
aortic Wistar VSMCs and SHRs VSMCs. The concentration of IL-6 secreted by 
the aortic VSMCs in the culture media was measured in picogram per mL (pg/mL). 
The data are represented as the mean ± SEM from three independent experiments 
performed using aortic VSMCs from three Wistar rats and three SHRs, 
respectively. In each experiment each treatment group had duplicates.  * indicates 
P < 0.05 Control group Wistar rats versus Control group SHRs; ### P < 0.001 
Oxytocin 100 nM in Wistar rats versus Oxytocin 100 nM in SHRs. Ang II indicates 
Angiotensin II. 
 
 
 
 
 
 
 
 
 
 
 157 
4.3.7. Comparison of the effect of oxytocin and its pre-treatment with Ang II 
on ROS production in aortic Wistar VSMCs and SHR VSMCs 
The ROS assay findings demonstrated that oxytocin significantly increased 
the ROS production in aortic VSMCs isolated from both Wistar rats and SHRs.  
In addition, the pre-treatment of oxytocin followed by Ang II significantly 
increased ROS production in both Wistar VSMCs and SHR VSMCs. However, 
there was a significant difference in the impact of oxytocin and its pre-treatment 
with Ang II on ROS production between Wistar VSMCs and SHR VSMCs.  
The control group Wistar VSMCs showed more ROS levels [7,542 ± 128 
(P < 0.001)] compared to the control group SHR VSMCs [5,411± 259 (Figure 
4.44)].    
The treatment with oxytocin (100 nM) resulted in a significantly more ROS 
production in Wistar VSMCs [8,584 ± 114 (P < 0.001)] than SHR VSMCs (6,657 
± 202) compared to their respective controls (Figure 4.44). 
Ang II (100 nM)-induced ROS production was significantly higher in 
Wistar VSMCs [8,336 ± 204 P < 0.001)] than SHR VSMCs [6,286 ± 208 (Figure 
4.44)].  
The pre-treatment of oxytocin (100 nM) followed by Ang II (100 nM) also 
showed significantly higher ROS production [9,346 ± 143 P < 0.001)] in Wistar 
VSMCs than SHR VSMCs (7,481 ± 162) compared to their respective Ang II 
(alone) and Oxytocin groups (alone), respectively (Figure 4.44). 
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Figure 4.44. The comparison of the effect of oxytocin, Ang II, pre-treatment of 
oxytocin with Ang II on ROS production between aortic Wistar and SHR VSMCs. 
VSMCs were seeded at 1×104 cells/well in 96-well plates. The ROS levels were 
measured as the function of the fluorescent unit. The data are represented as the 
mean ± SEM from three independent experiments performed using aortic VSMCs 
from three Wistar rats and three SHRs, respectively. In each experiment each 
treatment group had 12 replicates. *** indicates P < 0.001 Control group in Wistar 
rats versus Control group in SHRs; P < 0.001 Oxytocin 100 nM in Wistar rats 
versus Oxytocin 100 nM in SHRs; ### P < 0.001 Ang II 100 nM in Wistar rats versus 
Ang II 100 nM in SHRs;  P < 0.001 Oxytocin 100 nM + Ang II 100 nM in Wistar 
rats versus Oxytocin 100 nM + Ang II 100 nM in SHRs. Ang II indicates 
Angiotensin II. 
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Chapter 5: Discussion 
CVD is the leading cause of hospitalization in the United States and accounts for 
mortality more than other any other disease, including cancer and communicable 
diseases.263 Each year about 17 million deaths occur due to CVD, which is two times higher 
than deaths caused by cancer, and in all probability, this number is going to increase to 
about 23.3 million by 2030.264 
Despite advancement in diagnosis and improvement in efforts aimed at prevention, 
control, and treatment, CVD remains a primary cause of premature death and disability 
across the globe.265 Consequentially, CVD healthcare management has imposed an 
enormous financial burden on patients.266 
The current standard CVD management includes therapies aimed at controlling 
patients’ lipid-profiles (statins), blood glucose levels (metformin), and prescription of anti-
hypertensive (ACE inhibitors) and anti-platelet medications (aspirin).267 However, lesser 
favorable patient outcomes, as well as the rapidly rising rate of mortality due to CVD, paint 
a different picture. It reflects a growing need to expand CVD research so that new 
therapeutic options can be devised to effectively treat CVD. The present study was a step 
towards exploring the potential of oxytocin in CVS. 
Over decade oxytocin, which is often referred to as a female reproductive 
hormone,1,9,268,269 has garnered the attention of the scientific community as a hormone with 
cardioprotective effects.23,24 Much of the research so far has focused on oxytocin-mediated 
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protective effects in cardiomyocytes, vascular endothelial cells, and cardiogenesis. 
247,30,32,40 Besides identifying the presence of the oxytocin receptors in VSMCs,25 not much 
research has been done concerning the potential effect of oxytocin on VSMCs.  
VSMCs play a crucial role in cardiovascular physiology and are often at the center 
of the events in the pathophysiology of CVD including hypertension.270 They undergo 
increased cell proliferation in response to hypertension-induced stress on the vasculature, 
leading to hypertrophy and an aberrant increase in vascular contraction.271,80 These changes 
are mediated by complex signaling pathways mainly the ERK1/2 pathway,99 the PI3K/Akt 
pathway,105 and ROCK pathway.144 In addition, increased oxidative stress and prolonged 
inflammation add to and exacerbate injury to VSMCs, and manifest the long-term 
pathological changes in vasculature.272,273 
Interestingly, the interaction of oxytocin with other vital peptides playing crucial 
roles in CVD such as Ang II has not been well-researched. Ang II is the primary effector 
hormone and the central component of the RAAS. It causes vasoconstriction and maintains 
blood pressure in normal physiological conditions.50 
Ang II is also involved in CVD such as atherosclerosis, congestive heart failure, 
diabetes, hypertension, inflammation, and myocardial infarction.51 It mainly binds to 
AT1R in the CVS and executes its actions via activation of the ERK1/2 pathways 
(increasing phospho-ERK1/2),274,275 PI3K/Akt pathway (phosphorylating PI3K p110α and 
increasing phospho-Akt)276,277 and ROCK pathway (activation of ROCK-1 and ROCK-
2).278,279 These signaling pathways and kinases are involved in Ang II-induced 
hypercontraction of VSMCs, hypertrophy, hyperplasia, endothelial dysfunction, leading to 
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vascular diseases and their progression.53,54 In addition, in cardiovascular 
pathophysiological conditions Ang II precipitates inflammation and oxidative stress.280,59  
We hypothesized that oxytocin provides vascular protection in VSMCs via 
modulation of these pathways, inflammation, and reduction of oxidative stress, and 
antagonization of the Ang II effects on these pathways, inflammation and oxidative stress. 
We investigated oxytocin’s effect on cell proliferation, inflammation, oxidative stress and 
on vasocontraction pathway in primary aortic VSMCs, isolated from the adult 
normotensive Wistar rats and SHRs.     
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5.1. Oxytocin reduced the proliferation in aortic VSMCs  
The findings of the present study demonstrated that oxytocin significantly 
decreased cell proliferation of normotensive (Wistar) and hypertensive (SHR) 
VSMCs. This is in contrast with the proliferative effect of oxytocin on vascular 
endothelial cells derived from: immortalized human dermal microvasculature, 
breast-tumors, human umbilical vein; and cardiomyocytes.40,41 
It is noteworthy that the kind of effect oxytocin shows on cell proliferation 
depends on the type of cells involved.  While previous studies have shown oxytocin 
exerting a proliferative influence on, for instance, trophoblast and astrocytes, others 
have shown oxytocin mediating anti-proliferative effects on cell lines obtained 
from breast cancer, ovarian cancer, and prostate cancer.281–283 
Even within the cell lines derived from a similar source but from different 
stages of differentiation, oxytocin has shown a differential effect on proliferation. 
For example, in osteosarcoma cell lines (SaOS-2, TE-85, and UMR-106) obtained 
from different stages of differentiation, oxytocin showed dual action on 
proliferation. Oxytocin increased cell proliferation in SaoS-2 cells and decreased 
cell proliferation in both TE-85 cells and UMR-106 cells.284  
Although only one type of oxytocin receptor has been found across species,3 
these dual effects of oxytocin on proliferation suggest the probability of another 
subtype of oxytocin receptor. 
In addition to showing anti-proliferative effects of oxytocin on aortic 
VSMCs, the outcomes of the present study have revealed that oxytocin significantly 
reduced Ang II-induced cell proliferation of aortic VSMCs isolated from 
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normotensive Wistar rats. Importantly, this effect was consistent in hypertensive 
SHRs VSMCs. Further, the oxytocin receptor antagonist significantly attenuated 
both these effects, suggesting that oxytocin mediated these effects via its receptors.  
It is essential to understand the impact of oxytocin-induced inhibition of 
Ang II-mediated proliferation of SHR VSMCs in the broader context of CVD 
pathophysiology. 
In hypertension induced by hyperactivation of Ang II signaling, VSMCs 
undergo extensive remodeling including hypertrophy and fibrosis. Moreover, 
cardiomyocytes in the left ventricle of the heart undergo hyper-proliferation leading 
to cardiac hypertrophy and ultimately, over time, compromise the function of heart 
and blood vessels.285 These events lay the foundation for a cascade of numerous 
other intra-vascular and intra-cardiac pathophysiological events worsening 
CVD.286 
Evidence that oxytocin’s anti-proliferative action on VSMCs and oxytocin-
induced decrease in Ang II-mediated proliferation of SHR VSMCs generated from 
this study underline the potential oxytocin might have in vascular protection in 
CVD such as hypertension, and this merits further investigation.  
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5.2. Oxytocin deactivated the proliferation signal transduction pathways in aortic 
VSMCs  
For greater understanding about how oxytocin reduces cell proliferation in 
aortic VSMCs, this study explored the two key downstream cell signaling pathways 
involved in the proliferation of VSMCs: the ERK1/2 MAPK pathway and the 
PI3K/Akt pathway. 
This study results revealed that oxytocin significantly reduced the 
phosphorylation of ERK1/2 in normotensive and hypertensive VSMCs. This is in 
contrast with reports from previous studies, which reported that oxytocin treatment 
increased phosphorylation of ERK1/2 in cardiomyocytes and vascular endothelial 
cells.40,102  
The differential effects of oxytocin on the phosphorylation of ERK1/2 have 
been proposed to be based on the type of cells involved, location of oxytocin 
receptors, activation of the different G-proteins, and interaction with a phosphatase. 
For example, oxytocin demonstrated dual effects on phosphorylation of ERK1/2 in 
human embryonic kidney cells. These effects were based on the site of oxytocin 
receptors. Oxytocin decreased the phosphorylation of ERK1/2 when oxytocin 
receptors were present outside the caveolin-1-enriched microdomains and resulted 
in reduced cell proliferation. And, oxytocin increased the phosphorylation of 
ERK1/2 when oxytocin receptors were present inside the caveolin-1-enriched 
microdomains and henceforth, increased cell proliferation.103  
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It is worth stating that caveolin-1 is vital in the trafficking of Gαs 
(stimulatory) protein, inhibition of Gαs/adenylyl cyclase pathway,104 and is also 
thought to be involved in the regulation of cell proliferation and cell survival.287 
In another study, oxytocin caused the dephosphorylation of eukaryotic 
elongation factor 2 (eEF2) and contributed to an increase in protein translation and 
synthesis in myometrial cells via PKC.288 The eEF2 kinase is responsible for the 
phosphorylation of eEF2. The phosphorylated form of eEF2 is inactive and causes 
downregulation of protein translation, whereas, the dephosphorylated form is the 
active form and leads to an increase in protein translation and synthesis. The eEF2 
kinase is regulated by a phosphatase known as protein phosphatase 2 A (PP2A).289 
In addition to oxytocin inducing dephosphorylation of eEF-2 through 
PKC,288 it could very well be that oxytocin might increase the phosphatase (PP2A) 
leading to reduced activity of eEF2 kinase and thus inducing dephosphorylation of 
eEF2. Furthermore, oxytocin reduced Ang II-induced phosphorylation of ERK1/2, 
and these effects were significantly abolished by pre-treatment with an oxytocin 
receptor antagonist. Interestingly, these effects of oxytocin were consistent in aortic 
VSMCs isolated from hypertensive rats.  
The significance of the study results demonstrating oxytocin-induced 
inhibition of phosphorylation of ERK1/2 and oxytocin-mediated inhibition of Ang 
II-induced ERK 1/2 phosphorylation in SHR VSMCs can be understood by 
assessing the implication of the ERK1/2 signaling pathway in CVD 
pathophysiology.290  
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An upregulation of agonist (Ang II)-stimulated ERK1/2 signaling for 
prolonged duration has been shown to induce pathological hypertrophy in VSMCs 
and decompensated cardiac hypertrophy in the heart.291 Thus, the ERK 1/2 
signaling pathway plays a crucial role in the precipitation of CVD, for example, 
hypertension, myocardial infarction, and stroke.99,  
The present study provided evidence, that by decreasing the 
phosphorylation of ERK1/2, oxytocin deactivated Ang II-stimulated ERK1/2 
signaling in SHR VSMCs, and thus supports a protective role of oxytocin in 
pathophysiological conditions, for instance, hypertension. However, in vivo studies 
are required to further shed more light on oxytocin’s protective effect on 
hypertension.   
The PI3K/Akt signaling pathway has been shown to alter vascular function 
by increasing the myogenic tone of resistant arteries.107  It also results in an aberrant 
increase in the activity of L-VGCC leading to increased intracellular calcium, 
increased cell volume in cardiomyocytes, and hyper-proliferation of VSMCs.120,110 
Thus, the PI3K/Akt pathway leads to various cardiovascular pathophysiological 
conditions including hypertension, pathological cardiac hypertrophy, and cardiac 
arrhythmia .119  Ang II has been known to participate in and worsen these 
pathophysiological events via hyper-activation of the PI3K/Akt signaling. 276,53 
The findings of this study showed that oxytocin remarkably reduced the 
phosphorylation of PI3K p110α and Akt in aortic VSMCs isolated from 
normotensive and hypertensive rats. These findings are consistent with a previous 
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study, wherein oxytocin reduced the phosphorylation of PI3K p110α and Akt, albeit 
in gut cells.292  
Similar to the effect of oxytocin on Ang II-induced induced phosphorylation 
of ERK1/2, oxytocin prominently diminished Ang II-induced phosphorylation of 
PI3K p110α and Akt, whereas, the oxytocin receptor antagonist prevented these 
effects of oxytocin. These findings were also consistent in aortic SHR VSMCs, 
which further suggests that oxytocin induced-deactivation of PI3K/Akt signaling 
pathway in SHR VSMCs might provide vascular protective effects in hypertension 
in vivo.   
There is a possibility that in aortic VSMCs, oxytocin via its receptors, which 
belong to GPCRs superfamily,3 might be recruiting Gαi (inhibitory) protein, and 
thus inhibiting downstream cell signaling by reducing the levels of phospho-
ERK1/2, phospho-PI3K p110α, and phospho-Akt, leading to the deactivation of the 
ERK1/2 pathway and the PI3K/Akt pathway. 
Alternatively, it could very well be that oxytocin might regulate the 
phosphatase and thereby reduce the phosphorylation of ERK/12, PI3K p110α, and 
Akt.  
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5.3. Oxytocin deactivated the ROCK pathway in aortic VSMCs  
The present study explored the effect of oxytocin on the ROCK pathway. 
The agonist-mediated phosphorylation of Rho kinases leads to the activation of 
both ROCK-1 and ROCK-2, along with concurrent calcium mobilization, causing 
the organization and remodeling of the actin cytoskeleton, extracellular matrix, and 
contraction of  VSMCs.146 The ROCK signaling pathway has been implicated in 
the pathogenesis of various CVD such as hypertension, pulmonary hypertension, 
angina pectoris, stroke, and heart failure. 140–144  It is also established that Ang II 
activates ROCK signaling in these pathophysiological conditions.135,53  
Together with the reduction in cell proliferation and deactivation of the 
proliferation signal transduction pathways by oxytocin, the present research 
demonstrated for the first time that oxytocin significantly reduced Rho kinase-
mediated vasocontraction in aortic VSMCs. The study results highlight that 
oxytocin reduced the activation of both ROCK-1 and ROCK-2 in aortic VSMCs 
isolated not only from normotensive rats but also from hypertensive rats. These 
findings suggest that oxytocin could provide vascular protective effects in 
pathophysiological conditions associated with hyper-signaling of ROCK pathways 
such as hypertension and stroke.  
However, to state definitively about oxytocin’s anti-vasocontraction effect 
on VSMCs, direct measurement of oxytocin’s impact on vasocontraction would be 
needed. The study was limited in this regard as this study did not directly assess 
oxytocin’s effect on vasocontraction. Instead, it investigated the impact of oxytocin 
on the vasocontraction pathway (ROCK pathway). Future studies could be carried 
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out by employing an ex vivo model such as the organ bath to directly measure 
vasocontraction. 
The study outcomes further revealed that oxytocin reduced Ang II-mediated 
activation of both ROCK-1 and ROCK-2 in normotensive as well as in hypertensive 
VSMCs, and these effects were blocked by an oxytocin receptor antagonist, 
indicating that oxytocin causes these effects via its receptors. Based on the study 
results, the fact that oxytocin antagonized Ang II-stimulated ROCK pathway in 
aortic VSMCs suggests the potential cardioprotective effects oxytocin might have 
in conditions where Ang II-mediated hyper-signaling of ROCK causes 
vasoconstriction of blood vessels and disrupts the hemodynamics, culminating in 
the development and worsening of CVD such as hypertension, angina pectoris, and 
stroke.   
This study was the first attempt to investigate the impact of oxytocin and its 
pre-treatment with Ang II on the ROCK pathway. However, future in vivo studies 
would be needed to further explore oxytocin’s effect on the contraction of blood 
vessels in normal and pathophysiological conditions, for example, hypertension. 
All three pathways: the ERK1/2 pathway, the PI3K/Akt pathway, and the 
ROCK1/ROCK2 pathway are crucial in precipitating deleterious events such as 
hypertrophy and hyper-contractility in VSMCs, which further lead to 
cardiovascular complications manifested in CVD such as hypertension and 
arrhythmia.99,119,144   
Our results indicate that oxytocin may prevent these changes in the 
dynamics of the vasculature by reducing the phosphorylation of ERK1/2, PI3K, and 
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Akt and by decreasing the activation of ROCK-1 and ROCK-2 in normotensive as 
well as hypertensive conditions (Figure 5).  
 
Figure 5. Inhibition of the ERK1/2 pathway, the PI3K/Akt pathway, and the Rho-
kinase pathway by oxytocin in aortic VSMCs. Oxytocin mediates anti-proliferative 
effects by inhibiting phosphorylation of ERK1/2, PI3K, and Akt. Oxytocin 
deactivates Rho-kinase pathway involved in vasocontraction of VSMCs by 
inhibiting the phosphorylation of ROCK-1 and ROCK-2. It may be possible that 
either via the recruitment of Gαi proteins or by stimulating phosphatases oxytocin 
decreases phosphorylation of ERK1/2, PI3K, Akt, ROCK-1, and ROCK-2. ERK 
indicates extracellular signal-regulated kinase; PI3K, phosphoinositide-3-kinase; 
ROCK, rho-associated coiled-coil containing protein kinase; Ang II, angiotensin 
II; AT-1, angiotensin type-1; Gαi, G alpha inhibitory protein. Dotted red arrows 
indicate inhibition; black arrows, activation. 
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5.4. Oxytocin increased IL-6 in aortic VSMCs 
One of the objectives of the current study was to investigate the effects of 
oxytocin on inflammation responses using aortic VSMCs. Hence, IL-6, a biomarker 
of inflammation, was measured. 
 In contrast to previous studies carried out on vascular endothelial cells,34 
the outcomes of the present study, conducted on aortic VSMCs, revealed that 
oxytocin significantly increased IL-6, but remarkably reduced Ang II-stimulated 
IL-6 levels.  
It is essential to understand the role of IL-6 while interpreting these results. 
IL-6 has been known for its pleiotropic effects.172 It is involved in various 
physiological events including inflammation (production of CRP) and 
immunological responses (activation and differentiation of T-cells and B-
cells).174,175,178,180,181   
Several studies have shown that an increase in IL-6 levels by any 
treatment(s) or peptide(s) under investigation can be detrimental, especially in 
conditions, for example rheumatoid arthritis and heart disease, wherein IL-6 
mediated immunological and pathophysiological events contribute in worsening of 
the symptoms.293,294 
However, the effects of IL-6 can be both harmful and protective.192  It is the 
duration of the pathogenic stimuli or pathophysiological conditions that determines 
which one of the two effects IL-6 will manifest.  For example, IL-6 elicits 
cardioprotective effects on cardiomyocytes when exposed to acute 
pathophysiological condition(s).192    
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Conversely, IL-6 signaling can prove detrimental if the exposure to 
pathophysiological condition(s) is chronic. In such a scenario, IL-6 may result in 
pathological changes, for instance, reduced cardiac contractility, pathological 
cardiac hypertrophy, and ultimately leading to decreased cardiac function.197,198 
In this context, based on this study findings, oxytocin-induced IL-6 
secretion in VSMCs could be vascular protective, as oxytocin-induced IL-6 
secretion might boost the immunological defense required to counter the 
pathogenic stimulus for a shorter period. The fact that oxytocin’s effect on IL-6 was 
consistent in VSMCs isolated from hypertensive rats suggests oxytocin could 
similarly bolster immune defense against an acute exposure to a pathogen in 
diseased condition. However, further in vivo studies are required to explore the 
beneficial effect of oxytocin-induced IL-6 secretion against an acute exposure to 
pathogenic stimuli. 
Another aspect of the present study was to determine the impact of oxytocin 
on Ang II-stimulated IL-6 secretion. The study results demonstrated that oxytocin 
reduced Ang II-stimulated IL-6 secretion not only in aortic VSMCs from 
normotensive rats but also in aortic VSMCs from hypertensive rats, indicating that 
oxytocin could show protective effects against Ang II-induced inflammation 
(increase in IL-6), which more likely happens in a chronic basis under 
cardiovascular disease conditions such as atherosclerosis and rheumatoid arthritis.  
Based on the study findings that the singular treatment of oxytocin increased 
IL-6 secretion, it can be suggested that oxytocin might provide beneficial effects in 
conditions where a short-term inflammatory response is required to arrest the host 
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damage, for example, in cardiomyocytes where short-term IL-6 signaling provided 
cardioprotective effects.192 Furthermore, oxytocin's antagonistic action against Ang 
II-induced IL-6 secretion could provide protection against chronic inflammation 
such as in coronary heart disease and atherosclerosis. 293,294 
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5.5. Oxytocin increased ROS in aortic VSMCs 
The current study was carried out to determine the effect of oxytocin on 
oxidative stress. Oxidative stress is often at the center of many pathophysiological 
conditions in the CVS.295 It is caused by an imbalance between oxidants and ant-
oxidants.296 The oxidants are ROS such as hydrogen peroxide (H2O2) and 
superoxide (O2-). On the other hand, antioxidants include superoxide dismutase 
(SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase 
(GRx).297  
In cardiovascular cells such as VSMCs, endothelial cells, and 
cardiomyocytes, ROS is primarily produced by NADPH oxidase.217  Others include 
mitochondrial transport chain and uncoupling of eNOS.225,227 The vasoconstrictor 
peptides such as Ang II and ET -1 increase oxidative stress via increased production 
of ROS, contributing to the pathogenesis of CVD including hypertension.219,221  
The results of the ROS measurement in the present study showed that 
oxytocin increased ROS production in aortic VSMCs. These results are in contrast 
with the effect of oxytocin on ROS production in vascular endothelial cells as 
reported in previous studies.34 Also, oxytocin’s pre-treatment with Ang II further 
increased ROS production, suggesting an additive effect. These effects of oxytocin 
were consistent in SHR VSMCs. The basal levels of ROS were higher in Wistar 
VSMCs, and consequently, oxytocin-induced ROS production was higher in Wistar 
VSMCs than SHR VSMCs.  
These results suggest that oxytocin increases oxidative stress and further 
potentiate Ang II-induced oxidative stress in cultured aortic VSMCs. However, it 
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is essential to mention that the current study employed the in vitro experimental 
models, the effect of oxytocin was measured on isolated aortic VSMCs, of which 
the findings showed oxytocin increased ROS production. It cannot be assumed that 
oxytocin would show similar effects in vivo, where VSMCs are not separate and 
co-exist with endothelial cells.  
It is worth noting endothelial cells, VSMCs, and their interaction plays a 
crucial role in maintaining vascular homeostasis. However, events such as 
increased ROS production causing oxidative stress and reduced availability of NO 
can lead to endothelial dysfunction. This can adversely impact the functions of 
VSMCs. VSMCs in such conditions are prone to excessive proliferation and hyper-
contraction owing to lack of vasorelaxants (NO) and can lead to the development 
of CVD, for example, atherosclerosis.298  
As stated earlier, oxytocin has been shown to induce protective effects in 
vascular endothelial cells via reduction of ROS production. It might be that in vivo, 
where both endothelial cells and VSMCs co-exist, oxytocin-mediated opposite 
effects on ROS production in VSMCs and endothelial cells might negate each other. 
This might not disrupt the overall redox equilibrium and may not adversely impact 
oxidative stress in blood vessels. This could be useful in conditions associated with 
increased oxidative stress such as hypertension, atherosclerosis, and rheumatoid 
arthritis.  
However, the present study did not investigate the interaction between 
endothelial cells and VSMCs with regards to oxytocin’s effect on ROS production, 
and this could be a subject of future investigation where oxytocin’s effect on ROS 
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production in VSMCs and endothelial cells can be determined simultaneously by 
employing co-cultures of VSMCs and endothelial cells and in vivo studies. 
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5.6. Summary of the dissertation research 
In the last decade and a half, the status of oxytocin as a contractor of the 
pregnant uterus, and an initiator of milk-ejection reflex have transcended to a 
hormone eliciting protective effects in the CVS, in general, and on cardiovascular 
cells including cardiomyocytes and vascular endothelial cells, in particular. 
However, oxytocin's impact on VSMCs, which form an integral layer of blood 
vessels and play a crucial role in physiological and pathophysiological conditions 
associated with CVS, have not been well-established. This study was carried out to 
investigate oxytocin's effect on proliferation, oxidative stress, inflammation, and on 
vasocontraction pathway in aortic VSMCs isolated from both normotensive and 
hypertensive rats.  
In addition, this study also examined the interaction of oxytocin with Ang 
II, a vital hormone of the RAAS in the CVS. Ang II-induced proliferation, oxidative 
stress, inflammation, and vasocontraction of VSMCs have been associated with the 
development and worsening of various vascular diseases, including hypertension 
and atherosclerosis. This study investigated the effect of oxytocin's pre-treatment 
on Ang II-induced proliferation, oxidative stress, inflammation, and Ang II-
stimulated vasocontraction pathway in VSMCs in aortic VSMCs isolated from both 
normotensive and hypertensive rats.  
The present study employed primary aortic VSMCs isolated from 
normotensive Wistar rats and hypertensive SHRs. For investigating the effect of 
oxytocin, and its interaction with Ang II, on the proliferation of VSMCs, this study 
utilized various methods: Hemocytometer method for cell counting; MTT assay for 
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cell viability assessment; 3H-Thymidine incorporation assay for cell growth 
measurement; and flow cytometry to determine apoptosis and necrosis. 
 To gain a better understanding of the impact of oxytocin on VSMCs 
proliferation, the two key proliferation signal transduction pathways were 
investigated: the ERK1/2 pathway and the PI3K/Akt pathway. Western blot 
technique was utilized to study the effect of oxytocin on these two pathways. For 
studying the impact of oxytocin, and its interaction with Ang II, on the 
vasocontraction pathway in VSMCs, the ROCK pathway was investigated. The 
western blot technique was utilized to study oxytocin's effect on the ROCK 
pathway.  
To investigate the effect of oxytocin, and its interaction with Ang II, on 
inflammation and oxidative stress, the ELISA-based IL-6 assay, and the fluorescent 
spectroscopy-based ROS assay were carried out, respectively. 
The outcomes of proliferation studies indicated that oxytocin reduces 
VSMCs proliferation by inhibiting the phosphorylation of ERK1/2, PI3K p110α, 
and Akt. Besides, oxytocin also reduced Ang II-induced proliferation by reducing 
Ang II-mediated phosphorylation of ERK1/2, PI3K p110α, and Akt not only in 
VSMCs isolated from normotensive rats but also in hypertensive rats. This may 
have clinical relevance in conditions associated with higher levels of Ang II and 
Ang II-mediated hyper-signaling of proliferation pathways in the CVS, such as in 
hypertension and atherosclerosis. Nonetheless, further in vivo studies are required 
to demonstrate the protective effects of oxytocin against deleterious effects of Ang 
II in these pathophysiological conditions. 
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The study findings further revealed that oxytocin and its pre-treatment with 
Ang II led to dysregulation of the ROCK pathway via inhibition of the activation 
of ROCK1 and ROCK2. These findings suggest a possible cardioprotective role of 
oxytocin in conditions where there is an excessive vasocontraction of blood vessels 
linked with Ang II-mediated hyper-signaling of ROCK pathway, for example, 
hypertension. However, this study was limited in its scope with regards to 
oxytocin's effect on vasocontraction as the study did not directly measure 
vasocontraction of VSMCs and rather investigated the vasocontraction pathway, 
and this could be further investigated in the future. 
Furthermore, the results of an ELISA-based IL-6 assay indicated that 
oxytocin's treatment increased IL-6 secretion in aortic VSMCs. This may be 
beneficial in conditions where a short-term increase in IL-6 release bolsters 
immunological response against a pathogenic stimulus for a shorter duration.  Also, 
our findings demonstrated that oxytocin reduced the Ang II-mediated IL-6 
secretion in aortic VSMCs isolated from both Wistar rats and SHRs. This could be 
favorable in conditions associated with Ang II-induced prolonged inflammation 
such as rheumatoid arthritis. However, further studies investigating oxytocin's 
effect on inflammation and its interaction with Ang II on the inflammatory 
response, especially in vascular conditions associated with aggravated 
inflammation such as atherosclerosis, are required. 
The ROS assay findings showed that oxytocin increased ROS production 
and its pre-treatment with Ang II further increased ROS production in aortic 
VSMCs isolated from both Wistar rats and SHRs. This suggests that oxytocin might 
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increase oxidative stress in cultured VSMCs. However, it cannot be assumed that 
in vivo, oxytocin would exhibit similar effects. In vivo, VSMCs co-exist with 
vascular endothelial cells, wherein oxytocin has been previously shown to reduce 
ROS production. It could very well be that the opposite effects of oxytocin on ROS 
production in VSMCs and endothelial cells cancel out each other and might not 
disturb the overall redox equilibrium. Henceforth, oxytocin might not contribute to 
a change in oxidative stress in blood vessels, which could be significant in 
pathophysiological conditions associated with increased oxidative stress in CVS. 
Nevertheless, further studies would be required where oxytocin's effect on ROS can 
be assessed simultaneously in both VSMCs and endothelial cells, such as in vitro 
studies employing co-culturing of VSMCs and endothelial cells and in vivo 
studies.   
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5.7. Conclusion 
VSMCs undergo various pathophysiological changes in hypertension and 
other CVD, which render them as a potential target for newer approaches for their 
therapeutic management. The present in vitro study investigated the effects of 
oxytocin on cell proliferation, inflammation, oxidative stress, and also on the 
pathways involved in cell proliferation and vasocontraction in primary aortic 
VSMCs, isolated from normotensive (Wistar rats) and hypertensive rats (SHRs).  
This study demonstrated that oxytocin inhibits proliferation and increases 
inflammation (IL-6) and oxidative stress (ROS) in aortic VSMCs obtained from 
Wistar rats and SHRs. Based on the study outcomes, it can be suggested that the 
anti-proliferative effect of oxytocin is mediated by inhibition of ERK1/2 and 
PI3K/Akt phosphorylation. Also, oxytocin deactivated Rho-kinase signaling 
pathway, a critical pathway involved in the contraction of VSMCs, by inhibiting 
the phosphorylation of ROCK-1 and ROCK-2.  
The increased proliferation in VSMCs and hypercontraction mediated by 
peptides such as Ang II, worsen hypertension and precipitate other CVD and their 
progression. Oxytocin not only decreased VSMCs proliferation but also reduced 
Ang II-induced VSMCs proliferation and Ang II-stimulated vasocontraction 
pathways.  
Overall, this study indicates that oxytocin might have therapeutic potential 
in the management of CVD including hypertension. However, future in vivo studies 
are required to examine the cardiovascular protective effect of oxytocin in 
hypertension.   
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5.8. Future recommendation 
The present study utilized all the existing techniques available to assess the 
effect of oxytocin and its pretreatment with Ang II on cell proliferation in VSMCs. 
However, the study was limited in its scope with regards to the direct measurement 
of vasocontraction in aortic VSMCs.  
The current study indirectly assessed vasocontraction by investigating the 
vasocontraction pathway — ROCK pathway. In the future, this aspect can be 
addressed. The effect of oxytocin on vasocontraction can be studied by determining 
the intracellular calcium levels in aortic VSMCs. This can be achieved by 
employing techniques such as fluorescent-based calcium measurement assay and 
more directly employing organ bath studies using vascular smooth muscle tissue.  
Furthermore, to understand the mechanism of how oxytocin decreases the 
phosphorylation of the ERK1/2, PI3K p110α, and Akt, Gαi inhibitors may be 
employed. Since oxytocin receptors are GPCRs and have been previously shown 
to recruit different G-proteins in different cells and in different physiological 
conditions, it is a likely that oxytocin recruits Gαi and thus inhibits ERK1/2 and 
PI3K/Akt-mediated downstream signaling pathways involved in the proliferation 
of VSMCs.  
Another such possibility could be that oxytocin stimulates phosphatases and 
consequently inhibits the phosphorylation of ERK1/2, PI3K p110α, and Akt. This 
can be explored in future research endeavors.  
Also, the present study employed in vitro experimental models. All the 
study experiments were performed on primary aortic VSMCs isolated from Wistar 
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rats and SHRs. This study has generated sufficient scientific evidence to warrant 
the use of in vivo experimental models in the future. And, based on the results of a 
future in vivo study, the next step would be to conduct a pilot clinical trial as 
oxytocin is a peptide that has been approved by the food and drug administration 
(FDA), and has been subjected to various clinical trials.  
As demonstrated by the study outcomes, this research highlighted the 
significant vascular protective effects of oxytocin and its antagonistic actions on 
Ang II effects in VSMCs isolated from both normotensive and hypertensive rats. 
These findings suggest that oxytocin may have therapeutic implication in 
conditions where hyper-activation of Ang II leads to hyper-signaling of Ang II-
mediated signaling pathways resulting in the development and progression of 
various CVD, including hypertension.  However, future in vivo studies and clinical 
studies would be required to explore the protective effect of oxytocin in CVD. 
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